<html lang="en"><head>
	<!-- Required meta tags -->
	<meta charset="utf-8">
	<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
	<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

	<!-- Favicon -->
	<!-- cpcommit -->
	<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

	<script>
		(function () {
			var hostName = window.location.hostname;

			var browserAccepted = function () {

				var ua = window.navigator.userAgent;
				var trident = ua.indexOf('Trident/'); //IE 11;
				var msie = ua.indexOf('MSIE '); // IE 10 or older
				if (msie > 0) {
					return false;
				}
				return true;
			}();

			var pathToLibs = './js';
			var pathToError = './';
			// uncomment following lines only when running ix symlink to ix.xhtml on *.sec.gov
			/* commented out for running ix redirector script
			if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
				pathToLibs = './ixviewer/js';
				pathToError = '/ixviewer/';
			}
			*/
			if (browserAccepted) {

				// css
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
				document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

				// js
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.7.1.slim.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
				document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

				var date = new Date();
				var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
				document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
			} else {
				// user us on a browser that we do not support
				var currentUrl = window.location.href.split('?')[0];
				var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
				browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
				window.location.href = browserError;
			}
		})();
	</script><link rel="stylesheet" href="./js/css/custom-bootstrap.css"><link rel="stylesheet" href="./js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="./js/css/app.css"><script type="text/javascript" src="./js/lib/jquery-3.7.1.slim.min.js"></script><script type="text/javascript" src="./js/lib/popper.min.js"></script><script type="text/javascript" src="./js/lib/bootstrap.min.js"></script><script type="text/javascript" src="./js/lib/moment.js"></script><script type="text/javascript" src="./js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="./js/lib/he.js"></script><script type="text/javascript" defer="true" src="./js/production.min.js?d=22-4-2024"></script>
	<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} #dynamic-xbrl-form .text-block-indicator-left{border-left:.75rem solid ##003768;} #dynamic-xbrl-form .text-block-indicator-right{border-right:.75rem solid ##003768;} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>

<body>
	<noscript>This application relies heavily on JavaScript, you
		will need to allow JavaScript to use this application.</noscript>
	<nav class="reboot navbar navbar-expand-md navbar-dark navbar-height bg-sec fixed-top w-100 pl-0">
		<button class="reboot navbar-toggler ml-1" type="button" data-test="" data-toggle="collapse" data-target="#main-navbar" aria-controls="main-navbar" aria-expanded="false" aria-label="Toggle navigation">Inline Viewer</button>
		<div class="reboot navbar-height collapse navbar-collapse bg-sec w-100" data-test="main-navbar" id="main-navbar">
			<ul class="reboot navbar-nav mr-auto bg-inherit">
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a id="menu-dropdown-link" data-test="menu-dropdown-link" class="reboot nav-link dropdown-toggle click disabled" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="1" accesskey="1">
						<i class="reboot nav-loading fas fa-bars" title="Menu"></i>
						<span class="reboot d-md-none d-lg-inline">Menu</span>
						<span class="reboot sr-only sr-only-focusable">Menu</span>
					</a>
					<div class="reboot dropdown-menu">
						<a id="menu-dropdown-information" data-test="menu-dropdown-information" class="reboot dropdown-item click text-body" tabindex="1">Information</a>
						<a id="form-information-instance" data-test="form-information-instance" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL
							Instance</a>
						<a id="form-information-zip" data-test="form-information-zip" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Save XBRL Zip
							File</a>
						<a id="form-information-html" data-test="form-information-html" class="reboot dropdown-item click text-body" target="_blank" tabindex="1">Open as HTML</a>
						<a id="menu-dropdown-settings" data-test="menu-dropdown-settings" class="reboot dropdown-item click text-body" tabindex="1">Settings</a>
						<a id="form-information-help" data-test="form-information-help" class="reboot dropdown-item click text-body" tabindex="1">Help</a>
						<span id="form-information-version" class="reboot dropdown-item-text text-body" tabindex="1"></span>
					</div>
				</li>
				<li class="reboot nav-item my-auto ml-1">
					<a id="sections-dropdown-link" data-test="sections-dropdown-link" class="reboot nav-link click disabled meta-required" tabindex="2" accesskey="2">
						<i class="reboot fas fa-layer-group" title="Sections"></i>
						<span class="reboot d-md-none d-lg-inline">Sections</span>
						<span class="reboot sr-only sr-only-focusable">Sections</span>
					</a>
				</li>
				<li class="reboot nav-item my-auto ml-1 mr-1">
					<form id="global-search-form" data-test="global-search-form" class="reboot my-2 my-lg-0 input-group disabled" novalidate="">
						<div class="reboot input-group-prepend">
							<button data-name="global-search-options" class="reboot dropdown btn btn-outline-light disabled" type="button" data-toggle="dropdown" tabindex="3">
								<i class="reboot nav-loading fas fa-cog" title="Additional Search Options">
									<span class="reboot sr-only sr-only-focusable">Additional
										Search Options</span>
								</i>
							</button>
							<div class="reboot dropdown-menu px-2">
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="1" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Name</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="2" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Fact Content</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="3" checked="" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Labels</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="4" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Definitions</span>
									</label>
								</div>
								<div class="reboot form-check">
									<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="5" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Include Dimensions</span>
									</label>
								</div>
								<div class="reboot bg-light border p-1">
									<span class="reboot dropdown-item-text">Reference
										Options</span>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="6" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="7" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Sub-Topic</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="8" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Paragraph</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="9" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="reboot">Include Publisher</span>
										</label>
									</div>
									<div class="reboot form-check">
										<input disabled="" class="reboot form-check-input meta-required" type="checkbox" name="search-options" value="10" tabindex="3">
										<label class="reboot form-check-label mb-0">
											<span class="disabled">Include Section</span>
										</label>
									</div>
								</div>
								<div class="reboot form-check">
									<input class="reboot form-check-input" type="checkbox" name="search-options" value="11" tabindex="3">
									<label class="reboot form-check-label mb-0">
										<span class="reboot">Match Case</span>
									</label>
								</div>
							</div>
						</div>
						<input type="text" class="reboot form-control disabled" id="global-search" data-test="global-search" placeholder="Search Facts" disabled="" aria-label="Search all Facts and highlight them accordingly." tabindex="4">
						<div class="reboot input-group-append">
							<button id="search-btn-clear" data-name="global-search-clear" class="reboot btn btn-outline-light disabled" type="button" tabindex="5">
								<i class="reboot nav-loading fas fa-times-circle" title="Clear Search"></i>
								<span class="reboot sr-only sr-only-focusable">Clear
									Search</span>
							</button>
							<button class="reboot btn btn-outline-light disabled" type="submit" tabindex="6">
								<i class="reboot nav-loading fas fa-search" title="Submit Search"></i>
								<span class="reboot sr-only sr-only-focusable">Submit
									Search</span>
							</button>
						</div>
					</form>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-data" data-test="nav-filter-data" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="7" accesskey="3">
						<i class="reboot nav-loading fas fa-list-alt" title="Data"></i>
						<span class="reboot d-md-none d-lg-inline">Data</span>
						<span class="reboot sr-only sr-only-focusable">Data</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-dropdown" data-name="data-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="0" checked="" tabindex="7">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="1" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Amounts Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="2" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Text Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="data-radios" value="3" disabled="" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Calculations Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="4" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Negatives Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="data-radios" value="5" tabindex="7">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Additional Items Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-tags" data-test="nav-filter-tags" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="8" accesskey="4">
						<i class="reboot nav-loading fas fa-tags" title="Tags"></i>
						<span class="reboot d-md-none d-lg-inline">Tags</span>
						<span class="reboot sr-only sr-only-focusable">Tags</span>
					</a>
					<div class="reboot dropdown-menu">
						<form id="nav-filter-tags-dropdown" data-name="tags-dropdown" class="reboot px-2">
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="0" aria-label="Radio Button for All Tag Types" checked="" tabindex="8">
								<label class="reboot form-check-label mb-0">All</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input" type="radio" name="tags-radios" value="1" aria-label="Radio Button for Standard Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span>Standard Only</span>
								</label>
							</div>
							<div class="reboot form-check">
								<input class="reboot form-check-input meta-required" type="radio" name="tags-radios" value="2" disabled="" aria-label="Radio Button for Custom Only Tag Types" tabindex="8">
								<label class="reboot form-check-label mb-0">
									<i title="Facts whose tags are outside the realm of DEI, US-GAAP, etc." class="reboot far fa-question-circle"></i>
									<i title="The first time choosing this will take a few moments." class="reboot far fa-clock d-none performance-concern"></i>
									<span class="reboot">Custom Only</span>
								</label>
							</div>
						</form>
					</div>
				</li>
				<li class="reboot nav-item dropdown my-auto ml-1">
					<a href="#" id="nav-filter-more" data-test="nav-filter-more" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="9" accesskey="5">
						<i id="loading-more-filters" class="reboot nav-loading fas fa-filter" title="More Filters"></i>
						<span class="reboot d-md-none d-lg-inline">More Filters</span>
						<span class="reboot sr-only sr-only-focusable">More Filters</span>
						<span title="Total active filters." class="reboot badge badge-warning"></span>
					</a>
					<div class="reboot dropdown-menu dropdown-menu-width">
						<label class="reboot dropdown-item-text d-none performance-concern">
							Selecting any of the below will take a few moments.</label>
						<div class="reboot accordion" id="more-filters-accordion">
							<form class="reboot" data-test="more-filters-form">
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Period" data-target="#user-filters-periods" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Periods</span>
											<span data-test="Period-count" id="filters-periods-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-periods" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Measures" data-target="#user-filters-measures" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Measures</span>
											<span data-test="Measures-count" id="filters-measures-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-measures" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot  px-0 py-0">
										<a href="#" data-test="Axis" data-target="#user-filters-axis" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Axis</span>
											<span data-test="Axis-count" id="filters-axis-count" class="reboot badge badge-secondary">
												<i class="fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-axis" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="axes-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#axes-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="axis-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Members" data-target="#user-filters-members" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Members</span>
											<span data-test="Members-count" id="filters-members-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-members" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-0" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-0" data-toggle="collapse" tabindex="9">Explicit</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-explicit-count"></span>
											</div>
										</div>
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush d-none">
											<div class="reboot d-flex justify-content-between align-items-center w-100 px-1">
												<div class="reboot form-check">
													<input id="members-all-1" title="Select/Deselect all options below." class="reboot form-check-input" type="checkbox" tabindex="9">
													<label class="reboot form-check-label mb-0">
														<a class="reboot" href="#members-filters-accordion-1" data-toggle="collapse" tabindex="9">Typed</a>
													</label>
												</div>
												<span class="reboot badge badge-secondary" id="members-typed-count"></span>
											</div>
										</div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Scale" data-target="#user-filters-scales" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Scale</span>
											<span data-test="Scale-count" id="filters-scales-count" class="reboot badge badge-secondary">
												<i class="reboot fas fa-spinner fa-spin"></i>
											</span>
										</a>
									</div>
									<div id="user-filters-scales" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<!-- Below is populated dynamically VIA JS -->
										<div class="reboot list-group list-group-flush"></div>
									</div>
								</div>
							</form>
							<form>
								<div class="reboot mx-1">
									<div class="reboot px-0 py-0">
										<a href="#" data-test="Balance" data-target="#user-filters-balances" data-toggle="collapse" class="reboot d-flex justify-content-between align-items-center w-100 click text-primary" tabindex="9">
											<span class="reboot">Balance</span>
											<span data-test="Balance-count" id="filters-balances-count" class="reboot badge badge-secondary">2</span>
										</a>
									</div>
									<div id="user-filters-balances" class="reboot collapse height-200 overflow-y-auto" data-parent="#more-filters-accordion">
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-debit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Debit</label>
											</div>
										</div>
										<div class="reboot d-flex justify-content-between align-items-center w-100 px-2">
											<div class="reboot form-check">
												<input id="user-filters-balances-credit" title="Select/Deselect this option." class="reboot form-check-input" type="checkbox" tabindex="9">
												<label class="reboot form-check-label mb-0">Credit</label>
											</div>
										</div>
									</div>
								</div>
							</form>
						</div>
					</div>
				</li>
				<li id="current-filters-reset" data-test="current-filters-reset" class="reboot nav-item d-none my-auto ml-1">
					<a href="#" id="current-filters-reset-all" data-name="current-filters-reset" class="reboot nav-link dropdown-toggle text-danger disabled click" tabindex="11" accesskey="7">
						<i class="reboot nav-loading fas fa-redo"></i>
						<span class="reboot d-md-none d-lg-inline">Reset All
							Filters</span>
					</a>
				</li>
				<li id="links-dropdown" data-test="links-dropdown" class="reboot nav-item dropdown d-none my-auto ml-1">
					<a href="#" id="additional-links-dropdown" class="reboot nav-link dropdown-toggle disabled click" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" tabindex="12" accesskey="8">
						<i class="reboot nav-loading fas fa-link"></i>
						<span class="reboot d-md-none d-lg-inline">Links</span>
					</a>
					<div id="links-dropdown-content" class="reboot dropdown-menu dropdown-menu-width w-auto"></div>
				</li>
			</ul>
			<ul class="reboot navbar-nav pull-right bg-inherit">
				<li class="reboot nav-item my-auto ml-1">
					<a id="facts-menu" data-test="facts-menu" class="reboot nav-link click" tabindex="13" accesskey="9">
						Facts
						<span class="reboot taxonomy-total-count badge badge-light"><i class="fas fa-spinner fa-spin"></i></span>
					</a>
				</li>
			</ul>
		</div>
	</nav>
	<div class="reboot main-container">
		<div id="error-container" data-test="error-container" class="reboot px-0"></div>
		<div id="xbrl-form-loading" data-test="xbrl-form-loading" class="reboot jumbotron h-100 d-none">
			<h2 class="reboot display-4 text-center">
				<i class="reboot fas fa-spinner fa-spin"></i>
				Loading Inline Form.
			</h2>
		</div>
		<div id="sections-menu" data-test="sections-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">
			<div class="reboot mb-2">
				<span class="reboot lead">Tagged Sections</span>
				<a id="sections-menu-toggle" class="reboot float-right click color-inherit" tabindex="2">
					<i class="reboot fas fa-times-circle mt-2 text-dark"></i>
				</a>
			</div>
			<form id="sections-menu-search-submit" data-name="sections-menu-search" class="reboot my-2 my-lg-0 input-group" novalidate="">
				<div id="sections-search-additional" class="reboot input-group-prepend d-none">
					<button class="reboot dropdown btn btn-sec" type="button" data-toggle="dropdown" tabindex="2">
						<i class="reboot nav-loading fas fa-cog"></i>
					</button>
					<div class="reboot dropdown-menu px-2">
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="1" checked="" tabindex="2">
							<label class="reboot form-check-label">Search in All.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="2" tabindex="2">
							<label class="reboot form-check-label">Search in Internal
								Sections Only.</label>
						</div>
						<div class="reboot form-check">
							<input class="reboot form-check-input" type="radio" name="sections-search-options" value="3" tabindex="2">
							<label class="reboot form-check-label">Search in External
								Sections Only.</label>
						</div>
					</div>
				</div>
				<input type="text" class="reboot form-control" id="sections-search" data-test="sections-search" placeholder="Search Sections" aria-label="Search all Sections by their associated label." name="search-sections" tabindex="2" required="">
				<div class="reboot input-group-append">
					<button id="section-menu-search-btn-clear" data-name="sections-menu-search-clear" class="reboot btn btn-sec" type="button" tabindex="2">
						<i class="nav-loading fas fa-times-circle" title="Clear Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Clear
							Sections Search</span>
					</button>
					<button class="reboot btn btn-sec" type="submit" tabindex="2">
						<i class="reboot nav-loading fas fa-search" title="Submit Sections Search"></i>
						<span class="reboot sr-only sr-only-focusable">Submit
							Sections Search</span>
					</button>
				</div>
			</form>
			<hr>

			<div class="reboot accordion" id="tagged-sections">
				<!-- Below is populated dynamically VIA JS -->
			</div>
		</div>



		<div id="help-menu" data-test="help-menu" class="reboot left-sidenav col-sm-3 bg-light overflow-x-auto invisible">

			<div class="reboot mb-2">
				<span class="reboot lead">Help</span> <a id="help-menu-close" data-test="help-menu-close" class="reboot float-right click"> <i class="reboot fas fa-times-circle mt-2"></i>
				</a>
			</div>
			<div class="reboot accordion" id="help-sections">
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-getting-started">
								<span class="reboot font-size-1 ">Getting Started</span>
							</button>
						</h5>
					</div>
					<div id="help-getting-started" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Inline XBRL viewer allows a user
							to quickly and easily review details of the tagged information in
							an Inline document by automatically placing a top and bottom
							highlight border around each tagged numeric fact and left and
							right border for each block tagged fact. Hovering over a tagged
							fact will highlight (shade) all content related to the tagged
							fact, and clicking on a tagged fact will reveal its tagging
							details in the Fact Review Window. Navigation, search and filter
							options are also provided to easily refine and identify specific
							types of tagged information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-fact-review-window">
								<span class="reboot font-size-1">Fact Review Window</span>
							</button>
						</h5>
					</div>
					<div id="help-fact-review-window" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The Fact Review Window shows the tagging
							details for the currently selected fact, which is highlighted
							with a solid blue border. There are four categories of fact detail
							which can be viewed; an "N/A" value indicates there is no
							available information for the item within the given category:</p>
						<ul class="reboot">
							<li class="reboot">Attributes - All primary information (as
								applicable) describing the tagged fact including period, sign,
								decimals, dimensional detail (axes and members), scale, measure
								and data type.</li>
							<li class="reboot">Labels - Detailed documentation
								(definition) for the tag used, and other labels.</li>
							<li class="reboot">References - Authoritative reference
								information (as applicable) for the selected tag.</li>
							<li class="reboot">Calculation - Balance and calculation
								hierarchy details (numeric non-dimensioned items only).</li>
						</ul>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-search">
								<span class="reboot font-size-1">Searching</span>
							</button>
						</h5>
					</div>
					<div id="help-search" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">There are two ways to search the
							document: FACTS AND SECTIONS. To search information, enter a
							keyword in a search box and select the magnifying glass icon to
							return matching results. Search operators "and" (via "AND" or
							"&amp;") and "or" (via "OR" or "|") are available to further refine a
							search.</p>
						<p class="reboot m-2">
							<strong>FACTS</strong>
						</p>
						<p class="reboot m-2">The Search Facts box can be used to find
							tagged facts matching entered keywords. By default, tag name, tag
							labels, and tagged content are included in Search. Tagged facts
							matching the search criteria are shown with a yellow-colored
							(default) shading on the page and appear in the Facts List.
							Select the "X" button to the left of the magnifying glass icon to
							clear the search.</p>
						<p class="reboot m-2">The content included in Search can be increased to
							included tag definitions, dimensions, and authoritative
							references by selecting the cog / wheel icon to the left of the
							search box. See Settings for more information.</p>

						<p class="reboot m-2">
							<strong>SECTIONS</strong>
						</p>
						<p class="reboot m-2">The Search Sections box can be used to
							filter the tagged sections of the financial statements.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-filter">
								<span class="reboot font-size-1">Filters</span>
							</button>
						</h5>
					</div>
					<div id="help-filter" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">Filters change the number of highlighted
							facts and items in the fact list by providing several ways to
							review and pinpoint certain tagged information. Multiple filters
							can be used at once.</p>
						<p class="reboot m-2">
							<strong>DATA FILTERS</strong>
						</p>
						<p class="reboot m-2">These filter options allow the user to
							refine the highlighted tagged facts by data type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Amounts Only - Numeric facts only</li>
							<li class="reboot">Text Only - Textual facts only</li>
							<li class="reboot">Calculations Only - Numeric facts
								participating in a calculation only</li>
							<li class="reboot">Negatives Only - Negative Numeric amounts
								only</li>
							<li class="reboot">Additional Items Only - Tagged facts
								without a corresponding HTML presentation (i.e., hidden facts)
								only</li>
						</ul>
						<p class="reboot m-2">
							<strong>TAGS FILTER</strong>
						</p>
						<p class="reboot m-2">These filters allow the user to refine
							the highlighted facts by tag type:</p>
						<ul class="reboot">
							<li class="reboot">All - Displays all tagged data (default)</li>
							<li class="reboot">Standard Only- Facts with standard tags
								from a common taxonomy (e.g., US_GAAP, IFRS, DEI).</li>
							<li class="reboot">Custom Only - Facts with extension
								"custom" tags unique to the entity's document.</li>
						</ul>
						<p class="reboot m-2">
							<strong>MORE FILTERS</strong>
						</p>
						<p class="reboot m-2">Additional filters that allow user to
							further refine the highlighted facts:</p>
						<ul class="reboot">
							<li class="reboot">Periods - List of all used context years
								and reporting periods</li>
							<li class="reboot">Measures - List of all used units of
								measure (e.g., US Dollars); as applicable</li>
							<li class="reboot">Axis - List of all used axis
								(dimensions); as applicable (dimensions); as applicable</li>
							<li class="reboot">Scale - List of all used scaled options
								(e.g., thousands, millions); as applicable</li>
							<li class="reboot">Balance - Debit, credit; as applicable</li>
						</ul>
						<p class="reboot m-2">Multiple filters work in conjunction
							with each other. For example, selecting the "Amounts Only" Data
							filter and "Custom Only" Tags filter will highlight only numeric
							tagged facts using custom tags and list them in the fact list.
							Active filters are displayed in the Filter toolbar as they are
							selected. Active filters can be removed individually by
							unchecking or selecting ALL option for each filter, or all at
							once via the "Reset All Filters" option.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-facts-results-list">
								<span class="reboot font-size-1">Facts List (Results)</span>
							</button>
						</h5>
					</div>
					<div id="help-facts-results-list" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">On the toolbar, select the "count" to
							the right of the word Facts (e.g., Facts 234) to reveal the Facts
							List results - a navigable listing of all currently highlighted
							tagged facts. The count represents the current number of facts.</p>
						<p class="reboot m-2">By default, all tagged facts are
							displayed in the Fact List Results. The list content and count
							reflects the currently highlighted facts (i.e., both Filters and
							Search criteria refine the list to match the highlighted tagged
							facts). Navigation controls are available to move through the
							list as well as move the current view to the corresponding
							highlighted fact location automatically. When a fact in the Facts
							Results List is selected, it will reveal the Fact Review Window.</p>
						<p class="reboot m-2">Certain letters may appear to the right
							of an item in the Fact Result list to indicate a certain
							property. If the letter "A" appears for a fact, it indicates the
							fact is additional data (i.e., hidden with potentially no
							corresponding HTML presentation). If the letter "C" appears, the
							fact is tagged with a custom tag. If the letter "D" appears, the
							fact is tagged with dimensional information.</p>
					</div>
				</div>
				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-sections">
								<span class="reboot font-size-1">Sections</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-sections" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">The SECTIONS toolbar item provides a
							listing of the tagged sections of the Inline document. Sections
							are divided into three groups:</p>
						<ul class="reboot">
							<li class="reboot">Document &amp; Entity Information</li>
							<li class="reboot">Financial Statements</li>
							<li class="reboot">Notes to the Financial Statements</li>
						</ul>
						<p class="reboot m-2">By expanding a group and selecting a
							section item in the listing, Inline XBRL viewer will navigate to that section.
							When the Tagged Sections feature is open, the Search Sections box
							will additionally filter the list of sections to only those
							sections that match the entered criteria.</p>
					</div>
				</div>

				<div class="reboot card">
					<div class="reboot card-header px-0 py-0">
						<h5 class="reboot mb-0">
							<button class="reboot btn btn-link d-flex justify-content-between align-items-center w-100" type="button" data-toggle="collapse" data-target="#help-tagged-menu">
								<span class="reboot font-size-1">Menu</span>
							</button>
						</h5>
					</div>
					<div id="help-tagged-menu" class="reboot collapse" data-parent="#help-sections">
						<p class="reboot m-2">
							<strong>Information</strong>
						</p>
						<p class="reboot m-2">The Information menu item provides
							additional detail about the current Inline document and
							customizable viewer settings.</p>
						<ul class="reboot">
							<li class="reboot">Company and Document - Basic company and document
								information</li>
							<li class="reboot">Tags - Fact and tag (standard and custom)
								information</li>
							<li class="reboot">Files - Files used</li>
							<li class="reboot">Additional Items - Additional hidden data
								that's been tagged but potentially does not have a corresponding
								location in the HTML</li>
						</ul>
						<p class="reboot m-2">
							<strong>Save XBRL Instance</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Instance menu item allows
							an XBRL instance document (*.xml) that is extracted from the
							Inline document to be saved locally for use by software
							supporting the XBRL format.</p>
						<p class="reboot m-2">
							<strong>Save XBRL Zip</strong>
						</p>
						<p class="reboot m-2">The Save XBRL Zip menu item allows a zip
							file (*.zip) that contains the as-provided XBRL instance document
							and related custom taxonomy files to be saved locally.</p>
						<p class="reboot m-2">
							<strong>Settings</strong>
						</p>
						<p class="reboot m-2">The Settings menu item provides the
							ability to customize Viewer features.</p>
						<p class="reboot m-2">
							<strong>Tagged Fact Hover</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">On - Displays the hover fact review
								window for any tagged fact*</li>
							<li class="reboot">Off - Hides the hover fact review window
								for any tagged fact (default)</li>
						</ul>
						<p class="reboot m-2">* May impact performance with certain
							web browsers.</p>
						<p class="reboot m-2">
							<strong>Auto Scrolling Position </strong>(This setting will have
							no effect on IE 10 or Safari)
						</p>
						<ul class="reboot">
							<li class="reboot">Top - Selecting a fact from the Sections
								Menu or the Fact Menu will automatically scroll that element to
								the Top of the Inline XBRL viewer window (default)</li>
							<li class="reboot">Center - Selecting a fact from the
								Sections Menu or the Fact Menu will automatically scroll that
								element to the middle of the Inline XBRL viewer window</li>
						</ul>
						<p class="reboot m-2">
							<strong>Highlight Colors</strong> (Use the save and reset buttons
							to save the selected setting or reset to default)
						</p>
						<ul class="reboot">
							<li class="reboot">Tagged Data - Change the highlight color
								of the tagged fact border</li>
							<li class="reboot">Search Results - Change the background
								color of tagged items matching the Search results</li>
							<li class="reboot">Selected Fact - Change the color of
								highlight border used to identify the currently selected fact</li>
							<li class="reboot">Tag Shading (hover) - Change the color of
								the shading applied to tagged data on hover</li>
						</ul>
						<p class="reboot m-2">
							<strong>Search Options</strong>
						</p>
						<ul class="reboot">
							<li class="reboot">Match Case - Matches the specific case of
								the entered Search keyword</li>
							<li class="reboot">Include Labels - Extends Search to
								include tag labels</li>
							<li class="reboot">Include Definitions - Extends Search to
								include tag definitions</li>
							<li class="reboot">Include Dimensions - Extends Search to
								include dimensional detail</li>
							<li class="reboot">Include References - Extends Search to
								include authoritative reference information. Optionally specify
								the reference parts to include in the search (e.g., topic,
								subtopic, section)</li>
						</ul>
						<p class="reboot m-2">
							<strong>Help</strong>(this content)
						</p>
						<p class="reboot m-2">
							<strong>Version</strong>
						</p>
						<p class="reboot m-2">Indicates the current build of the Inline XBRL viewer
							application.</p>
					</div>
				</div>

			</div>
		</div>



		<div data-test="taxonomies-menu" id="taxonomies-menu" class="reboot right-sidenav col-sm-3 bg-light invisible">
			<div class="reboot d-flex flex-column flex-fill h-100">
				<div class="reboot mb-2">
					<span class="reboot lead">Facts</span>
					<a id="taxonomy-menu-secondary-toggle" data-test="taxonomy-secondary-toggle" class="reboot float-right click">
						<i class="reboot fas fa-times-circle mt-2"></i>
					</a>
				</div>
				<div id="taxonomies-menu-list-pagination" class="reboot d-flex flex-column flex-fill h-100 w-100">
					<div class="reboot pagination"></div>
					<div class="reboot form-group">
						<select id="taxonomies-menu-page-select" class="reboot form-control" aria-label="Quickly jump to a page in the Fact Menu." tabindex="13">
							<option class="reboot">Select Page</option>
						</select>
					</div>
					<div class="reboot list-group list-group-flush overflow-x-auto w-100"><span class="text-center py-5">Loading.</span></div>
				</div>
			</div>
		</div>
		<div id="back-to-top" class="reboot d-none">
			<button id="back-to-top-btn" type="button" class="btn btn-sm btn-primary">
				<i class="reboot fas fa-arrow-up"></i>
			</button>
		</div>

		<div id="dynamic-xbrl-form" class="position-relative"><!--?xml version="1.0" ?--><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:0e578a32-5d52-4fa5-bd50-6a69d32e46b1,g:64d64043-0b2b-4d0b-82b3-a8ac7a34a7bf,d:a10991337ee64bfe975ff621c73a0ff6--><meta http-equiv="Content-Type" content="text/html">


<title>mrk-20220331</title><div style="display:none"><ix:header><ix:hidden><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80L2ZyYWc6NzMxMTNiNjA5YWJiNDRhOGJhNTY4ZmY1MzJjOGJhMmQvdGFibGU6ODE5ZWE2MzViNmUzNDQ3N2JlNDZmNzBhZGRlOTk3NmEvdGFibGVyYW5nZTo4MTllYTYzNWI2ZTM0NDc3YmU0NmY3MGFkZGU5OTc2YV8zLTEtMS0xLTUyNjky_f63bb275-8f49-44c9-ac06-07393da6ad4e">FALSE</ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80L2ZyYWc6NzMxMTNiNjA5YWJiNDRhOGJhNTY4ZmY1MzJjOGJhMmQvdGFibGU6ODE5ZWE2MzViNmUzNDQ3N2JlNDZmNzBhZGRlOTk3NmEvdGFibGVyYW5nZTo4MTllYTYzNWI2ZTM0NDc3YmU0NmY3MGFkZGU5OTc2YV80LTEtMS0xLTUyNjky_d873ca78-eaf5-410d-af3f-311de6fd6142">2022</ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80L2ZyYWc6NzMxMTNiNjA5YWJiNDRhOGJhNTY4ZmY1MzJjOGJhMmQvdGFibGU6ODE5ZWE2MzViNmUzNDQ3N2JlNDZmNzBhZGRlOTk3NmEvdGFibGVyYW5nZTo4MTllYTYzNWI2ZTM0NDc3YmU0NmY3MGFkZGU5OTc2YV81LTEtMS0xLTUyNjky_80cadff0-8b27-451b-bdf9-f570f3ef67ab">Q1</ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80L2ZyYWc6NzMxMTNiNjA5YWJiNDRhOGJhNTY4ZmY1MzJjOGJhMmQvdGFibGU6ODE5ZWE2MzViNmUzNDQ3N2JlNDZmNzBhZGRlOTk3NmEvdGFibGVyYW5nZTo4MTllYTYzNWI2ZTM0NDc3YmU0NmY3MGFkZGU5OTc2YV82LTEtMS0xLTUyNjky_204194ba-0217-4cb9-b14a-e07906fbb62a">0000310158</ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80L2ZyYWc6NzMxMTNiNjA5YWJiNDRhOGJhNTY4ZmY1MzJjOGJhMmQvdGFibGU6ODE5ZWE2MzViNmUzNDQ3N2JlNDZmNzBhZGRlOTk3NmEvdGFibGVyYW5nZTo4MTllYTYzNWI2ZTM0NDc3YmU0NmY3MGFkZGU5OTc2YV83LTEtMS0xLTUyNjky_155656e5-1f4d-41ee-9787-f002357edfe0">12/31</ix:nonnumeric><ix:nonfraction unitref="number" contextref="i6aaba7e8a9ea49fd9f1860628d45fb65_D20210602-20210602" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNy9mcmFnOmY5ODYzNmNjNWFiYjQ2NmFhZDVhODA5MjcwZDNjN2VhL3RleHRyZWdpb246Zjk4NjM2Y2M1YWJiNDY2YWFkNWE4MDkyNzBkM2M3ZWFfMjc_31d64eb2-33f5-4ff9-8825-8cb01542211e">0.1</ix:nonfraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaref xlink:type="simple" xlink:href="mrk-20220331.xsd"></link:schemaref></ix:references><ix:resources><xbrli:context id="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i800b2b8dc02b4e7cba73396b083422cb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic9befdfafe184463a85f53aa001a48b7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib1aad4c6f9d3496281510ea08b1c9ecb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A0.500Notesdue2024Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9daf0dea25f74143a61fce222a8118f9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.875Notesdue2026Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9be4a45dc2434ead944d7e7db5e5aaeb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A2.500Notesdue2034Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia688aa3beffd40909a4c75a429723668_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">mrk:A1.375Notesdue2036Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7362b5c790a345339a6b199ec4044889_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitnumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitnumerator><xbrli:unitdenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitdenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6a111b75f22542d9a20b9262e2295716_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18adaae581f9469896445184e25ae852_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i866b60422112474194bfe1e56bc43a8a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6e28b8146e48e58a44f95cd279905a_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9541a59d786444c0836c050cfd8f88bc_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="dei:LegalEntityAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice580b1f0d804d4eb27ba4913705b736_I20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0634666520a4c228e24847f4cfd662b_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:TransitionServicesAgreementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaed879fa16e64bec9790214d26986664_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icec6e11c8292484daa19574361b29faa_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RelatedPartyTransactionAxis">mrk:ManufacturingAndSupplyAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e823ab9d0994c558932b1e029fc559f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i04c57aa042974d61988f663829946a9a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7338ae38e1e34ab9b4c22c66456eefcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aaba7e8a9ea49fd9f1860628d45fb65_D20210602-20210602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:OrganonCoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-06-02</xbrli:startdate><xbrli:enddate>2021-06-02</xbrli:enddate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i284dc6709bb44029afc31b29037d6c94_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c00fc7b88294d8b927e27f45cb8fe15_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:DevelopmentMilestonesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i746e8a7c0a1c498ab4dacb68c18a9554_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i708d360a06994f3d948b7b63d03cbfbb_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ief1437f601034f54996109a141e66f86_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6563318cc424274a7067a679835cc3d_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:ArtivaBiotherapeuticsIncMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2a83d6caa0d74560a0ab857f415a00b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:COVID19Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie5d042ddfaf346f1ba1da6482da61e9e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic33dcf7ddd324b24a90d58c352183695_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d2d79e90df442a98ec0b0c330a71f6b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i075513e9c1114e55a1234d36528b2ef0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i85f6a0d65b0d429c964541ef5de96b19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0323c8cd1d7b457aa9351a4fc1a06259_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aba0e51340f46bdbd5362d2eab661b3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idc3fa49797e441079f219f636745aa3a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idc283b903bf24c4f83de222e93631982_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd49b180ffac41cf89b375262bb4bfcc_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueKoselugoMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic1ee42be285d46419401f3f81e0151ee_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia9cac74667bc48efa05255f7577ddb2a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab8ace176a2c49b7906c55bbe952cfcd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8265e0dd48f248a5bb9def2083b37474_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i19f707bad99e4500b6c587c05f6beabc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ief83125ccfbf4f128673e94c4677f01e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8af87705c5664e8284b95d224f72b26e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4514555fbe1446c59007e8c8f1b49a37_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7190d3f7c376447d96add2c0bceeeca4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b09115003e494298cbc95d98f804ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b24502dbec348cd860a15e4d13142d5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1584a6a8ea624a9d91aedd55be353743_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie68ec0adfa4d477e871d44fb6b610e62_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26044cf92e0440a5af9b31fd2cfd6daa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:AstraZenecaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac7328d91d2948958236b87e13bdebe6_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-03-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i146e5552a39c420c9d99509c7b0feea1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3af0330d453438f98d1bde0f5d58922_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91177e6abf9042c885ee81412dddb7f8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic189df92d25646fba47e3536e145b8b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i878d9d0a26c1439fb0957325d44c493b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8caf4fecb9094fbb885141dd8b5ab6c3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i648df1ab6834452390cdd6bcfa03a089_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id9e59dbcc01b411082fb58e643fe4154_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibd50e5543ee24ef1834e21e5ee069c4d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7a127b1be90347ea84e67018e6c84107_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i56d8870074884fe19b55cc514001ba49_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id45fa1df009f4ca480ef6e4ade4cc469_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c363b8205844f41b1f842b551c0a954_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5452402de8e24767b0d13c7da9e9976b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9822411d5ec84b17831f658227c3f09c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:EisaiMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf2bfc97e2b646b08a81902523e34894_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-01-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02abe152752b4efdb54396b0af1db5dc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08d753963d2944928e751d73bbcf303e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4f0445baeb4f61b8ab5688ea1c0d8e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0eb58f6cc86240b9820064f968b16313_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0023dc3ab76c4a5c99bf9025876e7e29_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3efb3dc7010d4a86944ff34f6a2a1c3f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9de20bf0cf994bef95335ac29fd55faf_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i85cd454c231b4ef2899b619f8ba49ddb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i636d7ce145164faf906ab8051d81f273_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic55d32e7c25b4cfaa3bc2a9613c4f778_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e525576197f43e5807f6f0b2804224f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia7fd8f2469bc41b8af76d26086d01004_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i843bba0dfb2c4037843974aeb4c255d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1338709b904e470a949ceddec7751620_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c1c0e9c98cb46198b4b4eb8c46b1d2e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc64220511304158b21dd32ddc6b51d7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c739a0342cf48ceaadce72bd39cf97f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i263e6282debc499eb206982dd9529223_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BayerAGMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="market"><xbrli:measure>mrk:market</xbrli:measure></xbrli:unit><xbrli:unit id="course"><xbrli:measure>mrk:course</xbrli:measure></xbrli:unit><xbrli:context id="ie2a02c33f0b44e148e142580b1ecd20a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i211feabf348242a592ceb0456c74abfe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0513d264fdea4a348c635a6b4e044dc2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i02691f575b99471e8cac5270a76ce9c3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i67e7661ddcea45db831890aee08fa91f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4e4651ada5e442508352a1606884ed94_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia15e4b94c41c4936a90ba1d76a8ec4c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i97dd799f119d4acaa239e6efdf70960f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icc51509ec0c345079307c9662151568f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ff35c8e4fe944528f8b17c81e715975_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:RidgebackBiotherapeuticsLPMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsPayableAndAccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ed92363f93647b79f87158925f98db5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib65300c2eb314c6a90964489ddab40c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6302fc043a8d426fa6cd462674ef17e1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c81597249484c5d862395460b415ba1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:SalesBasedMilestonesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9866070ee97e4d06bf9db13bdb8d5c38_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3782aea0e3041b7834c00ecab4a6fcd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:CounterpartyNameAxis">mrk:BristolMyersSquibbMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ContingentConsiderationByTypeAxis">mrk:RegulatoryMilestonesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0ea56790543f46faaadc62f8684bce2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a4dc6b96994ee4ba0841ba49735e35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if4125cb4dd394284a4580f883d77350d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2fcfa9624723489ba6a80c70b7d5c289_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1aa6936088be466ab1be753be2e716ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iff49428b271f42b6bced0e3d8d872ca5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8b826ca8aafc4e629596840de918f17a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i993f80b2b16d45fea1697609818b297a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i215dd120a9954b8094887d237f17bba0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifb80d581758541d8a7db1b76793efce1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idbf67844f93a41efaf5174ec247bd79a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6b88a67ffb7240ab8f7dd5fe46f74ce3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c0e45f79c5640c483ef5639922c9662_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id92474540ec941eba6f42f5fb3483971_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8da6b50745e3485f8bda19fb7667c337_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7d47f975397341ee91942114a468432d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6d7dd7a28a46403fb3f8310dd7946c8e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i756643c6ceb64997a6af745ef2b23dae_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia177d15a13db422990d77d15c46a7332_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib3bf9a60a14242b9a59afceaa84c88b1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i083001a6813642d3aadbb46f80ecd098_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6ec4d2ba98004e5cb08557100661cc87_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9120aa0d7e0d44c792e46468e63e93c1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0e9ca0ba953440c6bf9ef5d5e994ebef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib149b55e183840ecbe597bc6945ef0ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie73073b284314c7d8748e4f99eac9f48_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id0e1b1a70ac9400799d8b3cb608817ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5b7c3ee57c364d2093f51a0b7ac798a9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie6b96c327cb0456daa06604876c3b60b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c89529c8bf94022bd0be4c3eadfb62b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id5811fd28eb74cd68a897f8628ed8d8e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie19c73faaeb2467aa49b692beae087db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c1fbaf16fca45dda0edd4d80b6b36f1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia40c6a005a8f4eedbfda0c60ee32f379_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1911669813834f89b0648370d8e01e4c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i104aaab5ee9c40a2bff8cae945a1b866_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic22973668e3a46059375ee40f0c73712_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i132549b6a36942d69f014bf8582f442f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9b3e1c3e201c42b29bd17a1add2ee2ba_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i05798371747b45c199001751f7abe23c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f2ae88aa8d14c12a33bf4d8e8fc5f54_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c7500ab772482a92fd2e5dac4b47ef_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i142090cd4b09439285bc712604cc568b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7d63b752e60485fae90b17ee58e976f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">mrk:AcceleratedDepreciationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39b6d99b38ba4e278974adb8a832ef19_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1131c496a0ee4c2fb87142bf03620fce_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib23f5de2e6364aef8d294f417184975c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4bf5519b00f14ff5a470c47005b300d0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i06ec6961ec5f401389c48e535ff46fb4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i99c9a3d4ebfd426db78c80d3da415662_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i04c957f5468648da9ae763ce245aa7b3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifd5cc35ac9c349e8b4c1ac63211fa54e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ica54be2dee1b437d88bd886a3f2565d6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2f50717d64cd4e5c81ae4cee1966eec7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id627fe4c400c40eca27607598ac180f5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">mrk:EurodominatedNotesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6ceecbab094742dfa41de3ea9a97a557_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="interest_rate_swap"><xbrli:measure>mrk:interest_rate_swap</xbrli:measure></xbrli:unit><xbrli:context id="i6e0b94edb4164c418f9f13e185935729_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DebtInstrumentAxis">mrk:A2.35NotesDue2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8615839501ea408fb7490e432802996e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i156e7362feab48919b4eac83c9ed17e5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LongtermDebtTypeAxis">mrk:A2.40NotesDue2022Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic787f6bbc99f421884366f628bd5b20e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28d0c434076a41b7b58281c1421da539_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">mrk:LongTermDebtCurrentMaturitiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84df9ebcb6e249b19b8c65abf2f51afa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic80869c9916c4f3182f5f1350d321cb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic58e613848c84850b802e16f2446e287_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcf11f7d39174deb85575c3236863ed0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf10bff6ef994f5390993e6748298938_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b526e855cd94aae8975c28ab280e3b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aa9308da6b34a0485af1842344b0316_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6bb899590e49088d607dbe3f6d0b39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib604f9403b4d4bf89b2a4adb03975da0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b36a47629843b99a34c827ca9295e1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d9a7e5941144369913a515e4e7bfc6_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168e76fe57954e69a56f509855769b31_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i376cb0cd1f4a49d39b22e1d7c29a4444_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cd283e82c243c88676c6ae6dcb0ee7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16730a36e519417bb54981b32dbf2cb9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1c161bae8ad46a79a1341906268cb7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8bddef458f3b4c5fb9672550af5f7a97_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8b41770f9644bf59fb55850d5ceb2e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife71d5c0fc5f4f848de0b11fdd67eea6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic1f02aeb9ea1476fb0c433f8859d06c4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic1d7d0b1ad9945b1a7ae596cacb65fda_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2fd8e131edc14305952828bea95e6c14_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i65bfaada786f453bb1ac34787c8e1216_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i61c1473d795f48b0b06a08146f9355ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53aae0c518854acf83522df504d07e4c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5256e90e8c7c488599f91eb12c5ca8a5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4a635a711e444518a5bc98f59d33afca_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i86bb9e8cd0bc4d449fcb29e8666c0a9b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeFutureMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i14e42ef5c15e4cc4b90826fe4fe87191_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2493ec10d2914f8882dd1f55bbe1cd74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44167d75dc2f4d418e6ddf1fd6751beb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44ce7d8d13ba48ae8a571e69a7f54ce9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bf4a45e94534529ac1947bcc0b3a138_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0d747a14a1549afafa300095b8cbf00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bfae8729b2f40538fdad12a6f09ee7c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2215a71340744b95b2bfd090a9c51f79_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief69ef50aac84d68859ca7c590a9fefd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie9a0d28cc055444882014830f4dc1e4f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquityFundsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i19fd8267373c484eb4577b24d021f871_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b3ac36ac61e4e30a59026ba389c4521_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78c97e839a044ceca9dc4c6d46a7e30e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icad87ec0429c4aafa2367208cc9a35bb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058b744e350e4d37b18173eed07706c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00be2778a35042578ac5940ad025a162_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e2dd8c1250d42feb61783187b40b51a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ac5eca5208c42ca9da3f2e492e3f7ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1ba976024d048e59f4225613ee1e674_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11037a410e5649299700d6b8f3a0432d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i508c444df6354c518af0b243171959de_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a617267a104bfc851fbebc1558cd54_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5afe9754eff748e086f47c6c114acb74_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2016debe972145bc98c3c25f1aa41b87_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06f313ec9d8a4dc1a75bccac7278fd22_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24c3193be6a042d0af52807bce70ecda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cbb3082e2644156843c8824062a7557_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if85d5119138f46fb8cdbf0fe1efaf24b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5781272ef99e4f83bbe40ea807776a10_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72fc65d345c746a6ada52bf9d2e84f7c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e8ba41deb584dc59a7bba3cc7ae5669_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89063d17a7524107aa093d098e3dc3a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4526b0eac0744eccbf73718ad53e4f2c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c311677e06141488580cf4163bb8dee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c153486b35548988b8e854138265838_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaedbd4bdda9646cab4a985f1707ec76b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ba131d09314cdc8ecd3b07bf530589_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if030bfa28e754701848677a020bbae82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i595357f3962a47df94dfc2693b9fbcb6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873b5a8d74304ec7b4354dec1d9f90d7_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f6ff63ba5be4b52aabecb169fa52722_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5be3a3163942b98163c1596faa6f6c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e360316d573495ebc4756cad1721c2b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i506d5cfd75cf461da8ce1b0b5a919a4d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03f146fa9b2349669cba9352f1d8e8b1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff1a794b0e884fb2b74ec29d1b022c8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f72cb1f8564c60979721b97816a447_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i462a05784a5d4fb390f1ce1698ae9d59_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ae92003c3ca44eaac051a7ccb801cd9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i781fe021baea49cbbbadd17d2d3c23c9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821128012d944b9b89e26d92f448187f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf90f5f8b4f465a9b2f2a812adeb5d4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc703e9ac74452693a59794f39a39fd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia33e3ebe6ac44bf380de57dedb6df3c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec8f14e1d6d3489c9e2345c77d66d5a6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a894e3c7de94746bb7076620527450b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b749683577344bb9d612ab4ee18010f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68f391c66714b649ad9f46eca9223d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90699b79bf61454d8bff5340c54d3eb2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib191c3745a5b437abb310a27c2b61de8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56f64528a30f499f8acb3e5e48ddc37d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ideda08d68af841649ba8a54a96663719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09c83e8675a247d08046df72a466fccf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafd08e88c9f249c0a805905dc35016e3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1167fc16115840aa8ffc6b3af27b7649_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8198a8617a6e479ebc1b1e733a86998d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2dc3737f560d4ebe92d5e7eb5cfd7d0c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45a789d9da35420fbfe7638ebd042627_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77789de03f614d58b866b84ba8a0f6cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a47b1e009574aa3aaa91a70d30a5858_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3fd373a74d74951a1e4cd3e326cddf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeOptionMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e748a24f084da795c60693831ed5fc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i008adb89e343430489011984e43b69e8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia84cc74eab5647dd968209fa6a792fb2_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfa215068fd4942971b106029db9040_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaec951ec4b5e4261a5ab63f0bcbe89a1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0759b405a04a4443951e4f30e3abd266_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i136dd348c81a454c8124ea6791b9afa1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aadef6c3c7b4eff8169224531cfd935_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cc8c4747c7c48f3a46c864d8d719810_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc764995a38e4fb386a52f5427d915bf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e3c4a0d9dc842b0b896df5bdbf8f9c3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i296c894765054ec796a8893e029f09e0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bcd093a311846d483b85ff16cb11e50_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis">mrk:SanofiPasteurMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9074269624d0486f958a02678eecdb2f_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startdate>2021-10-01</xbrli:startdate><xbrli:enddate>2021-12-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i33f0265719e0496eb57d78b92ca47991_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ab33cb07df549d893db0991189976f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoryNotExpectedtobeSoldWithinOneYearMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i303c573a9967470a927cfd2797389b32_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1748811c5bee4a9d8c37844a62128658_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:PublicUtilitiesInventoryAxis">mrk:InventoriesProducedinPreparationforProductLaunchesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf694a8cdad74109872af987bd236b31_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="case"><xbrli:measure>mrk:case</xbrli:measure></xbrli:unit><xbrli:context id="idee85c8998654d22829a19bfaa792815_D20140301-20140331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:FosamaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:FederalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:FemurFractureLitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2014-03-01</xbrli:startdate><xbrli:enddate>2014-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0c5975a461004aefa1f84879bc18ca78_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>mrk:claim</xbrli:measure></xbrli:unit><xbrli:context id="ic249d5f64be94c4ba42d8e0d08f01af1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:OtherStateCourtMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ce78d919a424343b550fe2aa711ab67_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eebc9efbe164eca98287ede312ba518_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">mrk:ZetiaantitrustlitigationMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b4e06253e024eeebe9194651ea94b81_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iec7ed14666dd45dcb45d6638db9a83a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:LitigationCaseAxis">us-gaap:PatentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaAndJanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i44e0eaee7a8f4256a0faf20e53fff644_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6f5d387d9334baaaacde5a04c3a0c51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">mrk:LegalDefenseCostsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide2da8218e1c4af4825a176997cbbcbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1443f0f0b960439dab747f16cc5bc588_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49237e599c524d95ab14bbe9d7c419f6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab28075d402e4ad9ac4ac4c3641fdf1d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5cb2adf38d934a58bb760e95785409a5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42a93558d82f406f9ad4a89f27edcd96_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied574a7294fb41989cbb70d3122b883a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8ad697e3368343c7919b7dd3273b3410_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iad37d7d7a2e348e2bd3eda54cebe4097_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i514acae560c54b4bb8231d1ce5dcd76f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifb57492bab6e48b7836070385115bfa0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53a0a89ea3b54892a65055ce371fb98e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14867d580e04b399eb725d467bc805d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b8a21f43da47c1ade213512e51477f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68676726a1254cd4845299523b924c36_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie684996ed0954f7e97d7fee6bbde21b1_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfa93baa9609499080ad1e1f74dc86ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84b4767925647209c5222bd0a0dbe6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1531c1718983403c863b19ea7f471a60_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if84b5a70a078433ea9402fc49b7c46a8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3887784c2224aad9004e572def3ab66_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce2e4b1a08045b6b19059f506912c04_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia466e356c7ac4d43b134063092b70bec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie136701fb9f24134ae604f5b6f0c1970_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifbc101a99c394b61a87e53e12bd2c43d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i93f7b31f62a84d71bd2d076d745e615a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6522f7a5335d4e668aa0f115930308e9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic95aad46020143b09177438a9c4b2837_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i569ec33f48d74348bdd4d6f901790fb0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20619e693d1542d58ca14d0e7360873c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ddfa6cfc2540b09aab7403b62c4afe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8b43a3143c447289f9e943f75e08163_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0732fd93fb42dd939a8a10b16cb8ec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13b37526517428c88988a9ca38929b0_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cb2f0fd7de9416c874ac85ecf17441a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia2a29800f66240688de941c099b47bd0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieff37403743248c6b0412f84a58b886b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4997b6e3663c4f838b0a7631c305249c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1a0cf1b8de8d4747b40955501b90028d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-04-01</xbrli:startdate><xbrli:enddate>2022-06-30</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5545d6274b6d4e7ebf69a25bbe09d26c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i722194ef527244e7a0dbe92e91b2d199_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f59125c6bbe48bb88c3cfe119fec9de_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id61a3e58809341d7a4d794616833beb7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb28ff42f1b4f8e9eaa37f6e70aee28_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18d94e3476884c45be0248c4ec69fd85_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3b973ff519747f085a3dc65ff1c1d1e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40b4346129b5496b92f90d13a2ab678c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98eb42d0251f4537a6f17d79aa48cb2e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60156c387cf345abb90a9ef946ec3248_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44a102637a5141308efca9ba686f71c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ca2053e683b45e3b6831b4ef691041f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i54569a21dcd945d3a0ccd5c1fa57a69d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia60c4136abf045e5b267ba9a6119f8a1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5af03731af2e458f94fb496c82505c6a_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mrk:segment</xbrli:measure></xbrli:unit><xbrli:context id="i2e20d7ab5de543189c7cf8412b527d91_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5c74c81f5c5848f7b6e0d02515994746_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i59f0a1b106fb4080ab3a1f36cf82f84e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2a397fcb3142441ab06e1baf08c9a722_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6cef69b39c01439c999f212fce44ae46_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8eb7b724f079410499ef45133c491127_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:KeytrudaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1378f05e1d974c3ca238effcc1061478_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8f1bdc3bdf3b4a73bd66b0c8de1a282c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d3b992d66c145ee9b4de5a44211145a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2304d957e48c4123ba09bda499b2d23e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic70d2ca596904f71a73677ba284cc40d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0ad1b075422749bda5cab7e535626e43_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AlliancerevenueLynparzaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie39cf686456342a2a5b66bcf8844e2e7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie59504a27285489990a160f7597466ba_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i10c8790583e745e5884414f13c237f59_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d85c438f0794b93b403a542b9f547e9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icdb3340ce88447fb8ec56ddedb0a9613_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2777ab5df4a04c53943c51b99e654204_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LenvimaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i430607cc58d54dae9f78ee68eb170d71_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba955f563da04b5bab9409f14b1489c9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4c2ade46f88949858cb25d24064a3022_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1755d070f6e64a8c815d655fa303d6a7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if66aeae0bba947d1a8fd303f4cd0fb33_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueReblozylMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3c128862bc5343b087e092c74da567c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3504a83c127d4e359c262077a8ad4937_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibe365a7ec2da4ab3ba5739bdcc1d5b43_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c48e69a260a47678c638d3f0443574e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5ddb3fa9a42640bf8f91ebf091b18bb2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i838bf6dbbb1441a38d01e394886cd47e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:GardasilGardasil9Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia95362eebb4d4129b5da0bfea68690b7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i388d1c7fcb724149afdcbc135beb7bf1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic287bd3ac4174f009f5fff050055d549_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i53447d9d3c8f4921905c3f995cfa0af1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4d1c72d338764cd9b5c9993a8d7dc13a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0eea09aa7ba84aec98f08abd7dbb2d78_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ProQuadMMRIIVarivaxMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idd18a522fe054206a57830a86c371f89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5834efb4cd2f49a98240297687acd797_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8aae9208f3d8457e9b21275c1d73198d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1fed20a2ab2c48cbac68fbcc8bd07eed_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic9d2a7af1b184d2ea6dc8cbc5e01096c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7ee9e5e8e731421fbf23451888573a74_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RotateqMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b676ade4f634770a2257c0bb201fdf8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i83aac4908f344299afbc6ae433a1f0af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icb46708dbe9746aba6e4befe3b17efb8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22eafc9339474ccfa21087916f78f6b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0dcdd3046920429498dad4bae9f17593_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab0182afac194a5fb81a1c96977cddcf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:Pneumovax23Member</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8052b0b3db74426782acc8b83c74328f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1864645c4d0744b0ab18f7faf2df55a3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib212bb0719a14f2a8f94c612a65306bd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i33fbbd3074a14a4093926946d00bf9ce_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia43e0b0a29cf46f6aa2e4a25f68539b2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4fae42aaa56041e698ffba39abde1724_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:VaqtaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9caf3514be7245078400fd569244bc9e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0c98d3de72a46189d71d82351a42f04_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8dd109f470494dd1bb8437978682a1e0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i857899174bd6427390552a84e60057af_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4b6eed4d805a4aeebc6c7f0360690d12_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia7871d0715f34b86a8252114d3825cf7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BridionMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0912660964c148c5ac628105e11a43de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7b6cbff393cd412cb163a3c1d00ddf02_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="idf506a2ad624416f8c885812d21a79e5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia8f26fbda981444bb87c932a8c8b22a0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic581eb34f89d4cc88fef686876979dac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic29d1c42753f4a70a8e0bfec27c982dd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrevymisMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibb6bcf16d7634857b3a41025fc1e5a48_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i31ef62147d294376ad3e6b572d5fa670_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i11d11267dbc74238ae8ca79161f06bbd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i22d9aa0f9b2b44c38916d0502515d3aa_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i42e26677453249db9ead107c4de5b019_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i04e6e1b20ab942b0a2f7ae504b7566d5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:PrimaxinMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3bb775fc2a5449b4a22e2aa06c800df6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e65bdf4cd884592969b00480a8f084d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib7c4d6b47ddc45aba6614bd2d7dbb95e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia0154b7a75a64b6288d5772b8f5d2e96_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if1bf26dd8e8f4dd3b9c1aa19e216657b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i55fcdef6d50641ada8cbf2dc6e04923d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:NoxafilMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6c302287c10d4bbba92104de6015674b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i51625423201f4036aaaa3448bc46e451_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8a92cf715e5748528d2cbf3f4e939a8c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8845af6d649d47a1b15777a446d60622_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia67d0514f105435b8cc5eb4a4d139459_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i294a9a3d373d43c8b9c22d4ae6652cd8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CancidasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iede1c9ca1a5f402baa8b5a1a52d8b34a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i250fe35362a1407db2b756c0a0b8e38d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaff416e85bc6431ea58ec7f72f7bfa35_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic0ab75e20bb74c62a2e6a8161dc8aa74_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ife864b353c764785a4fd4b6d6c5d4cd8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iab2ab04147f14d6b82d4eb4e2db69840_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:DificidMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id890b7eb85fb4ec5adaedafb87a577d6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i27cce489f4214d679226b5c1a2f29002_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if23e2963b2b24cf38e3d3a0273e7ff8a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i386e1dee7980403d90579134e5a034ad_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i98871de672bc4cf9a2f9c2893864dba2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0daa1a20926f47dba8e3f9d6f3ccdec6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:InvanzMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ieb0e057b94c24ec7ad57d18b99d50040_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1fda497fd81c49d1ac2ea34d0e8d89e7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ice5a78f7e33447faa37a77afb681e64f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i221d9f3c2d7d4781a89faee3f94a7786_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic3078484ed0d409abf5fde684285c4fd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i87e8d96cd86641c9a2bbceab6b5e3885_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:ZerbaxaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4576e4055fd34ac8b561387532885764_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id77091160deb4ea3a554852c67d0f417_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id52fdebd7d444eb8b2fada047216591c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2fccec8055c748b59514bf2db4c364e6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia34189615c3f44f5a67d7c54dbd83e5e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i466f7808cc7f4c93822461872f46cac8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AllianceRevenueAdempasVerquvoMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib6af84104ab04015bbc4e6c75ac1eee5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i78a96cf136e54d65b5505ce4b6553f59_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i3acadbfd1b374d1c95fab2bf669d36e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i144ca4b663ce43abb161ecdb7289738b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i78e605930642452d843e15d0458f5b45_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i389b83ea828049f79aa3b7472a1ab6e6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:AdempasMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i93120915ebaf4bd0bc59ae2b3fd1221f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i202ece257bc745d0ab5d95dd1197149b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if54e2cbb0b6b4117bc02076df5389b97_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if7bc6d405a2c43e1a20d5f9ee6f9a891_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib80cf6ef4ac0422cb4934b1f3b2e55de_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0483b507af3f43039ee3bb2e5e4fd59f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LagevrioMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iae02871fbc134bf98ef610b495a82e89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i16f81d66fdb946b193eda2ce7dd938e1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ice1929e1a7514fe6a29683f034c9675b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i639c1fa4f7e8493c8567be263134699d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i880fd33cce254b1680f267ef07d64b3b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13bfa8c23a6c456b80ecc1b51a699afe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:IsentressIsentressHDMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id12d23aaa8b2478d8967537b0f69ce0e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i00401343fcb744118f01cc535f510acd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i845ed8a825cd41168120c2947d015353_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib91461efd77540f090cbb84ba6705b1a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i384a11b2f6834b88925abd09a13e8d5d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i17c934d811824b10a26f34f53efcf99e_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:BelsomraMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2c3e534d81884c479a27f2b7c59fcca5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13292a2df1a34e39b930bab123f399a9_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iaa2af135a2604c0e94c271eedca94076_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i46aa67a564c54ba58235e0dae468d04b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if534ef43448248289888c3900c05a79c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icbfc0c60922645e7bf0f37a55452ecf4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:SimponiMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if5614b02cb16456ab7e83ce0861710b4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if9a7dfd597324f94ae1e71b3f6af49de_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7f6b9edb8b8e4f949c9afac42a3ac8ad_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5298bb50d64a41048da6da4a04a1980b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2b1f8f65e7884ecea84ef1dd35dfe143_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1d2d623551394f889c8c888bf7f2b9d9_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:RemicadeMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i212ddd8af81949fd8cd393de736a7f6c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i687695b299054f1981462e305070aab7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia96f98391f8b48db8fe6d5484e8e1bec_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5405f7e963764f13b153ed1803e7a5d2_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i72b4065eae864dfd93bda2580923b71d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie3f68079a3f040028ea0bdc9d042eeeb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanuviaMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b3b0ce0ab3b4f41a451e06195d62a3d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4c716dc1fa514d2f993c196fe3d53e44_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if3e23ddc07914e189538f083e1ad125d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i61536937a0ac42c491620f652f2dbaca_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8973bcd961044a5281efec8e23f6e50c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icf5ab1d2973f456ba487a84f6954b05c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:JanumetMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie2c39a6aeaa14a958580471dfc51ee3c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8535a1c06ba548a6b73396107ebec8a0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7076d79036d14c0faafccd118812554e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia1d7ced6b9324fa2991b658827fd9316_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i003b720f4b71442888b2d1e2aa744677_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9fe330b8315c4a97bc08fdd8a66f169d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:OtherPharmaceuticalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1f85bc45c38440e7921d6dcc8810ca98_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if83bee032b3b42e8ae62bfee1e18669a_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ide544608790948358cf81ce72951b721_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ie597c94174af4d3080b24040f97f6fcd_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i940a565e481444658f371bb6280b4a5b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="if3e3bb9ecf1a4310bad6d9416ca7a442_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:PharmaceuticalsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icfd78e52591248fca78b77b79c337185_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib318698f0b26449eaba9aebb81c2af09_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9f60150344394470aafbfa1fa5034ae8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1b6a806ead72464c82b3623135bc8567_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i18383af3d15545d7be0cf119645ba24f_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i689f14e1dd0a414baaf55098628f39ef_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:LivestockMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i919eda4a1c0042eba0c03bbf7a6753f7_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0587557c686b4a04bbbcc0624c6f30b5_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i0ed6c1a8ab034ca38bf825b813b3d1d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib31f6a3b25304b2b933451ed454c2e2c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ib26ae74a9cf34f3a8fe2534f4f3d8978_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia4932b41093243e09414fa51871cd517_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ProductOrServiceAxis">mrk:CompanionAnimalsMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7c38a413632b48d9bbc9b9e2167e547d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="iba4aa5e714cd445db9dc73c878ec26d3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i832f6c2312634b0c8efe98724d677a4f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id1ade9e4ea4e44a4a02621381fe81567_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i38114a565eee42cfb3866c874b66eb26_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i36cc3bf951424ddd9bd95a8877f34254_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="us-gaap:StatementBusinessSegmentsAxis">mrk:AnimalHealthsegmentMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i7b4419b653b14e8ba56a856ed72eac11_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="icec5a3da921945199b8a928157f0653d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia017ccd654a14a9a9e1beb2f5bd9307f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ic43c11130efe4612b952e3280ff31240_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i903b19cdc2174d5aa6f83e1099ddd056_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i69a378a7cacf4454a96200e18d69ff63_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i13dc1a7cc27b48ae966d1fbdc9d497d0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ifc5a92bedff6472d86337c9ad9998d7f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i39edcaf7f9b94ecbbcadf2eb6aaa704c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia5e3212388de4741bfbf8ede7fd7715d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i67837cf6ae1f432bb479a5d818e4d8c7_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i5fe49c5e8275436c9c48915ae0beb1b1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8370199418d341dfa57f78fc76f97e5b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i09120a7cb50145928e2cceb69ce5563d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i457eb00986ce4537a0b974a2ae7dbefe_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ia44515344512485e8df76049ac18fb59_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:InternationalMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i4f5ff3fcb89d427498588b0678cfdcd0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i9fdba45d4cc24dd2b4ce2b0668b04cb3_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">us-gaap:EMEAMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i175ececc8f324759bce16a986b23197b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i12cbfa0800eb4e0daf5239e28d6a0fb1_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i823435b3705e4f13ba33400ed97666e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i091a65baf09e4e87b90261585534d803_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i1e5059094caf46cb86bcb13fb9c7d58f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6f280dd8028c47a1a0b553f2d503416c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:AsiaPacificMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id7deb17350664f0a98fe1efcec5a5c64_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i6de9ef09922d477c812801d4a0d1a6e8_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">srt:LatinAmericaMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="ibcaace6f2a59466b9a8e4608f6f4c6a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i2e850ef397c144d3b7ca0fb1a8463120_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:StatementGeographicalAxis">mrk:OtherCountriesMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2022-01-01</xbrli:startdate><xbrli:enddate>2022-03-31</xbrli:enddate></xbrli:period></xbrli:context><xbrli:context id="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000310158</xbrli:identifier><xbrli:segment><xbrldi:explicitmember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitmember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startdate>2021-01-01</xbrli:startdate><xbrli:enddate>2021-03-31</xbrli:enddate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia10991337ee64bfe975ff621c73a0ff6_1"></div><div style="min-height:45pt;width:100%"><div><span><br></span></div><div><span><br></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODky_e4bae2b9-f80c-47f0-ae25-6f5810e3a8b9">10-Q</ix:nonnumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:219.75pt"><tbody><tr><td style="width:1.0pt"></td><td style="width:217.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt"><span style="color:#333333;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6Y2JhY2VhZGQ3YjBkNGIyMzkwMzg4NTUyNmZmYjljNDQvdGFibGVyYW5nZTpjYmFjZWFkZDdiMGQ0YjIzOTAzODg1NTI2ZmZiOWM0NF8wLTAtMS0xLTUyNjky_b1ddd41e-8d44-4e13-955d-ce6857746b38">☒</ix:nonnumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></tbody></table></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xNDA_a8f0d1db-d816-4444-8dc6-4c9894eaecfa">March 31, 2022</ix:nonnumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tbody><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:9pt"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6OWExY2FlYjY5M2I0NGI3NTk2ZTM3ZGViMTQ1YTZlMGEvdGFibGVyYW5nZTo5YTFjYWViNjkzYjQ0Yjc1OTZlMzdkZWIxNDVhNmUwYV8wLTAtMS0xLTUyNjky_8fd64f3c-62d3-41b4-8351-a175fa31bc3d">☐</ix:nonnumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For the transition period from ______ to ______</span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File No.&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODkz_126100e8-59bf-4453-aa38-8181e3ae5336">1-6571</ix:nonnumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODk0_550a1a09-c518-4e91-adaf-e5a45df12a7b">Merck&nbsp;&amp; Co., Inc.</ix:nonnumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.545%"><tbody><tr><td style="width:1.0%"></td><td style="width:41.606%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjU2YzM0ODNhYzI1NDI4N2E2N2RkMDFjM2I4Yjg0YmYvdGFibGVyYW5nZToyNTZjMzQ4M2FjMjU0Mjg3YTY3ZGQwMWMzYjhiODRiZl8wLTAtMS0xLTUyNjky_bb42d4e0-a2b6-47f9-8aac-d6fce9b35296">New Jersey</ix:nonnumeric></span></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjU2YzM0ODNhYzI1NDI4N2E2N2RkMDFjM2I4Yjg0YmYvdGFibGVyYW5nZToyNTZjMzQ4M2FjMjU0Mjg3YTY3ZGQwMWMzYjhiODRiZl8wLTEtMS0xLTUyNjky_7a689580-1711-44b8-9ff5-c332915b4a2e">22-1918501</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjU2YzM0ODNhYzI1NDI4N2E2N2RkMDFjM2I4Yjg0YmYvdGFibGVyYW5nZToyNTZjMzQ4M2FjMjU0Mjg3YTY3ZGQwMWMzYjhiODRiZl8zLTAtMS0xLTUyNjky_e95a0078-af19-47e4-84a8-1425b7c971b4">126 East Lincoln Avenue</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjU2YzM0ODNhYzI1NDI4N2E2N2RkMDFjM2I4Yjg0YmYvdGFibGVyYW5nZToyNTZjMzQ4M2FjMjU0Mjg3YTY3ZGQwMWMzYjhiODRiZl80LTAtMS0xLTUyNjky_95a3b77b-3246-41b4-ac0c-971d758ea725">Rahway</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjU2YzM0ODNhYzI1NDI4N2E2N2RkMDFjM2I4Yjg0YmYvdGFibGVyYW5nZToyNTZjMzQ4M2FjMjU0Mjg3YTY3ZGQwMWMzYjhiODRiZl80LTEtMS0xLTUyNjky_399e5c99-b302-4db1-b9ae-873b00318674">New Jersey</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjU2YzM0ODNhYzI1NDI4N2E2N2RkMDFjM2I4Yjg0YmYvdGFibGVyYW5nZToyNTZjMzQ4M2FjMjU0Mjg3YTY3ZGQwMWMzYjhiODRiZl80LTItMS0xLTUyNjky_73f584c3-b09b-49fc-9e62-86ba9e28a9ec">07065</ix:nonnumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices) (zip code)</span></td></tr></tbody></table></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant’s telephone number, including area code)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODk1_140b8389-d0af-40e4-8107-6bf4a2d8ffe7">(908)</ix:nonnumeric>&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODk2_a113540e-f2a5-446d-8230-41ccef3bfaa1">740-4000</ix:nonnumeric> </span></div><div style="margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.425%"><tbody><tr><td style="width:1.0%"></td><td style="width:20.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.011%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i800b2b8dc02b4e7cba73396b083422cb_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MzNkZDQ4NTJlYjA2NDUwNzk5ZGQ1MjhlZjU0NzJjMWUvdGFibGVyYW5nZTozM2RkNDg1MmViMDY0NTA3OTlkZDUyOGVmNTQ3MmMxZV8wLTEtMS0xLTY4NTkzL3RleHRyZWdpb246MDlkMDNjOTRiZTRkNDQ5ZWI4OTk3OTY3MDc1ODNiMjdfNzY5NjU4MTM5NDU0Mg_07bac4fa-71ad-4d46-977b-4be1d424dcf7">2000 Galloping Hill Road</ix:nonnumeric>, <ix:nonnumeric contextref="i800b2b8dc02b4e7cba73396b083422cb_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MzNkZDQ4NTJlYjA2NDUwNzk5ZGQ1MjhlZjU0NzJjMWUvdGFibGVyYW5nZTozM2RkNDg1MmViMDY0NTA3OTlkZDUyOGVmNTQ3MmMxZV8wLTEtMS0xLTY4NTkzL3RleHRyZWdpb246MDlkMDNjOTRiZTRkNDQ5ZWI4OTk3OTY3MDc1ODNiMjdfNzY5NjU4MTM5NDU1NQ_d81f5f80-49b4-4392-ac6b-ad720859a5df">Kenilworth</ix:nonnumeric>, <ix:nonnumeric contextref="i800b2b8dc02b4e7cba73396b083422cb_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MzNkZDQ4NTJlYjA2NDUwNzk5ZGQ1MjhlZjU0NzJjMWUvdGFibGVyYW5nZTozM2RkNDg1MmViMDY0NTA3OTlkZDUyOGVmNTQ3MmMxZV8wLTEtMS0xLTY4NTkzL3RleHRyZWdpb246MDlkMDNjOTRiZTRkNDQ5ZWI4OTk3OTY3MDc1ODNiMjdfNzY5NjU4MTM5NDU2OA_858517bc-258b-4ff1-ba6b-e246d10ce993">New Jersey</ix:nonnumeric> <ix:nonnumeric contextref="i800b2b8dc02b4e7cba73396b083422cb_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MzNkZDQ4NTJlYjA2NDUwNzk5ZGQ1MjhlZjU0NzJjMWUvdGFibGVyYW5nZTozM2RkNDg1MmViMDY0NTA3OTlkZDUyOGVmNTQ3MmMxZV8wLTEtMS0xLTY4NTkzL3RleHRyZWdpb246MDlkMDNjOTRiZTRkNDQ5ZWI4OTk3OTY3MDc1ODNiMjdfNzY5NjU4MTM5NDU3Ng_e1d6e36f-a24f-4f71-8366-8934a75ed90a">07033</ix:nonnumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Former name, former address and former fiscal year, if changed since last report.)</span></td></tr></tbody></table></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.557%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.571%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.735%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities Registered pursuant to Section&nbsp;12(b) of the Act:</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ic9befdfafe184463a85f53aa001a48b7_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml8yLTAtMS0xLTUyNjky_43651be8-0dc4-49dd-8e2d-fe2147a6a4dd">Common Stock ($0.50&nbsp;par value)</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ic9befdfafe184463a85f53aa001a48b7_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml8yLTEtMS0xLTUyNjky_aec185d3-b6c7-4c70-93ef-8a7bd75e3e63">MRK</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ic9befdfafe184463a85f53aa001a48b7_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml8yLTItMS0xLTUyNjky_3552ac49-8766-43f6-872f-84a0c74f2239">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ib1aad4c6f9d3496281510ea08b1c9ecb_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml8zLTAtMS0xLTUyNjky_cbb0950a-c6f0-466c-80ec-d84d3945aa6b">0.500% Notes due 2024</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ib1aad4c6f9d3496281510ea08b1c9ecb_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml8zLTEtMS0xLTUyNjky_1a3a4b30-b3fb-453a-8e2d-50e3bc70464f">MRK 24</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ib1aad4c6f9d3496281510ea08b1c9ecb_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml8zLTItMS0xLTUyNjky_2f69d892-da5f-4379-9297-98ba8e23937c">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9daf0dea25f74143a61fce222a8118f9_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml80LTAtMS0xLTUyNjky_6bfbf83d-30d6-4dbf-8471-bea07932cac4">1.875% Notes due 2026</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9daf0dea25f74143a61fce222a8118f9_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml80LTEtMS0xLTUyNjky_d49b7e0d-1fd1-4c5b-b9b8-d736899b7b1d">MRK/26</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9daf0dea25f74143a61fce222a8118f9_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml80LTItMS0xLTUyNjky_2465af00-1144-4b24-b548-2d9f943c3274">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9be4a45dc2434ead944d7e7db5e5aaeb_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml81LTAtMS0xLTUyNjky_8aac4885-55f3-4934-ac6d-8f0c90f18ab1">2.500% Notes due 2034</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9be4a45dc2434ead944d7e7db5e5aaeb_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml81LTEtMS0xLTUyNjky_f7fb3dc8-823a-4956-b500-5ece184c1ce8">MRK/34</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i9be4a45dc2434ead944d7e7db5e5aaeb_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml81LTItMS0xLTUyNjky_2b82c65f-128a-47f3-ba7b-8e1d26a1b50d">New York Stock Exchange</ix:nonnumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia688aa3beffd40909a4c75a429723668_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml82LTAtMS0xLTUyNjky_0d25757d-3963-4f7f-9674-7724c2a2d9bc">1.375% Notes due 2036</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia688aa3beffd40909a4c75a429723668_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml82LTEtMS0xLTUyNjky_807b8d52-54f6-4a0d-83b8-4e71ca600aee">MRK 36A</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="ia688aa3beffd40909a4c75a429723668_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6NDAwMWIzODg5YmZjNDE0Nzg3MzNiMjFiNTJlMGQ5NDIvdGFibGVyYW5nZTo0MDAxYjM4ODliZmM0MTQ3ODczM2IyMWI1MmUwZDk0Ml82LTItMS0xLTUyNjky_dc4e2735-ec90-423d-a591-44540cb3ec98">New York Stock Exchange</ix:nonnumeric></span></td></tr></tbody></table></div><div style="text-align:center"><span><br></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODk3_097a40f8-3c19-4968-b196-c2110ea10e7b">Yes</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">☒</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">☐</span></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required&nbsp;to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODkw_d666e3cd-c0b3-4dab-8926-0ae28b109c32">Yes</ix:nonnumeric>&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">☒</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">☐</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tbody><tr><td style="width:1.0%"></td><td style="width:17.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.268%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjZkZmM1NTA0OTc4NGZmN2E3OWE2NzJhYTg0ZDdlOWIvdGFibGVyYW5nZToyNmRmYzU1MDQ5Nzg0ZmY3YTc5YTY3MmFhODRkN2U5Yl8wLTAtMS0xLTUyNjky_d937004c-604c-4f44-8c32-dab3a99f703c">Large accelerated filer</ix:nonnumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">☒</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">☐</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">☐ </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjZkZmM1NTA0OTc4NGZmN2E3OWE2NzJhYTg0ZDdlOWIvdGFibGVyYW5nZToyNmRmYzU1MDQ5Nzg0ZmY3YTc5YTY3MmFhODRkN2U5Yl8yLTMtMS0xLTUyNjky_68bdbe7b-7784-453d-9be0-b4d0c8e7f946">☐</ix:nonnumeric></span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGFibGU6MjZkZmM1NTA0OTc4NGZmN2E3OWE2NzJhYTg0ZDdlOWIvdGFibGVyYW5nZToyNmRmYzU1MDQ5Nzg0ZmY3YTc5YTY3MmFhODRkN2U5Yl80LTMtMS0xLTUyNjky_0d762ba1-a0f4-4465-a098-5b7da4a7bd99">☐</ix:nonnumeric></span></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&nbsp;Yes&nbsp;☐&nbsp;&nbsp;No&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF83Njk2NTgxMzk2MzQ0_7edc9370-d4f1-43c0-a7b0-f03eda22e0a2">☒</ix:nonnumeric></span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The number of shares of common stock outstanding as of the close of business on April&nbsp;30, 2022: <ix:nonfraction unitref="shares" contextref="i7362b5c790a345339a6b199ec4044889_I20220430" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xL2ZyYWc6ZTRlNmExYWRjYTkwNGFjOGJmMGU2OTVlNDZhZGZkMTgvdGV4dHJlZ2lvbjplNGU2YTFhZGNhOTA0YWM4YmYwZTY5NWU0NmFkZmQxOF8xODg3_029965b4-dd7e-466b-bb79-8336d508bedb">2,528,805,025</ix:nonfraction></span></div><div style="margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.132%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></tbody></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_7"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div><div><span><br></span></div></div><div style="margin-top:3pt;text-align:center"><span><br></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tbody><tr><td style="width:1.0%"></td><td style="width:13.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.475%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Page No.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_10">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_10">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_16">Condensed Consolidated Statement of Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_19">Condensed Consolidated Statement of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_19">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_22">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_25">Condensed Consolidated Statement of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_31">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_82">Management’s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_82">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_115">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_115">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_118">42</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_121">Cautionary Factors That May Affect Future Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_121">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART II</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_124">OTHER INFORMATION </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_124">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_127">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_127">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_130">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_130">43</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_133">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_133">44</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_136">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_136">44</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_139">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia10991337ee64bfe975ff621c73a0ff6_139">45</a></span></div></td></tr></tbody></table></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br></span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_10"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Part I - Financial Information</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_13"></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;1. Financial Statements</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_16"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:77.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMi0xLTEtMS01MjY5Mg_c0200447-8007-49b4-96c5-2c1bc744a7cb">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMi0zLTEtMS01MjY5Mg_bf666d7c-b66b-425c-abfa-4306342b791b">10,627</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNC0xLTEtMS01MjY5Mg_8532db6f-3fc1-4146-9c3b-c1945eab91c8">5,380</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNC0zLTEtMS01MjY5Mg_cf8ca259-007b-4a2b-9c12-1c9fe9c9d84b">3,199</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNS0xLTEtMS01MjY5Mg_098bcd98-e2f5-41a7-93ba-d5a22ff5a790">2,323</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNS0zLTEtMS01MjY5Mg_30f1e331-f06c-410b-8455-ef6b702fd2f9">2,187</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNi0xLTEtMS01MjY5Mg_74de358d-2323-43c1-b7a0-f7c3f4fcb050">2,576</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNi0zLTEtMS01MjY5Mg_77ee4b6f-8501-4ddd-84cf-27523afa043e">2,412</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNy0xLTEtMS01MjY5Mg_79f80f70-cbc8-400c-b2be-4b95629c307a">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfNy0zLTEtMS01MjY5Mg_9e151827-3ad7-436a-b5f9-80ddd41af673">297</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfOC0xLTEtMS01MjY5Mg_57e85371-36e4-4905-a3a8-064eb352b79f">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfOC0zLTEtMS01MjY5Mg_00718ea2-9b44-40e6-99da-935ed54da7f3">455</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfOS0xLTEtMS01MjY5Mg_35f3cc9b-d603-46c7-aae5-4cc92cf43260">11,040</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="mrk:CostsExpensesAndOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfOS0zLTEtMS01MjY5Mg_4879db23-328c-4b69-8ae9-6f95e36c3bff">7,640</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTAtMS0xLTEtNTI2OTI_43477c48-9af5-4f78-92bb-348101c5b378">4,861</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTAtMy0xLTEtNTI2OTI_71ddbc9e-7715-4226-b5a4-7b65b0e3446d">2,987</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on Income from Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTEtMS0xLTEtNTI2OTI_d8c02d31-0fe0-4d28-8caa-591a1c294f3f">554</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTEtMy0xLTEtNTI2OTI_8e8640be-d076-455d-9c60-55865a6a6181">238</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTItMS0xLTEtNTI2OTI_8ae68ad3-cc9b-4266-94de-749e88dc136b">4,307</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTItMy0xLTEtNTI2OTI_0c8b1cfe-c662-49e7-8894-0ad39e720432">2,749</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (Loss) Income Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTMtMS0xLTEtNTI2OTI_80c70f47-3083-4788-b5b0-e1e2b82bdab4">3</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTMtMy0xLTEtNTI2OTI_ea9ac719-ed21-4303-b0c4-340bda1ea90a">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTQtMS0xLTEtNTI2OTI_9ef81902-7abb-4749-ab8d-8a96e7143d1e">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTQtMy0xLTEtNTI2OTI_d34e44aa-620c-4994-8b20-123069ccdb3b">2,745</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTUtMS0xLTEtNTI2OTI_7ae3ae63-a3fa-43f9-a7d3-2439381cf185">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTUtMy0xLTEtNTI2OTI_d359c1f9-88d6-47d2-be90-7c5c13fba8d7">434</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck &amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTYtMS0xLTEtNTI2OTI_4c0dd9ed-50a7-4730-82d6-8b286cdd7cc7">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTYtMy0xLTEtNTI2OTI_bc3e15fd-ac59-45e5-ac92-1826a2803b73">3,179</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTgtMS0xLTEtNTI2OTI_cf26c7a2-3e37-4c21-95cf-d906cfae97d3">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTgtMy0xLTEtNTI2OTI_f890b09f-4618-46d1-bf24-ce2ff12500cb">1.08</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTktMS0xLTEtNTI2OTI_605122ce-46e9-47b2-ae57-0f3a117cfd8b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMTktMy0xLTEtNTI2OTI_ebdd78aa-b08f-43d6-828f-8487d4ed1c41">0.17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjAtMS0xLTEtNTI2OTI_e9069e89-2ded-4b5d-8604-299c8ac5e151">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjAtMy0xLTEtNTI2OTI_3c21be8a-b104-49e8-9a9c-f59f414109f4">1.26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjItMS0xLTEtNTI2OTI_30290430-cbb8-4b48-82f7-53cf3591b2ea">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjItMy0xLTEtNTI2OTI_b2751bbb-1f12-4eee-8fff-e54c7e0a585f">1.08</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjMtMS0xLTEtNTI2OTI_eaffa527-c17d-4b18-9093-77d82526f14c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjMtMy0xLTEtNTI2OTI_1791ace2-cd74-4658-a1e9-82d626dafa49">0.17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjQtMS0xLTEtNTI2OTI_1c612783-1d8f-480d-a2c5-c052f25d978c">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xNi9mcmFnOjRkMmE4OGE3NDBiMzQ0MDQ5YTQ4NTk1NGZlZDlhNTYxL3RhYmxlOmM3MjE0OWM2NWIyMTQ4OWQ5OTkyMGZjZDI4OWQzZjA2L3RhYmxlcmFuZ2U6YzcyMTQ5YzY1YjIxNDg5ZDk5OTIwZmNkMjg5ZDNmMDZfMjQtMy0xLTEtNTI2OTI_2f03be94-39b6-4ac5-9c43-60b4212ed847">1.25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_19"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tbody><tr><td style="width:1.0%"></td><td style="width:78.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.783%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfMi0xLTEtMS01MjY5Mg_474d4917-2a22-471c-ac1f-d18ce56709f8">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfMi0zLTEtMS01MjY5Mg_796c13ca-0f34-4dc3-bc80-5a60f7e2cd72">3,179</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Comprehensive Income Net of Taxes:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gain on derivatives, net of reclassifications</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfNC0xLTEtMS01MjY5Mg_4244b052-50f8-4a60-9a45-a25f8cef1bc9">63</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfNC0zLTEtMS01MjY5Mg_44339d8b-0fcb-420a-a580-0bcf73081fad">230</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit plan net gain and prior service credit, net of amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfNi0xLTEtMS01MjY5Mg_e8ea7356-44d2-4d52-ba64-1e53525f829d">32</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfNi0zLTEtMS01MjY5Mg_0ef57a5f-cdb7-4e44-a002-071fb06da134">81</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative translation adjustment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfNy0xLTEtMS01MjY5Mg_32aa78e0-f6ec-4a99-8699-8cded6090f3f">35</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfNy0zLTEtMS01MjY5Mg_11355407-6886-4bfc-aa0c-1b18f35999cf">299</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfOC0xLTEtMS01MjY5Mg_204b3f9f-79c2-4e9c-bb7a-94c98097a1c3">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfOC0zLTEtMS01MjY5Mg_164d763a-6e7a-47c0-8cdf-ebe488809638">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfOS0xLTEtMS01MjY5Mg_032d1b78-73d2-47ec-a70f-f12d03d7d318">4,370</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8xOS9mcmFnOjc4N2QxNTgyMWI5YjRiNjI4YWI3ZDljZjU1ZWJjNzUxL3RhYmxlOmJhODU1OTY1YTM1YjQ0OWJhMDc0NGQyNzAwZjAyMTU0L3RhYmxlcmFuZ2U6YmE4NTU5NjVhMzViNDQ5YmEwNzQ0ZDI3MDBmMDIxNTRfOS0zLTEtMS01MjY5Mg_1e0498ac-15f7-4128-8858-7126154bbf0b">3,191</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 3 -</span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_22"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEET</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMy0xLTEtMS01MjY5Mg_604bdec8-c3fe-4e40-a724-b0fcdd826882">8,556</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMy0zLTEtMS01MjY5Mg_e4c24fb5-ddb7-45d3-b2bf-c3fb84c26454">8,096</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:ShortTermInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNC0xLTEtMS02ODQ0Mw_940743f3-9fd8-4504-bd6c-d580556df584">372</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:ShortTermInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNC0zLTEtMS02ODQ0Mw_77834fac-6097-4dfd-bb45-fa0228e0b61c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable (net of allowance for doubtful accounts of $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNC0wLTEtMS01MjY5Mi90ZXh0cmVnaW9uOmJmNzc4NjRjMGQxYzRkODRhMWZmMDI5OTA2YmYzMTcwXzY3_f00a9758-0608-4905-9752-20bf9fea5c62">95</ix:nonfraction> in 2022</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&nbsp;and $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNC0wLTEtMS01MjY5Mi90ZXh0cmVnaW9uOmJmNzc4NjRjMGQxYzRkODRhMWZmMDI5OTA2YmYzMTcwXzgx_ea284c33-14c1-413c-af06-b65cff451d25">62</ix:nonfraction> in 2021) </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNC0xLTEtMS01MjY5Mg_f9d3b3f1-1132-4f6a-85b9-ca443f92b772">9,828</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNC0zLTEtMS01MjY5Mg_6c994f1b-a225-4acd-b834-09c90265b3d6">9,230</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (excludes inventories of $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNS0wLTEtMS01MjY5Mi90ZXh0cmVnaW9uOjg4NTE1YTk5YTU1MTRlZGJiMGUxMzVmMTI1MTYyMzU3XzQy_9bf4df66-1099-40b5-917c-f3e4601fdd90">2,495</ix:nonfraction> in 2022 and $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNS0wLTEtMS01MjY5Mi90ZXh0cmVnaW9uOjg4NTE1YTk5YTU1MTRlZGJiMGUxMzVmMTI1MTYyMzU3XzU1_11bc5815-fdbd-4540-9fe1-7c02faa9ca59">2,194</ix:nonfraction> in 2021</span></div><div style="padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">classified in Other assets - see Note&nbsp;7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNS0xLTEtMS01MjY5Mg_d0bebe88-9e29-4440-97f0-9eceed2315a5">5,774</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNS0zLTEtMS01MjY5Mg_7439a9fe-ade8-479b-848a-5f1a510a73c3">5,953</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNi0xLTEtMS01MjY5Mg_817b365f-3ff8-4a49-8c20-c56a2ea64e76">6,654</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfNi0zLTEtMS01MjY5Mg_37526d5f-5da8-4709-a48e-a454bac6068f">6,987</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfOC0xLTEtMS01MjY5Mg_5e26186a-8a89-4fe8-80e1-d881558eac94">31,184</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfOC0zLTEtMS01MjY5Mg_e95e3b17-c66d-45b3-830f-1d5bab578e6e">30,266</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfOS0xLTEtMS01MjY5Mg_074c3242-9d17-4d32-96d6-0e7675928a1b">316</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfOS0zLTEtMS01MjY5Mg_744dd6a1-aaf7-4408-9740-5d2c295d0434">370</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, Plant and Equipment, at cost, net of accumulated depreciation of $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo0YTY0NjU1YjRiMDg0Y2I0OGViYTEzNDZjMDkxMjA0Zl83OQ_673d31a9-f3a2-456d-b984-3c08a48e3efd">18,498</ix:nonfraction></span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">in 2022 and $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo0YTY0NjU1YjRiMDg0Y2I0OGViYTEzNDZjMDkxMjA0Zl85Mg_d34e7c63-f6c1-4296-8977-108e1ef3404c">18,192</ix:nonfraction> in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTAtMS0xLTEtNTI2OTI_ff476848-7861-43d3-ad42-cf3ca08b2133">19,747</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTAtMy0xLTEtNTI2OTI_e352313c-3eef-46a5-afcc-fb3ebe6e86e9">19,279</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTEtMS0xLTEtNTI2OTI_c278c30b-13d4-40f4-af45-39b44aa48e78">21,258</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTEtMy0xLTEtNTI2OTI_f37c53e5-88f4-4fb1-92af-16bd92376247">21,264</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Intangibles, Net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTItMS0xLTEtNTI2OTI_aae96d80-0a74-4431-9cf0-67674821f15b">23,022</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTItMy0xLTEtNTI2OTI_702be9a5-f64e-4174-a1b3-34c60c4fbe44">22,933</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTMtMS0xLTEtNTI2OTI_fd68b6c2-0dcb-4e64-b2a8-a2c09e9793c2">11,141</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxesAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTMtMy0xLTEtNTI2OTI_f10cde66-58af-464b-a52a-f19ddfc6ece7">11,582</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTUtMS0xLTEtNTI2OTI_736ab30b-faf9-46a2-8575-2f6ffd9046b9">106,668</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTUtMy0xLTEtNTI2OTI_fbd999a6-5a40-4dcd-a822-a800020590e3">105,694</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTgtMS0xLTEtNTI2OTI_9370c037-aa44-43fb-a842-f07221191612">1,208</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTgtMy0xLTEtNTI2OTI_3ff5a288-9b9e-4b59-ab87-56e56faee2cf">2,412</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTktMS0xLTEtNTI2OTI_77456865-d55e-467b-9b82-4021035adb2d">3,715</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMTktMy0xLTEtNTI2OTI_3946522d-b15a-450f-a71c-fa3c4b59195f">4,609</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjAtMS0xLTEtNTI2OTI_1a705d7b-94df-4643-b72d-7acead26ccfb">14,051</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjAtMy0xLTEtNTI2OTI_36f2c9f8-4e0c-43ae-95be-3e977abfc2ed">13,859</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjEtMS0xLTEtNTI2OTI_e18d2b0b-33df-4d8c-b8bd-22edfad04bf7">1,571</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjEtMy0xLTEtNTI2OTI_9f502f3e-4f6f-453f-819c-b0481ee0e58a">1,224</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjItMS0xLTEtNTI2OTI_9cf14eb2-b09e-4b59-8038-35a7b5e70868">1,771</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DividendsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjItMy0xLTEtNTI2OTI_066247af-7077-4e6b-826a-559fffc1764e">1,768</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjQtMS0xLTEtNTI2OTI_a947f6a6-bf05-4b14-a594-d4d425586a4f">22,316</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjQtMy0xLTEtNTI2OTI_eef397ed-4156-45b5-b703-b6e3f16255c1">23,872</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjUtMS0xLTEtNTI2OTI_7339190b-4756-47c8-a918-0c00a7574383">30,586</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjUtMy0xLTEtNTI2OTI_a242ea90-7ab7-4a4a-996b-5d475b5ca0af">30,690</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred Income Taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjYtMS0xLTEtNTI2OTI_99b554e3-625b-473b-ba36-442bedac962e">3,071</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjYtMy0xLTEtNTI2OTI_07d8abcd-0145-41f1-b664-b66bc9a7b1c4">3,441</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjctMS0xLTEtNTI2OTI_2d9101c0-cb1e-4230-9886-d21be9a2118e">9,742</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMjctMy0xLTEtNTI2OTI_5931f420-a0b2-4dbf-8baa-8accf9c032f0">9,434</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Merck&nbsp;&amp; Co., Inc. Stockholders’ Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonfraction unitref="usdPerShare" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo5YzdmNGE3NjI3OTk0OTgxYTY4NmZjNGIyNmRmZTE3OV8xOQ_918817c9-9628-4ff6-b56d-b72b657dc09b"><ix:nonfraction unitref="usdPerShare" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo5YzdmNGE3NjI3OTk0OTgxYTY4NmZjNGIyNmRmZTE3OV8xOQ_df7d6808-7452-4b2f-8f45-3fba68dc3f0e">0.50</ix:nonfraction></ix:nonfraction> par value</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized - <ix:nonfraction unitref="shares" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo5YzdmNGE3NjI3OTk0OTgxYTY4NmZjNGIyNmRmZTE3OV80NQ_78b7715a-2983-4987-9aff-ace153c6d24f"><ix:nonfraction unitref="shares" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo5YzdmNGE3NjI3OTk0OTgxYTY4NmZjNGIyNmRmZTE3OV80NQ_9f156467-a155-4e43-b98d-1d19158e7e47">6,500,000,000</ix:nonfraction></ix:nonfraction> shares</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued - <ix:nonfraction unitref="shares" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo5YzdmNGE3NjI3OTk0OTgxYTY4NmZjNGIyNmRmZTE3OV82NA_1cf1db7c-2135-48e6-ba7a-55c3f512a3eb"><ix:nonfraction unitref="shares" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo5YzdmNGE3NjI3OTk0OTgxYTY4NmZjNGIyNmRmZTE3OV82NA_48d327fe-3cf3-4398-94ff-8e6883472731">3,577,103,522</ix:nonfraction></ix:nonfraction> shares in 2022 and 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMS0xLTEtNTI2OTI_8fb6d2e3-51ce-454d-9d65-b0f143edb82e">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzAtMy0xLTEtNTI2OTI_e0c4dadf-8c42-4673-ac3d-5c387f80c4e9">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other paid-in capital</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzEtMS0xLTEtNTI2OTI_499fff0e-dfd2-452c-bfe0-6fcc0470bded">44,275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzEtMy0xLTEtNTI2OTI_34c2c08c-bbe0-42ca-9517-63f1a0eb228c">44,238</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzItMS0xLTEtNTI2OTI_e11d28cd-abd2-43d7-9f9c-a63cd6d0df20">56,252</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzItMy0xLTEtNTI2OTI_d5b28198-b8d8-45ca-bbcf-da73ea24cfb3">53,696</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzMtMS0xLTEtNTI2OTI_2eee2694-f16b-4aa8-a81d-f16974c2b405">4,369</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzMtMy0xLTEtNTI2OTI_e9779b8c-fb00-4bec-afea-3e95a1118891">4,429</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzQtMS0xLTEtNTI2OTI_70fe1a61-0c0b-4044-aa48-f9668aa857e9">97,946</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzQtMy0xLTEtNTI2OTI_dbde72f5-cfdb-49d7-8410-47a5219b1d9a">95,293</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less treasury stock, at cost:</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzUtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjpiYWNkY2FiOWY4Nzg0Y2MzYTMxYWZmZTQzMmQ3YWQ1ZF8zNQ_a9aaf121-b17b-4a6d-97d9-e8caee04a0ef">1,048,727,225</ix:nonfraction> shares in 2022 and <ix:nonfraction unitref="shares" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzUtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjpiYWNkY2FiOWY4Nzg0Y2MzYTMxYWZmZTQzMmQ3YWQ1ZF81NQ_a9f11616-c650-4ca3-acce-4a6d7504187b">1,049,499,023</ix:nonfraction> shares in 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzUtMS0xLTEtNTI2OTI_38f7ec3d-333e-4374-8968-de86e88ba37a">57,063</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzUtMy0xLTEtNTI2OTI_31ff1083-8721-4a15-b3ca-045479951433">57,109</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Merck&nbsp;&amp; Co., Inc. stockholders’ equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzYtMS0xLTEtNTI2OTI_3bc71724-50ec-41dc-af7e-2a0800634528">40,883</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzYtMy0xLTEtNTI2OTI_8bfe6fb8-52ed-4f2c-9503-be9ecfdb7685">38,184</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzctMS0xLTEtNTI2OTI_b7aecafa-28f0-414a-9d57-97489e3c7af2">70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzctMy0xLTEtNTI2OTI_ad2662c4-c4e4-4b2f-a539-586e92ef263c">73</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzgtMS0xLTEtNTI2OTI_111cbfc2-8a29-4aeb-9ca8-3f897ac0fe89">40,953</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzgtMy0xLTEtNTI2OTI_3d12f0d0-9c94-4b4c-8e54-9e01357405dc">38,257</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzktMS0xLTEtNTI2OTI_20910726-ba30-47a7-90b4-657efdd5d183">106,668</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yMi9mcmFnOjUyYjZlMjQxOGEzNTRiMTk5ZDY3YWZkMzM2NDZmNTVlL3RhYmxlOjIyMDNlNjRhOTIyYTRmMjA5MTRmMjM3NmU3MGVjZjkzL3RhYmxlcmFuZ2U6MjIwM2U2NGE5MjJhNGYyMDkxNGYyMzc2ZTcwZWNmOTNfMzktMy0xLTEtNTI2OTI_151a75ce-6b97-43cd-98fd-192acb8d8b75">105,694</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 4 -</span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_25"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div><div><span><br></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MERCK&nbsp;&amp; CO., INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited, $ in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income from continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMy0xLTEtMS01MjY5Mg_c5694f60-2694-4851-9608-d6b7e5663f72">4,307</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMy0zLTEtMS01MjY5Mg_2bf82814-4484-4fbb-9357-110ee4d4c21d">2,749</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNS0xLTEtMS01MjY5Mg_74cd72b0-fa74-4a29-96b2-c9f7b613ff6f">699</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNS0zLTEtMS01MjY5Mg_53635166-9750-4ace-bd4a-1478760b71ab">514</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNi0xLTEtMS01MjY5Mg_a7ae9baf-0f52-4057-b450-5661fc8e1bcb">421</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNi0zLTEtMS01MjY5Mg_56584532-814f-4d10-bf70-c3110dc330c8">378</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfOC0xLTEtMS01MjY5Mg_8ea2a84c-0f0d-43bf-a6ec-848b7408f13b">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfOC0zLTEtMS01MjY5Mg_e06868d8-ea4d-483d-adf6-ef4aca4f32f7">574</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTAtMS0xLTEtNTI2OTI_7ede105b-83df-4e73-b91b-1b24a20140f4">338</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTAtMy0xLTEtNTI2OTI_f4dd6eb7-8a12-48dc-9c1d-1d03ebff777c">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTEtMS0xLTEtNTI2OTI_8b59f7f6-1720-436f-b6bf-7b3cb40a2def">120</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTEtMy0xLTEtNTI2OTI_829eefda-c80b-4eb6-919e-af8b14a9cd75">111</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTItMS0xLTEtNTI2OTI_24215054-96ee-4309-a959-bc2bc903e74a">143</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTItMy0xLTEtNTI2OTI_2325533b-62da-4c1f-8dc4-584af03bed61">236</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net changes in assets and liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTMtMS0xLTEtNTI2OTI_012ceba9-5769-4d23-a60c-a512b12d950f">1,299</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncreaseDecreaseInOperatingCapital" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTMtMy0xLTEtNTI2OTI_867730f2-6f5c-43eb-8816-2a59c1ff5952">2,192</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Operating Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTQtMS0xLTEtNTI2OTI_e67a45b9-c513-4be9-8006-6783a1539578">4,761</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTQtMy0xLTEtNTI2OTI_f8abb425-8165-4b31-ab73-7fa6be583958">1,240</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTYtMS0xLTEtNTI2OTI_15ec3017-af47-49ca-9a5f-7179cdb2ee2b">984</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTYtMy0xLTEtNTI2OTI_ea1af98c-d75e-4321-9bf1-6fadf556059c">1,082</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of securities and other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTctMS0xLTEtNTI2OTI_c4e49e27-842a-433a-ae58-b677b50d05c6">372</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTctMy0xLTEtNTI2OTI_c134fd0e-f6c3-49f8-a909-1ae8cdaf3459">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of securities and other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTgtMS0xLTEtNTI2OTI_ace3e988-6e83-43a4-a063-40de4d03d93b">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMTgtMy0xLTEtNTI2OTI_debca048-a5ca-4547-8229-207d3e4c484a">386</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjItMS0xLTEtNTI2OTI_c61a1c63-66b9-4e02-bf05-b6d953aad0c4">182</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjItMy0xLTEtNTI2OTI_9200c9ce-d004-434e-86a1-7fdb7ecf2fca">11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjMtMS0xLTEtNTI2OTI_ecc4b037-3256-4efe-92d4-b602ef3b7141">1,173</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjMtMy0xLTEtNTI2OTI_c390b8c6-dbda-45de-8739-5880d6a9daaa">686</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities of Continuing Operations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjUtMS0xLTEtNTI2OTI_69be788b-16a0-4232-95d1-4f73b3f376f4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjUtMy0xLTEtNTI2OTI_9d0bfbd8-109a-4625-97f7-cdefbf9677cd">788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments on debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjYtMS0xLTEtNTI2OTI_b2e3fb5a-54d5-45a2-85da-856d46a18b50">1,250</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMjYtMy0xLTEtNTI2OTI_76e0f699-6e06-4a3e-8769-e46012231f89">1,153</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid to stockholders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzAtMS0xLTEtNTI2OTI_ccf374c0-8f58-4f47-9d08-d88676f6d3a7">1,745</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzAtMy0xLTEtNTI2OTI_8e3fa4b8-f3ba-48ca-8384-e24ceb1964ee">1,645</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzEtMS0xLTEtNTI2OTI_4a93adb2-4cee-4195-8fbb-d225c2f3e224">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzEtMy0xLTEtNTI2OTI_67232584-f970-4fcf-9ddf-46052c66eb2a">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzItMS0xLTEtNTI2OTI_2085c50d-3bc9-4720-bcc8-fe17dec651be">103</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzItMy0xLTEtNTI2OTI_31911551-4557-4aa3-8988-d14eb1b7717b">97</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Financing Activities of Continuing Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzMtMS0xLTEtNTI2OTI_a0060745-568b-4499-a702-d164a53a734f">3,086</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzMtMy0xLTEtNTI2OTI_5b482b0b-8867-402d-a11f-c61d98ac8f8e">2,098</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash Flows from Discontinued Operations</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzUtMS0xLTEtNTI2OTI_609cf5dd-f10d-4189-aa35-669d029ec86d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzUtMy0xLTEtNTI2OTI_6af65a37-8cfe-4006-aca8-4fa304b562e0">551</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzYtMS0xLTEtNTI2OTI_6aaa9457-d39d-400a-b8fb-75c48aa6bcb0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzYtMy0xLTEtNTI2OTI_68750003-b1e7-4333-9946-293cacb608d9">52</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Flows Provided by Discontinued Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzgtMS0xLTEtNTI2OTI_04202f57-4a1a-4645-92d3-441283ee7cda">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetCashProvidedByUsedInDiscontinuedOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzgtMy0xLTEtNTI2OTI_c3501fcb-a12a-4c81-bd04-99ebd52271f7">499</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzktMS0xLTEtNTI2OTI_7049eff6-ea07-4d15-9ed0-941c1195f832">55</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfMzktMy0xLTEtNTI2OTI_e88639d0-07b3-4010-a51d-3d5f728cffea">97</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDAtMS0xLTEtNTI2OTI_d783cd38-e3bc-4ac6-bfad-ca4ee7ef470f">447</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDAtMy0xLTEtNTI2OTI_15070e0c-7f61-4379-8461-edef8d4ec8b4">1,142</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDEtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo2ZGNlYWFmYjY1Nzk0MTQ4YjhhZmFjYzIwNjExYjExY185OQ_6b13aec6-4ea9-4c95-9627-6b4d20abf483">71</ix:nonfraction> and $<ix:nonfraction unitref="usd" contextref="i866b60422112474194bfe1e56bc43a8a_I20201231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDEtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo2ZGNlYWFmYjY1Nzk0MTQ4YjhhZmFjYzIwNjExYjExY18xMDk5NTExNjI3OTI0_91ed92c4-ad6b-44d7-bb79-5b4994a4c4b3">103</ix:nonfraction> at January 1, 2022 and 2021, respectively, included in Other current assets)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDEtMS0xLTEtNTI2OTI_fbf8b97e-f5b3-4009-809d-9ac0fa5ff9f8">8,167</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i866b60422112474194bfe1e56bc43a8a_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDEtMy0xLTEtNTI2OTI_33ec3032-b2ac-4db5-a2a4-c94ed0cf4fe2">8,165</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Cash and cash equivalents related to discontinued operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDItMS0xLTEtNjA1Nzk_d07d5729-9459-4409-b891-b30b338b8071">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDItMy0xLTEtNjA1Nzk_31e66dc9-cf89-496a-a211-5d5c945a31d6">141</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDItMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjoxNWE0M2IxZTE1NWU0YTBjYjk0ZGFmN2JmM2JjM2FjNF85NQ_c179482a-ed1b-4184-a504-60e74c5c4c07">58</ix:nonfraction> </span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and $<ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDItMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjoxNWE0M2IxZTE1NWU0YTBjYjk0ZGFmN2JmM2JjM2FjNF8xMDk5NTExNjI3OTI4_ccbe15b1-a595-4938-ba9f-a86cf35e2213">42</ix:nonfraction> at March&nbsp;31, 2022 and 2021, respectively, included in Other current assets)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDItMS0xLTEtNTI2OTI_0310e7bb-b1ff-40fd-b765-e1c2a1036038">8,614</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8yNS9mcmFnOjc1NjY1NzExNmZhOTQ0ZmFiNjYxNDgzOTVkZDJjMTc2L3RhYmxlOjE2MjYzYjg2MDY2MTQ4MzY5OGRlYmQ3OTFjMTQ3YmExL3RhYmxlcmFuZ2U6MTYyNjNiODYwNjYxNDgzNjk4ZGViZDc5MWMxNDdiYTFfNDItMy0xLTEtNTI2OTI_e156169a-e84d-4dca-b605-370838290af8">6,882</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of this condensed consolidated financial statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 5 -</span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_28"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div><span><br></span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_31"></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zMS9mcmFnOmExZmQxZTdlNjc5YzQ1ZmZhYzdlZDIwZmQzNDBiZDMyL3RleHRyZWdpb246YTFmZDFlN2U2NzljNDVmZmFjN2VkMjBmZDM0MGJkMzJfNTI2OQ_090c5eb0-242d-47cc-b572-3723a0195414" continuedat="i3ed2d60814904657a2c052725b57b1ba" escape="true"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zMS9mcmFnOmExZmQxZTdlNjc5YzQ1ZmZhYzdlZDIwZmQzNDBiZDMyL3RleHRyZWdpb246YTFmZDFlN2U2NzljNDVmZmFjN2VkMjBmZDM0MGJkMzJfNTI3Ng_d2447a47-665d-41c9-aa0c-df1c595a5be9" continuedat="i531cd46e43684d83856559aa40801aa5" escape="true">Basis of Presentation</ix:nonnumeric></ix:nonnumeric></span></div><ix:continuation id="i3ed2d60814904657a2c052725b57b1ba" continuedat="i59d4e12cb6544b5ca9c2872a38eed524"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i531cd46e43684d83856559aa40801aa5" continuedat="i2e989cb286354d078b557a68a28ce511">The accompanying unaudited condensed consolidated financial statements of Merck&nbsp;&amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February&nbsp;25, 2022.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2e989cb286354d078b557a68a28ce511">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.</ix:continuation> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zMS9mcmFnOmExZmQxZTdlNjc5YzQ1ZmZhYzdlZDIwZmQzNDBiZDMyL3RleHRyZWdpb246YTFmZDFlN2U2NzljNDVmZmFjN2VkMjBmZDM0MGJkMzJfMTIwOTQ2Mjc5MTgwNTM_12efbce1-94d8-4da1-9351-2cfe3ba4be72" continuedat="i71c2f3438dc64b7c9a24e7ced292c041" escape="true">Reclassifications&nbsp;—&nbsp;</ix:nonnumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i71c2f3438dc64b7c9a24e7ced292c041">Certain reclassifications have been made to prior year amounts to conform to the current year presentation</ix:continuation>.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spin-Off of Organon &amp; Co.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zMS9mcmFnOmExZmQxZTdlNjc5YzQ1ZmZhYzdlZDIwZmQzNDBiZDMyL3RleHRyZWdpb246YTFmZDFlN2U2NzljNDVmZmFjN2VkMjBmZDM0MGJkMzJfNTI4NQ_6f554364-cd7d-4f35-92e8-f0af143fe934" continuedat="i7bf5496f1dc8456690e1a068c4f23662" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022.&nbsp;The Company is currently evaluating the impact of adoption on its consolidated financial statements. The Company is progressing in its evaluation of LIBOR cessation exposures, including the review of debt-related contracts, leases, business development and licensing arrangements, royalty and other agreements. The Company has amended certain agreements and continues to review other agreements for potential impacts. With regard to debt-related exposures in particular, the Company’s four remaining interest rate swaps linked to LIBOR will mature in September 2022. The Company will transition its LIBOR-based debt to an alternative reference rate upon LIBOR discontinuance. Based on its evaluation thus far, the Company does not anticipate a material impact to its consolidated financial statements as a result of reference rate reform.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the </span></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 6 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i59d4e12cb6544b5ca9c2872a38eed524"><ix:continuation id="i7bf5496f1dc8456690e1a068c4f23662">Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.</ix:continuation></ix:continuation></span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_34"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.      <ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfNjU4Mg_0f9e5d74-08a4-4bc9-9c78-5440048e976d" continuedat="i914ccab11ac946f7a72867e2a3da9ab3" escape="true">Spin-Off of Organon &amp; Co.</ix:nonnumeric></span></div><ix:continuation id="i914ccab11ac946f7a72867e2a3da9ab3" continuedat="i7a43cb641f8140fc873c56bb17a57b7b"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $<ix:nonfraction unitref="usd" contextref="i9541a59d786444c0836c050cfd8f88bc_I20210602" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfNDg1_95dadd30-60bc-46f0-b5a0-b3637116527f">9.5</ix:nonfraction>&nbsp;billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $<ix:nonfraction unitref="usd" contextref="ice580b1f0d804d4eb27ba4913705b736_I20210602" decimals="-8" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfNzE5_e1c56ed1-49ce-49e3-b405-ee87e80f76a5">9.0</ix:nonfraction>&nbsp;billion were distributed by Organon to Merck in connection with the spin-off. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within <ix:nonnumeric contextref="ia0634666520a4c228e24847f4cfd662b_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMTUyNg_925069ba-bfb2-4333-bb00-e3e333096149">25</ix:nonnumeric> months following the spin-off. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from <ix:nonnumeric contextref="iaed879fa16e64bec9790214d26986664_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMjg4NQ_3d919701-a7a2-4837-bdc6-bc45f827c7f4">four years</ix:nonnumeric> to <ix:nonnumeric contextref="icec6e11c8292484daa19574361b29faa_D20210602-20210602" name="us-gaap:DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMjg5MQ_513d7863-4f8a-4fb5-9b50-95fab8d95142">ten years</ix:nonnumeric>. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in the condensed consolidated statement of income for the above MSAs include sales of $<ix:nonfraction unitref="usd" contextref="i2e823ab9d0994c558932b1e029fc559f_D20220101-20220331" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMjE5OTAyMzI2MjQ2Nw_a287edf2-091c-40d1-a5dc-d0573d10234b">99</ix:nonfraction>&nbsp;million and related cost of sales of $<ix:nonfraction unitref="usd" contextref="i2e823ab9d0994c558932b1e029fc559f_D20220101-20220331" decimals="-6" name="us-gaap:RelatedPartiesAmountInCostOfSales" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMjE5OTAyMzI2MjQ2OA_56ba7099-e7a6-4ef7-b20d-604b918aea06">105</ix:nonfraction>&nbsp;million for the first quarter of 2022. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial in the first quarter of 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts due from Organon under all of the above agreements were $<ix:nonfraction unitref="usd" contextref="i04c57aa042974d61988f663829946a9a_I20220331" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMzExMg_5d3b3f22-e7b6-4a6c-8e8f-92458e7b3d85">719</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i7338ae38e1e34ab9b4c22c66456eefcf_I20211231" decimals="-6" name="us-gaap:DueFromRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfNjA0NzMxMzk2MjAzNA_487c5c25-8820-45eb-88c8-34d2f0fdd221">964</ix:nonfraction>&nbsp;million at March&nbsp;31, 2022 and December 31, 2021, respectively, and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amounts due to Organon under these agreements were $<ix:nonfraction unitref="usd" contextref="i04c57aa042974d61988f663829946a9a_I20220331" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMzIxNg_4856c0d0-0015-4e2d-af59-9f986688d986">344</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i7338ae38e1e34ab9b4c22c66456eefcf_I20211231" decimals="-6" name="us-gaap:DueToRelatedPartiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfNjA0NzMxMzk2MjA2MQ_7c341b0e-c7ba-483b-91f5-495d367d3549">400</ix:nonfraction>&nbsp;million at March&nbsp;31, 2022 and December 31, 2021, respectively, and are included in A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ccrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the women’s health, biosimilars and established brands businesses (previously included in the Pharmaceutical segment) that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s condensed consolidated statement of income as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for periods prior to the spin-off on June 2, 2021. Merck incurred separation costs of $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfMzkyOQ_76d62fbf-27f9-4ade-ae9e-b2fbcfb950b0">249</ix:nonfraction>&nbsp;million in the first quarter of 2021 related to the spin-off of Organon, which are also included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These costs primarily relate to professional fees for separation activities within finance, tax, legal and information technology functions, as well as investment banking fees. </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 7 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span></div></div><ix:continuation id="i7a43cb641f8140fc873c56bb17a57b7b"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RleHRyZWdpb246MmJmYTNlZThiZDA5NGViOWI3ZjBiOTIzZjI4YTE4M2JfNjU4Mw_27252ad5-628c-44a2-aa94-09c9be5fc5a3" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:85.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.328%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfMi0zLTEtMS01MjY5Mg_4515c380-f672-46af-9fff-56d2bfe5bb73">1,453</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs, Expenses and Other</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfNC0zLTEtMS01MjY5Mg_b8d5c173-2404-4eed-b2cb-46a0526410cf">471</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfNS0zLTEtMS01MjY5Mg_403113df-f48d-48ac-947e-da3eed09de16">446</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsResearchAndDevelopmentExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfNi0zLTEtMS01MjY5Mg_00642b46-59df-42b5-afe0-a08feca28f8f">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="mrk:DisposalGroupIncludingDiscontinuedOperationsRestructuringCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfNy0zLTEtMS01MjY5Mg_1a2c4b0e-18ab-49d6-ab9c-1a81429a9752">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="mrk:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfOC0zLTEtMS01MjY5Mg_872b5c13-c5a6-4ddb-a2dd-8a0c7e08d1b4">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfOS0zLTEtMS01MjY5Mg_e638e81b-02d7-4650-b787-5a62909d75b0">978</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations before taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodBeforeIncomeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfMTAtMy0xLTEtNTI2OTI_774a4953-6cb6-435e-b273-7f56ea771c7c">475</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfMTEtMy0xLTEtNTI2OTI_e0713870-116f-4775-a742-45182395086c">38</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of taxes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfMTItMy0xLTEtNTI2OTI_4840e827-99e2-477a-bbfe-8267e08237e3">437</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Income of discontinued operations attributable to noncontrolling interests</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfMTMtMy0xLTEtNTI2OTI_10e70eba-b1cf-428a-8438-0792ce4ffb04">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt 0 10pt;text-indent:-9pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl8zNC9mcmFnOjJiZmEzZWU4YmQwOTRlYjliN2YwYjkyM2YyOGExODNiL3RhYmxlOjliMjFjMjYzZDZmMDQ1MGZiNTI0ZDhjYTgwN2EyZTM3L3RhYmxlcmFuZ2U6OWIyMWMyNjNkNmYwNDUwZmI1MjRkOGNhODA3YTJlMzdfMTQtMy0xLTEtNTI2OTI_853c05d0-ae1f-415b-b017-566881d9307f">434</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div id="ia10991337ee64bfe975ff621c73a0ff6_40"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfMTc2NDA_e9e71097-ac22-4b19-915d-7ef301e8751d" continuedat="i4ae553ef4cf543e281a285c1e3fc4c2a" escape="true">Acquisitions, Research Collaborations and License Agreements</ix:nonnumeric></span></div><ix:continuation id="i4ae553ef4cf543e281a285c1e3fc4c2a"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Merck entered into an exclusive license and research collaboration agreement with Artiva Biotherapeutics, Inc. (Artiva) to discover, develop and manufacture CAR-NK cells that target certain solid tumors using Artiva’s proprietary platform. Merck and Artiva agreed to engage in up to three different research programs, each covering a collaboration target. Merck has sole responsibility for all development and commercialization activities (including regulatory filing and approval). Under the terms of the agreement, Merck made an upfront payment of $<ix:nonfraction unitref="usd" contextref="i284dc6709bb44029afc31b29037d6c94_D20210101-20210131" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNjkzMA_74e9c41c-697e-4119-90ab-9e8272acd25b">30</ix:nonfraction>&nbsp;million, which was included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first quarter of 2021, for license and other rights for the first two collaboration targets and agreed to make another upfront payment of $<ix:nonfraction unitref="usd" contextref="i284dc6709bb44029afc31b29037d6c94_D20210101-20210131" decimals="-6" name="mrk:UpfrontAndMilestonePaymentsToBeMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNzEzNw_350df85c-5954-44bb-95c5-90dd688b5a13">15</ix:nonfraction>&nbsp;million for license and other rights for the third collaboration target when it is selected by Merck and accepted by Artiva. In addition, Artiva is eligible to receive future contingent milestone payments (which span all three collaboration targets), aggregating up to: $<ix:nonfraction unitref="usd" contextref="i7c00fc7b88294d8b927e27f45cb8fe15_D20210101-20210131" decimals="-5" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNzQwMg_92b25f3b-9145-4d74-94a1-123130b34dd5">217.5</ix:nonfraction>&nbsp;million in developmental milestones, $<ix:nonfraction unitref="usd" contextref="i746e8a7c0a1c498ab4dacb68c18a9554_D20210101-20210131" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNzQzNA_53b72299-6c08-42ef-b674-e01a66e74785">570</ix:nonfraction>&nbsp;million in regulatory milestones, and $<ix:nonfraction unitref="usd" contextref="i708d360a06994f3d948b7b63d03cbfbb_D20210101-20210131" decimals="-7" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNzQ2Nw_1bd322e4-d876-46b9-bc10-1f7d715036ae">1.05</ix:nonfraction>&nbsp;billion in sales-based milestones. The agreement also provides for Merck to pay tiered royalties ranging from <ix:nonfraction unitref="number" contextref="ief1437f601034f54996109a141e66f86_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNzU3Mg_c74f41ad-0aa0-41ac-af6a-c9ca135a5bc3">7</ix:nonfraction>% to <ix:nonfraction unitref="number" contextref="id6563318cc424274a7067a679835cc3d_D20210101-20210131" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfNzU3OA_c40d72e3-b558-4d63-86b7-a32da846459f">14</ix:nonfraction>% on future sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of Merck’s 2020 acquisition of OncoImmune, Merck obtained MK-7110, a therapeutic candidate that was being evaluated for the treatment of patients hospitalized with COVID-19. In 2021, Merck received feedback from the U.S. Food and Drug Administration (FDA) that additional data would be needed to support a potential Emergency Use Authorization application and therefore the Company did not expect MK-7110 would become available until the first half of 2022. Given this timeline and the technical, clinical and regulatory uncertainties, the availability of a number of medicines for patients hospitalized with COVID-19, and the need to concentrate Merck’s resources on accelerating the development and manufacture of the most viable therapeutics and vaccines, Merck decided to discontinue development of MK-7110 for the treatment of COVID-19. Due to the discontinuation, the Company recorded charges of $<ix:nonfraction unitref="usd" contextref="i2a83d6caa0d74560a0ab857f415a00b4_D20210101-20210331" decimals="-6" name="mrk:ChargesRelatedToProgramDiscontinuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80MC9mcmFnOjQ2YWJjZWQyYzRjYTRmMjY5YTc2MjQ5ODQwODYyOTU5L3RleHRyZWdpb246NDZhYmNlZDJjNGNhNGYyNjlhNzYyNDk4NDA4NjI5NTlfOTIzMQ_fdad1894-d1ad-4965-bf55-d4a901973b17">170</ix:nonfraction>&nbsp;million in the first quarter of 2021, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and relate to fixed assets and materials written off, as well as the recognition of liabilities for purchase commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="ia10991337ee64bfe975ff621c73a0ff6_43"></div><div style="margin-top:15pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 8 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfODQwOA_b2e9f17b-045b-46de-8c74-98dc3c6001fc" continuedat="ia7352c827369484fb7dff014500aaef7" escape="true">Collaborative Arrangements</ix:nonnumeric></span></div><ix:continuation id="ia7352c827369484fb7dff014500aaef7" continuedat="ie5384deccca84c58b6a26b31840700b0"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below. For further details refer to Note 4 to the consolidated financial statements included in Merck’s 2021 Form 10‑K.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) and Imfinzi. The companies are also jointly developing and commercializing AstraZeneca’s Koselugo (selumetinib) for multiple indications. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo&nbsp;monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo&nbsp;product sales generated through monotherapies or combination therapies are shared equally. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca and also made payments over a multi-year period for certain license options. In addition, the agreement provides for contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2022, Merck determined it was probable that sales of Lynparza in the future would trigger a $<ix:nonfraction unitref="usd" contextref="ie5d042ddfaf346f1ba1da6482da61e9e_D20220101-20220331" decimals="-6" name="mrk:ProbableContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI4NDUyOQ_266e08c1-58d7-487a-9283-d342701b6d88">600</ix:nonfraction>&nbsp;million sales-based milestone payment from Merck to AstraZeneca. Accordingly, Merck recorded a $<ix:nonfraction unitref="usd" contextref="ic33dcf7ddd324b24a90d58c352183695_I20220331" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI4NDU0Mw_9f3a6573-4530-4a27-928f-c86b45437a0a">600</ix:nonfraction>&nbsp;million liability and a corresponding increase to the intangible asset related to Lynparza. Merck also recognized $<ix:nonfraction unitref="usd" contextref="i8d2d79e90df442a98ec0b0c330a71f6b_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI4NDU1Ng_368eb518-7588-41b1-a20b-c87e5e7e4417">250</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense related to the recognition of this milestone in the first quarter of 2022. In addition, Merck made a sales-based milestone payment to AstraZeneca (which had been previously accrued for) of $<ix:nonfraction unitref="usd" contextref="i075513e9c1114e55a1234d36528b2ef0_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjI3Ng_0fd7e225-d24d-492d-b14e-acfbacdf3af5">400</ix:nonfraction>&nbsp;million in the first quarter of 2022. Potential future sales-based milestone payments of $<ix:nonfraction unitref="usd" contextref="i85f6a0d65b0d429c964541ef5de96b19_I20220331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjMzMQ_d3224fbc-2bbf-4fca-ad65-3b62de70b5d7">2.1</ix:nonfraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2022, Lynparza received a regulatory approval triggering a capitalized milestone payment of $<ix:nonfraction unitref="usd" contextref="i85f6a0d65b0d429c964541ef5de96b19_I20220331" decimals="-6" name="mrk:MilestonePaymentsAccruedRegulatory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1MTkzMg_c23b004a-0745-4329-86cb-486d28ae8f8b">175</ix:nonfraction>&nbsp;million from Merck to AstraZeneca, which was paid in April 2022. Potential future regulatory milestone payments of $<ix:nonfraction unitref="usd" contextref="i85f6a0d65b0d429c964541ef5de96b19_I20220331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsRegulatory" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjQ5MQ_841e7549-1f35-4a9f-b96e-af36a4c9787a">1.3</ix:nonfraction> billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonfraction unitref="usd" contextref="i0323c8cd1d7b457aa9351a4fc1a06259_I20220331" decimals="-8" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjY1MA_5eb148d4-4fed-4c3c-8e73-604e2361f744">1.6</ix:nonfraction> billion at March&nbsp;31, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfODQwNQ_6d21a019-5988-4f39-91aa-22ba66421bf8" continuedat="i0062086270134a1abcdda88bcc24e741" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.089%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6aba0e51340f46bdbd5362d2eab661b3_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMi0xLTEtMS01MjY5Mg_91e6e9ca-9a0d-485f-b405-46b371104b64">266</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idc3fa49797e441079f219f636745aa3a_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMi0zLTEtMS01MjY5Mg_fc1a6b34-f5d6-4160-ad85-ce9ca4cc65dd">228</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idc283b903bf24c4f83de222e93631982_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMy0xLTEtMS01MjY5Mg_3babcfa3-076b-4d73-be76-f2e0cc9cd8dc">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd49b180ffac41cf89b375262bb4bfcc_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMy0zLTEtMS01MjY5Mg_74eea34a-5dda-4e65-adc3-daba55fe2f9f">5</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic1ee42be285d46419401f3f81e0151ee_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfNC0xLTEtMS01MjY5Mg_0f6bd603-17ae-442f-93f3-d03aef0eca6b">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia9cac74667bc48efa05255f7577ddb2a_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfNC0zLTEtMS01MjY5Mg_be104a73-2b2c-4757-ba59-1b7a93548dc8">233</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab8ace176a2c49b7906c55bbe952cfcd_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfNi0xLTEtMS01MjY5Mg_05b744e1-dee2-456a-9403-86fbbee98a46">299</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8265e0dd48f248a5bb9def2083b37474_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfNi0zLTEtMS01MjY5Mg_f6d7db95-9e13-4490-9e9b-758b609e1425">42</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i19f707bad99e4500b6c587c05f6beabc_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfNy0xLTEtMS01MjY5Mg_a22f4fac-73ec-4359-b5de-bdd2b4e8d99e">44</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ief83125ccfbf4f128673e94c4677f01e_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfNy0zLTEtMS01MjY5Mg_67ba9fce-bf90-40b4-9f80-c51165fb1b95">40</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8af87705c5664e8284b95d224f72b26e_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfOC0xLTEtMS01MjY5Mg_42f8f864-f04f-4af0-bb9a-15d3e37eebe8">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4514555fbe1446c59007e8c8f1b49a37_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfOC0zLTEtMS01MjY5Mg_3dd12d30-c22c-4303-b7e3-6c4d8d9438a3">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7190d3f7c376447d96add2c0bceeeca4_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMTEtMS0xLTEtNjI5NjI_c8a083a9-07b5-448d-9952-260a64e26232">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i34b09115003e494298cbc95d98f804ec_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMTEtMy0xLTEtNjI5NjI_1f9d94ac-4b85-41cf-b2f0-a9035228f7e8">271</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Trade accounts payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2b24502dbec348cd860a15e4d13142d5_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMTItMS0xLTEtNjI5NjI_fd066406-dee7-4496-a41b-a00e4cd0cf55">190</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1584a6a8ea624a9d91aedd55be353743_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMTItMy0xLTEtNjI5NjI_aaab36cc-da3c-4bf8-8c69-961b0415ba33">415</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie68ec0adfa4d477e871d44fb6b610e62_I20220331" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMTMtMS0xLTEtNjcyMTc_3e6fb6bc-1f8b-4585-8388-f0bc5898a503">600</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i26044cf92e0440a5af9b31fd2cfd6daa_I20211231" decimals="-6" name="us-gaap:LiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjM1NjI4NDdhZTA1ODRkNzVhNzdlNGExYzY1ZjVjNWJlL3RhYmxlcmFuZ2U6MzU2Mjg0N2FlMDU4NGQ3NWE3N2U0YTFjNjVmNWM1YmVfMTMtMy0xLTEtNjcyMjQ_8f688a1d-9384-40ca-bdc0-209e0e4709eb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments. Amount in the first quarter of 2022 includes $<ix:nonfraction unitref="usd" contextref="iab8ace176a2c49b7906c55bbe952cfcd_D20220101-20220331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI4NDY3OA_5b6f792b-6d39-4e60-a063-ebf94f18fc69">250</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense as noted above.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 9 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="ie5384deccca84c58b6a26b31840700b0" continuedat="i371ceb6b130d4bfabf50d9dc51341a85"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions) and Merck and Eisai share applicable profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development are shared by the two companies in accordance with the collaboration agreement and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. Certain expenses incurred solely by Merck or Eisai are not shareable under the collaboration agreement, including costs incurred in excess of agreed upon caps and costs related to certain combination studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lenvima.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai and also made payments over a multi-year period for certain option rights (of which the final $<ix:nonfraction unitref="usd" contextref="iac7328d91d2948958236b87e13bdebe6_D20210301-20210331" decimals="-6" name="mrk:Licenseoptionpaymentrelatedtocollaborativearrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNDI0Ng_2c5242ee-a7e5-43c1-a8ca-a69a49a4930b">125</ix:nonfraction> million option payment was made in March 2021). In addition, the agreement provides for contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. In the first quarter of 2022, Merck made sales-based milestone payments to Eisai (which had been previously accrued for) aggregating $<ix:nonfraction unitref="usd" contextref="i146e5552a39c420c9d99509c7b0feea1_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNDUwNQ_4a55c801-f77c-4592-b254-22a4aa22b998">300</ix:nonfraction> million. In April 2022, Merck made an additional $<ix:nonfraction unitref="usd" contextref="ie3af0330d453438f98d1bde0f5d58922_I20220331" decimals="-6" name="mrk:MilestonePaymentsAccruedSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNDYyMw_dca3f019-f545-42d4-a09d-85115e55bc58">300</ix:nonfraction>&nbsp;million sales-based milestone payment, which was accrued for as of March 31, 2022. Potential future sales-based milestone payments of $<ix:nonfraction unitref="usd" contextref="ie3af0330d453438f98d1bde0f5d58922_I20220331" decimals="-8" name="mrk:PotentialFutureMilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNDY3OA_7fc34d6f-ca1d-4e39-9541-de1ac0bd0e95">2.6</ix:nonfraction> billion have not yet been accrued as they are not deemed by the Company to be probable at this time. In the first quarter of 2022, Lenvima received a regulatory approval triggering a capitalized milestone payment of $<ix:nonfraction unitref="usd" contextref="i146e5552a39c420c9d99509c7b0feea1_D20220101-20220331" decimals="-6" name="mrk:MilestonePaymentsMadetoCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNDg4OQ_791fdaff-10a3-48c5-8afd-f4f6f8b30eeb">25</ix:nonfraction>&nbsp;million from Merck to Eisai. As of March 31, 2022, regulatory milestone payments accrued but not yet paid totaled $<ix:nonfraction unitref="usd" contextref="ie3af0330d453438f98d1bde0f5d58922_I20220331" decimals="-6" name="mrk:MilestonePaymentsAccruedRegulatory" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMzI5ODUzNDkwOTk4MA_65defb39-4dbc-42a2-89b2-565418382464">25</ix:nonfraction>&nbsp;million. There are no potential future regulatory milestone payments remaining under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $<ix:nonfraction unitref="usd" contextref="i91177e6abf9042c885ee81412dddb7f8_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNTEyMQ_c8fd06ae-4890-4724-a98e-c0baa65c52fa">973</ix:nonfraction> million at March&nbsp;31, 2022 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><ix:continuation id="i0062086270134a1abcdda88bcc24e741" continuedat="i3d200525d5cb4b4a85d86d87f1ad0349"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic189df92d25646fba47e3536e145b8b1_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfMi0xLTEtMS01MjY5Mg_8a1c83b7-2b08-4bcd-a77a-a3812748fd30">227</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i878d9d0a26c1439fb0957325d44c493b_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfMi0zLTEtMS01MjY5Mg_20378748-f704-4953-b692-64035241fafc">130</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8caf4fecb9094fbb885141dd8b5ab6c3_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfNC0xLTEtMS01MjY5Mg_ca3b2904-0e69-488d-bdf9-f5d0663b9739">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i648df1ab6834452390cdd6bcfa03a089_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfNC0zLTEtMS01MjY5Mg_c78b7b0d-165f-4496-85e4-8a7dbaa1c517">47</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id9e59dbcc01b411082fb58e643fe4154_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfNS0xLTEtMS01MjY5Mg_36609603-073c-4de1-98e4-7585dee423b8">31</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibd50e5543ee24ef1834e21e5ee069c4d_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfNS0zLTEtMS01MjY5Mg_6af253e3-aae4-4531-ae2e-534b45670d86">23</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7a127b1be90347ea84e67018e6c84107_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfNi0xLTEtMS01MjY5Mg_ca3354ec-3a9b-47a9-9c18-1805db56e883">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i56d8870074884fe19b55cc514001ba49_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfNi0zLTEtMS01MjY5Mg_9d846d4a-1bc6-42f4-93fb-c41ea0825109">64</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id45fa1df009f4ca480ef6e4ade4cc469_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfOS0xLTEtMS02Mjk3MQ_8d1f4cd4-f1a7-4957-bea1-431eee699c42">241</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c363b8205844f41b1f842b551c0a954_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfOS0zLTEtMS02Mjk3MQ_f6f8c2a9-73eb-40fc-913f-ff047b42dde7">200</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5452402de8e24767b0d13c7da9e9976b_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfMTAtMS0xLTEtNjI5NzE_eb25a6aa-0e8d-448a-94a5-5507c41ce893">325</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9822411d5ec84b17831f658227c3f09c_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOjY3NDc3YTU2MTQ5NzRlODlhOWY5NjczYzI4YzgxNTJjL3RhYmxlcmFuZ2U6Njc0NzdhNTYxNDk3NGU4OWE5Zjk2NzNjMjhjODE1MmNfMTAtMy0xLTEtNjI5NzE_b76673b1-a3e4-43c8-850e-4a7e196381d5">625</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat). The two companies have implemented a joint development and commercialization strategy. The collaboration also includes development of Bayer’s Verquvo (vericiguat), which was approved in the U.S. in January 2021, in Japan in June 2021 and in the EU in July 2021. Under the agreement, Bayer commercializes Adempas in the Americas, while Merck commercializes in the rest of the world. For Verquvo, Merck commercializes in the U.S. and Bayer commercializes in the rest of the world. Both companies share in development costs and profits on sales. Merck records sales of Adempas and Verquvo in its marketing territories, as well as alliance revenue. Alliance revenue represents Merck’s share of profits from sales of Adempas and Verquvo in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs. Cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the agreement provided for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones. In January 2022, Merck made the final $<ix:nonfraction unitref="usd" contextref="icf2bfc97e2b646b08a81902523e34894_D20220101-20220131" decimals="-6" name="mrk:MilestonePaymentsSalesBased" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNzAyNg_c8a88a78-da3d-44a0-9dd6-7f155dfc910f">400</ix:nonfraction> million sales-based milestone payment under this collaboration to Bayer.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 10 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i371ceb6b130d4bfabf50d9dc51341a85" continuedat="i07b5967acc9b41e690c4ca9b7077ebba"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balances related to Adempas (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments attributed to Adempas) and Verquvo (which reflects the portion of the final sales-based milestone payment that was attributed to Verquvo) were $<ix:nonfraction unitref="usd" contextref="i02abe152752b4efdb54396b0af1db5dc_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNzU1NA_7e300440-d613-43d7-8d20-4ab95765db1d">758</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i08d753963d2944928e751d73bbcf303e_I20220331" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfNzg2MQ_0e1e0e90-02dc-4756-a108-c6663ec2aa3d">65</ix:nonfraction> million, respectively, at March&nbsp;31, 2022 and are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets are being amortized over their estimated useful lives (through 2027 for Adempas and through 2031 for Verquvo) as supported by projected future cash flows, subject to impairment testing. </span></div><ix:continuation id="i3d200525d5cb4b4a85d86d87f1ad0349" continuedat="i3bdae2ee252c4840b451988600b071c5"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d4f0445baeb4f61b8ab5688ea1c0d8e_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMi0xLTEtMS01MjY5Mg_8a6eb959-4d9d-482d-8409-67fe3af1a3ae">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0eb58f6cc86240b9820064f968b16313_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementProfitSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMi0zLTEtMS01MjY5Mg_ce6798b9-ff8f-4090-abd4-8c1b9cc49ccc">74</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0023dc3ab76c4a5c99bf9025876e7e29_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMy0xLTEtMS01MjY5Mg_e2dea8b4-7b0c-4421-9ea1-5ee14c8d52a3">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3efb3dc7010d4a86944ff34f6a2a1c3f_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMy0zLTEtMS01MjY5Mg_bce6782e-bd24-4a1d-8038-78d60c42472d">55</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Verquvo recorded by Merck</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9de20bf0cf994bef95335ac29fd55faf_D20220101-20220331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfNC0xLTEtMS01MjY5Mg_4d97e1d9-4c57-4c1d-8534-6746a9066372">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85cd454c231b4ef2899b619f8ba49ddb_D20210101-20210331" decimals="-6" name="mrk:CollaborativeArrangementSalesNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfNC0zLTEtMS01MjY5Mg_55179425-c55f-45c6-8b79-333f0a0a9bd7">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3d4f0445baeb4f61b8ab5688ea1c0d8e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfNS0xLTEtMS01MjY5Mg_694e07a8-8679-404f-a839-0e9713d5ed7c">136</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0eb58f6cc86240b9820064f968b16313_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfNS0zLTEtMS01MjY5Mg_7f80a219-d49d-4b91-8c13-65a124b8c1a1">129</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i636d7ce145164faf906ab8051d81f273_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfNy0xLTEtMS01MjY5Mg_c2959d46-73a0-44c5-8990-747f84e0452a">50</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic55d32e7c25b4cfaa3bc2a9613c4f778_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfNy0zLTEtMS01MjY5Mg_6b5e9559-f4ca-458c-8a2f-b8880fa4571a">208</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e525576197f43e5807f6f0b2804224f_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfOC0xLTEtMS01MjY5Mg_906a6b8c-5bb8-48f2-b2ff-a9b1d1e62ec5">23</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7fd8f2469bc41b8af76d26086d01004_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfOC0zLTEtMS01MjY5Mg_2daf4dc7-7ebd-45c4-906b-779a856b2b7b">17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i843bba0dfb2c4037843974aeb4c255d3_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfOS0xLTEtMS01MjY5Mg_f1a72c1d-24d7-42ad-9cf4-221cad0683d9">17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1338709b904e470a949ceddec7751620_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfOS0zLTEtMS01MjY5Mg_547a970a-d904-4449-b907-b7566419e1ec">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c1c0e9c98cb46198b4b4eb8c46b1d2e_I20220331" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMTItMS0xLTEtNjI5ODA_5b1e082b-e061-4bc2-a701-e299b4e8d7cf">129</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idc64220511304158b21dd32ddc6b51d7_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMTItMy0xLTEtNjI5ODA_e917cbf5-ff5c-41f4-9bdf-f8bad47f7a4b">114</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c739a0342cf48ceaadce72bd39cf97f_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMTMtMS0xLTEtNjI5ODA_987f04ee-0240-4604-b9c9-fc117fddf0c5">74</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i263e6282debc499eb206982dd9529223_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmE2MTk1ZDNlNjFiMTQ1ZTM5MTQzYjI1ZGNjZWM4NDMyL3RhYmxlcmFuZ2U6YTYxOTVkM2U2MWIxNDVlMzkxNDNiMjVkY2NlYzg0MzJfMTMtMy0xLTEtNjI5ODA_bca272e9-ab40-4281-ac44-f80aa0f41d06">472</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes amortization of intangible assets. Amount in the first quarter of 2021 includes $<ix:nonfraction unitref="usd" contextref="ic55d32e7c25b4cfaa3bc2a9613c4f778_D20210101-20210331" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfODE5MQ_6bfafaea-f5b0-4526-84ee-6e76ff64eab1">153</ix:nonfraction>&nbsp;million of cumulative amortization catch-up expense. In addition, cost of sales includes Bayer’s share of profits from sales in Merck’s marketing territories.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Amount as of December 31, 2021 includes accrued milestone payment.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ridgeback Biotherapeutics LP</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback), a closely held biotechnology company, entered into a collaboration agreement to develop </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir), an orally available antiviral candidate in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and related molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, Ridgeback received an upfront payment and is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones. The agreement also provides for Merck to reimburse Ridgeback for a portion of certain third-party contingent milestone payments and royalties on net sales, which is part of the profit share calculation. Merck is the principal on sales transactions, recognizing sales and related costs, with profit sharing amounts recorded within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Profits from the collaboration are split equally between the partners. Reimbursements from Ridgeback for its share of research and development costs (deducted from Ridgeback’s share of profits) are reflected as decreases to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received multiple authorizations or approvals worldwide and Merck has entered into advance purchase and supply agreements for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than <ix:nonfraction unitref="market" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-1" name="mrk:SupplyCommitmentMinimumNumberOfMarkets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI3Mjg2NQ_05c3a72d-7722-41d0-b215-e363763a17e0">30</ix:nonfraction> markets. As of March 31, 2022, the Company has <ix:nonfraction unitref="course" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-5" name="mrk:SupplyCommitmentRemainingMinimumCoursesCommitted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1OTkxMA_c3575c91-ce4b-4ccb-974b-2c0b59f7c1c9">3.4</ix:nonfraction> million remaining courses to be supplied under these agreements.</span></div><ix:continuation id="i3bdae2ee252c4840b451988600b071c5"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> sales</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie2a02c33f0b44e148e142580b1ecd20a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfMi0xLTEtMS02MjQzNQ_4aa800b8-5d7a-4641-959b-06b846a9d72e">3,247</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i211feabf348242a592ceb0456c74abfe_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfMi0zLTEtMS02MjQzNQ_918e616b-7ce8-4dab-b0a1-3e5e7a2bb1f0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0513d264fdea4a348c635a6b4e044dc2_D20220101-20220331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfNC0xLTEtMS02MjQzNQ_338360d5-97c4-46a5-a6b3-214ed6781f15">1,724</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i02691f575b99471e8cac5270a76ce9c3_D20210101-20210331" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfNC0zLTEtMS02MjQzNQ_06d5eace-d32d-47ca-989a-7b5880ab1064">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i67e7661ddcea45db831890aee08fa91f_D20220101-20220331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfNS0xLTEtMS02MjQzNQ_9e0fc7fe-f009-488f-a81b-8d49e74cd9dc">34</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e4651ada5e442508352a1606884ed94_D20210101-20210331" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfNS0zLTEtMS02MjQzNQ_3881eec3-4245-461f-991d-dc31df58b144">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia15e4b94c41c4936a90ba1d76a8ec4c1_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfNi0xLTEtMS02MjQzNQ_4ac4e640-7ee2-45a1-9352-821d0f6389e1">6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i97dd799f119d4acaa239e6efdf70960f_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfNi0zLTEtMS02MjQzNQ_e7836fb2-00cc-40d2-bd44-9b03fecc8351">42</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Ridgeback included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icc51509ec0c345079307c9662151568f_I20220331" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfOS0xLTEtMS02MjQ0OA_cca2c0e5-8d28-4dd0-b534-54e1b674229d">1,568</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1ff35c8e4fe944528f8b17c81e715975_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RhYmxlOmMwN2I2N2JlYzljYjQxNGE5NDVlMTU3NzAxNWMwNzZmL3RhYmxlcmFuZ2U6YzA3YjY3YmVjOWNiNDE0YTk0NWUxNTc3MDE1YzA3NmZfOS0zLTEtMS02MjQ0OA_ea98d5d5-2da6-46f1-94af-66cc85d5856b">283</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes royalty expense and amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Includes accrued royalty and milestone payments.</span></div></ix:continuation></ix:continuation><div style="margin-top:6pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 11 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i07b5967acc9b41e690c4ca9b7077ebba"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bristol Myers Squibb</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reblozyl (luspatercept-aamt) is a first-in-class erythroid maturation recombinant fusion protein obtained as part of Merck’s November 2021 acquisition of Acceleron that is being developed and commercialized through a global collaboration with Bristol Myers Squibb (BMS). Reblozyl is approved in the U.S., Europe, Canada and Australia for the treatment of anemia in certain rare blood disorders and is also being evaluated for additional indications for hematology therapies. BMS is the principal on sales transactions for Reblozyl; however, Merck co-promotes Reblozyl (and will co-promote all future products approved under this collaboration) in North America, which is reimbursed by BMS. Merck receives a <ix:nonfraction unitref="number" contextref="i0ed92363f93647b79f87158925f98db5_D20220101-20220331" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1MTI3OQ_a4911b9d-26a9-48cd-99ae-703a111a136b">20</ix:nonfraction>% sales royalty from BMS which could increase to a maximum of <ix:nonfraction unitref="number" contextref="ib65300c2eb314c6a90964489ddab40c8_D20220101-20220331" decimals="2" name="mrk:RoyaltyRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1MTM0Mw_8c912f55-3ccf-4d98-afcc-943249eaf78c">24</ix:nonfraction>% based on sales levels. This royalty will be reduced by <ix:nonfraction unitref="number" contextref="i6302fc043a8d426fa6cd462674ef17e1_D20220101-20220331" decimals="2" name="mrk:RoyaltyRateDeductionPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1MTQwMg_45028883-1d12-4630-a69c-a28f3eaf1073">50</ix:nonfraction>% upon the earlier of patent expiry or generic entry on an indication-by-indication basis in each market. Additionally, Merck is eligible to receive future contingent sales-based milestone payments of up to $<ix:nonfraction unitref="usd" contextref="i7c81597249484c5d862395460b415ba1_D20220101-20220331" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1MTYzMQ_969b7cd1-40b1-4fd1-85d4-7d9207933733">80</ix:nonfraction>&nbsp;million. Merck recorded alliance revenue of $<ix:nonfraction unitref="usd" contextref="i9866070ee97e4d06bf9db13bdb8d5c38_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMTA5OTUxMTY1NjIxNA_64615d7d-3f3c-4bff-9b1d-f4a1783745ea">52</ix:nonfraction> million within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2022 related to this collaboration, which includes royalties of $<ix:nonfraction unitref="usd" contextref="i6302fc043a8d426fa6cd462674ef17e1_D20220101-20220331" decimals="-6" name="us-gaap:RoyaltyIncomeNonoperating" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI4NTIyMA_ca4f6b59-73f0-41fe-9c7b-7e3177bf177f">32</ix:nonfraction>&nbsp;million, as well as the receipt of a regulatory approval milestone payment of $<ix:nonfraction unitref="usd" contextref="ic3782aea0e3041b7834c00ecab4a6fcd_D20220101-20220331" decimals="-6" name="mrk:ContingentPaymentsCollaborativeArrangement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80My9mcmFnOmNmN2E5NzEzNTQ2MzRhMDA5NTlmMWM5MzNlYjUyYzNhL3RleHRyZWdpb246Y2Y3YTk3MTM1NDYzNGEwMDk1OWYxYzkzM2ViNTJjM2FfMjE5OTAyMzI4MTI1NQ_14a34a4d-63c2-45cf-8a0f-8c57824e28c3">20</ix:nonfraction>&nbsp;million.</span></div></ix:continuation><div id="ia10991337ee64bfe975ff621c73a0ff6_46"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMzYzMw_5c8af367-008f-4051-9f88-918915b1bc77" continuedat="ia1fbc9ec5bb544c492a92265ac0c809f" escape="true">Restructuring</ix:nonnumeric></span></div><ix:continuation id="ia1fbc9ec5bb544c492a92265ac0c809f" continuedat="i21f36f30c0ff4834ad33eba7e167dd1d"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&nbsp;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint.&nbsp;This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-8" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfOTE1_78eed6a0-b2cb-4529-8924-efa8effc391a">3.5</ix:nonfraction> billion. The Company estimates that approximately <ix:nonfraction unitref="number" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfOTYw_ea577e6d-ed6f-4525-ab7e-9c99ffbeb2c2">70</ix:nonfraction>% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately <ix:nonfraction unitref="number" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="mrk:EstimateOfCumulativePreTaxCostsThatWillBeNoncash" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMTExNg_b43e16a4-32e5-4c39-beef-da57724e079c">30</ix:nonfraction>% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMTMwMw_d77f36bc-0926-4388-a3c8-c2aa34abaacc">127</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMTMxMA_9c097ac9-85ac-4d3c-897d-4dfe4fb2fb26">334</ix:nonfraction> million in the first quarter of 2022 and 2021, respectively, related to restructuring program activities. Since inception of the Restructuring Program through March&nbsp;31, 2022, Merck has recorded total pretax accumulated costs of approximately $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMTU5NA_0e9d3458-0d34-4823-8148-b2246630259e">2.8</ix:nonfraction> billion. For the full year of 2022, the Company expects to record charges of approximately $<ix:nonfraction unitref="usd" contextref="i0ea56790543f46faaadc62f8684bce2b_I20221231" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMTY3OA_bed895df-88f2-4d65-915f-d8c84e344db1">400</ix:nonfraction> million related to the Restructuring Program. For segment reporting, restructuring charges are unallocated expenses.</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMzY1NA_0e71284d-73e9-49c7-806e-b96ec0800e8a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.653%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42a4dc6b96994ee4ba0841ba49735e35_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMi0xLTEtMS01MjY5Mg_15485d01-466a-4b40-b3d7-b867892b136f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if4125cb4dd394284a4580f883d77350d_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMi0zLTEtMS01MjY5Mg_42d6a483-6feb-43e9-af93-7b9c6d329925">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2fcfa9624723489ba6a80c70b7d5c289_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMi01LTEtMS01MjY5Mg_5ec2a240-4546-4f72-b3b2-e5c506e512fc">28</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1aa6936088be466ab1be753be2e716ba_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMi03LTEtMS01MjY5Mg_76ecd602-7852-4a68-b258-ab13e8ea1c5b">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff49428b271f42b6bced0e3d8d872ca5_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMy0xLTEtMS01MjY5Mg_f510061b-7014-43e6-b34f-fd0e8085bfd8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8b826ca8aafc4e629596840de918f17a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMy0zLTEtMS01MjY5Mg_8153d32c-3896-4885-bc6f-18e3769be475">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i993f80b2b16d45fea1697609818b297a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMy01LTEtMS01MjY5Mg_cce5b1a8-208e-4b63-bbcd-66188337c45d">17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i215dd120a9954b8094887d237f17bba0_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfMy03LTEtMS01MjY5Mg_a2b80b41-539b-45a9-8663-57c35fbe5ec1">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb80d581758541d8a7db1b76793efce1_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNC0xLTEtMS01MjY5Mg_a6c1ec0d-5f72-4877-9612-d5d3368b765c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idbf67844f93a41efaf5174ec247bd79a_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNC0zLTEtMS01MjY5Mg_9768c307-726a-425f-b2ef-4c61518e43e3">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b88a67ffb7240ab8f7dd5fe46f74ce3_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNC01LTEtMS01MjY5Mg_40d9f2d8-b531-428a-ba68-32f12350b219">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c0e45f79c5640c483ef5639922c9662_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNC03LTEtMS01MjY5Mg_5f0fb2e8-df3b-49ee-9d80-3ed80877e69b">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id92474540ec941eba6f42f5fb3483971_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNS0xLTEtMS01MjY5Mg_48bb2bee-707e-4d73-934f-19ba1b0ed692">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8da6b50745e3485f8bda19fb7667c337_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNS0zLTEtMS01MjY5Mg_241bf3eb-9418-4cdb-abf0-211cbdd0ef3d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7d47f975397341ee91942114a468432d_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNS01LTEtMS01MjY5Mg_08e6d635-3613-45c5-93d1-f0ab3ab36e51">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6d7dd7a28a46403fb3f8310dd7946c8e_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNS03LTEtMS01MjY5Mg_d424291e-fa41-48ee-a057-af935eb95ae1">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i756643c6ceb64997a6af745ef2b23dae_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNi0xLTEtMS01MjY5Mg_5b6e7704-20a1-41b6-8b17-6ac38a0baa88">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia177d15a13db422990d77d15c46a7332_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNi0zLTEtMS01MjY5Mg_9fbc9823-58d8-45c5-a762-85d8785ba644">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3bf9a60a14242b9a59afceaa84c88b1_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNi01LTEtMS01MjY5Mg_56c57dfe-e8e4-4aa2-88e2-2974f4297c42">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjA5NWQ4N2JmN2Y1NTRkODI4YmVkMDAyYTJhYWI0YjM0L3RhYmxlcmFuZ2U6MDk1ZDg3YmY3ZjU1NGQ4MjhiZWQwMDJhMmFhYjRiMzRfNi03LTEtMS01MjY5Mg_8712ed7b-06ef-49c5-93da-1c017763d8d9">127</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i083001a6813642d3aadbb46f80ecd098_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMi0xLTEtMS01MjY5Mg_83b3af85-f1ed-4d63-b1cf-1aacbf657306">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6ec4d2ba98004e5cb08557100661cc87_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMi0zLTEtMS01MjY5Mg_ff772b2c-d68f-485a-8845-874d9a898ed5">10</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9120aa0d7e0d44c792e46468e63e93c1_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMi01LTEtMS01MjY5Mg_3e4599e8-d64c-436f-8908-69621c234500">17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0e9ca0ba953440c6bf9ef5d5e994ebef_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMi03LTEtMS01MjY5Mg_383b6ff7-b4ee-4fe8-8b75-177a36a793f6">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib149b55e183840ecbe597bc6945ef0ef_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMy0xLTEtMS01MjY5Mg_5ba532ae-8664-4d26-b631-9db47b066ade">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie73073b284314c7d8748e4f99eac9f48_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMy0zLTEtMS01MjY5Mg_751a1906-4c1e-4873-af24-385b835e24eb">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id0e1b1a70ac9400799d8b3cb608817ef_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMy01LTEtMS01MjY5Mg_ec2be9df-a6fc-4bcc-a212-2fac25728267">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5b7c3ee57c364d2093f51a0b7ac798a9_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfMy03LTEtMS01MjY5Mg_afc7599f-e2bb-4c45-a4ba-48660b347b6b">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie6b96c327cb0456daa06604876c3b60b_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNC0xLTEtMS01MjY5Mg_1bee3b6c-eb18-465a-a202-5496e8f80f52">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c89529c8bf94022bd0be4c3eadfb62b_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNC0zLTEtMS01MjY5Mg_a5359a2f-1d3a-4e57-902c-fbd4f1170ea9">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id5811fd28eb74cd68a897f8628ed8d8e_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNC01LTEtMS01MjY5Mg_c4d89412-ce57-4940-8029-f148d7cf0a4a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie19c73faaeb2467aa49b692beae087db_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNC03LTEtMS01MjY5Mg_5cd4a9ce-e90e-4807-b69f-be7dcc734ec0">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c1fbaf16fca45dda0edd4d80b6b36f1_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNS0xLTEtMS01MjY5Mg_f48c6a4f-afa9-403b-8809-8ef6eef2a87f">229</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia40c6a005a8f4eedbfda0c60ee32f379_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNS0zLTEtMS01MjY5Mg_af29bca1-a931-474e-a984-4de353833d9b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1911669813834f89b0648370d8e01e4c_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNS01LTEtMS01MjY5Mg_92e11269-bca9-4612-88fa-e17b865c28ba">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i104aaab5ee9c40a2bff8cae945a1b866_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNS03LTEtMS01MjY5Mg_3159dc3f-1983-4bff-b8eb-e9725d3f3356">297</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic22973668e3a46059375ee40f0c73712_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNi0xLTEtMS01MjY5Mg_5c1147ad-2526-444b-8d6f-07bf09087c9e">229</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i132549b6a36942d69f014bf8582f442f_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNi0zLTEtMS01MjY5Mg_6a7dd51b-851f-4dce-b7da-fdc6b77f0566">20</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9b3e1c3e201c42b29bd17a1add2ee2ba_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNi01LTEtMS01MjY5Mg_8abd2237-c974-4928-915d-3aac8c1ce575">85</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOjc0YWQ2YjA1YWExOTQzMjg5OWQyNzhlNDVlOWVmMmY1L3RhYmxlcmFuZ2U6NzRhZDZiMDVhYTE5NDMyODk5ZDI3OGU0NWU5ZWYyZjVfNi03LTEtMS01MjY5Mg_e36bd74a-1078-48d5-af87-7b1b93082b39">334</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 12 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i21f36f30c0ff4834ad33eba7e167dd1d" continuedat="i6462a575834d4587ab20162ba0cf4985"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2022 and 2021 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 10) and share-based compensation.</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RleHRyZWdpb246NjZjYWRlNGZiYTk2NDU5MGI3ZjdjYjY1MDFiNmIyZTJfMzY0MA_c199bceb-96f8-4493-8083-a55173bf44de" continuedat="id8a26f8678374382bad6bf576dac67e7" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the three months ended March&nbsp;31, 2022:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br>Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br>Depreciation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January&nbsp;1, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i05798371747b45c199001751f7abe23c_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMS0xLTEtMS01MjY5Mg_1eaebdb0-4229-47fb-9f30-92b16e2ea937">596</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f2ae88aa8d14c12a33bf4d8e8fc5f54_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMS0zLTEtMS01MjY5Mg_16388db1-208e-4cfa-9ec2-9d480dfa3b99">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie1c7500ab772482a92fd2e5dac4b47ef_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMS01LTEtMS01MjY5Mg_8c8f41c0-1cac-409b-b819-99900e3c225a">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMS03LTEtMS01MjY5Mg_7b9c47b4-4e20-4fbf-a4ab-97fec1fa0a69">637</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i756643c6ceb64997a6af745ef2b23dae_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMi0xLTEtMS01MjY5Mg_d3312f90-3116-4c58-a552-2fa3b1fbeae8">26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia177d15a13db422990d77d15c46a7332_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMi0zLTEtMS01MjY5Mg_1d37410f-4eeb-4cab-bfa8-c8a7b8560af6">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib3bf9a60a14242b9a59afceaa84c88b1_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMi01LTEtMS01MjY5Mg_8b7a0725-15ab-4aca-8b4d-ba2f5b40483b">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMi03LTEtMS01MjY5Mg_a425f809-7f3e-450c-bb0e-b2270cf01c80">127</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i756643c6ceb64997a6af745ef2b23dae_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMy0xLTEtMS01MjY5Mg_75e1e735-3172-490f-97ea-85daa110e3b4">68</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia177d15a13db422990d77d15c46a7332_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMy0zLTEtMS01MjY5Mg_61e751cb-91c0-400c-83d4-4e13989979ed">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib3bf9a60a14242b9a59afceaa84c88b1_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMy01LTEtMS01MjY5Mg_1e27f732-9457-4163-95bd-9317a9d9d5dd">45</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfMy03LTEtMS01MjY5Mg_b9ef4d5f-c37b-4113-867b-179f81c42169">113</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i756643c6ceb64997a6af745ef2b23dae_D20220101-20220331" decimals="-6" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNC0xLTEtMS01MjY5Mg_eb0c3e48-19ae-4d79-b34e-b482aff09a77">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia177d15a13db422990d77d15c46a7332_D20220101-20220331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNC0zLTEtMS01MjY5Mg_2889ba4e-34ff-422e-9e1d-6e9c4ae2b5ad">29</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib3bf9a60a14242b9a59afceaa84c88b1_D20220101-20220331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNC01LTEtMS01MjY5Mg_898f7b37-1b38-4f75-97de-f056a3cb039b">39</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="mrk:RestructuringReserveIncreaseDecreaseNoncashActivity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNC03LTEtMS01MjY5Mg_13560f17-76d0-4559-a042-e01529461353">68</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves March&nbsp;31, 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i142090cd4b09439285bc712604cc568b_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNS0xLTEtMS01MjY5Mg_04d3978b-edde-485c-a122-ad1b853b746c">554</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7d63b752e60485fae90b17ee58e976f_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNS0zLTEtMS01MjY5Mg_6234b594-a8fe-4d33-8b09-d9fc1f6c6462">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39b6d99b38ba4e278974adb8a832ef19_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNS01LTEtMS01MjY5Mg_63934ccf-e3d6-400b-bdc3-04ac0d7e6edc">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80Ni9mcmFnOjY2Y2FkZTRmYmE5NjQ1OTBiN2Y3Y2I2NTAxYjZiMmUyL3RhYmxlOmVkYTRjNDE3N2Y0MzQ0NzNhMGJkMDIzZTI3N2Y1YTg0L3RhYmxlcmFuZ2U6ZWRhNGM0MTc3ZjQzNDQ3M2EwYmQwMjNlMjc3ZjVhODRfNS03LTEtMS01MjY5Mg_8eed30b1-6f71-47e5-babb-d93c3e5447c1">583</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i6462a575834d4587ab20162ba0cf4985" continuedat="id0ce1ea3e9bc4757b55a0de7134c7856"><ix:continuation id="id8a26f8678374382bad6bf576dac67e7" continuedat="i4a37f5315f604fba9dd2cfe3649aecac">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"><ix:continuation id="id0ce1ea3e9bc4757b55a0de7134c7856"><ix:continuation id="i4a37f5315f604fba9dd2cfe3649aecac">The remaining cash outlays are expected to be substantially completed by the end of 2023.</ix:continuation></ix:continuation> </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_49"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1NTE_25845b92-b3b3-4943-ab4c-a3e433070e6f" continuedat="id2060273214c40a99d40240090ed1251" escape="true">Financial Instruments</ix:nonnumeric></span></div><ix:continuation id="id2060273214c40a99d40240090ed1251" continuedat="i46b181cf0fc34606b4b39e7c0e7f7eb8"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives of and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than <ix:nonnumeric contextref="i1131c496a0ee4c2fb87142bf03620fce_D20220101-20220331" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTQ4MQ_2940b193-8f19-4e52-9bdc-380d5c581694">two years</ix:nonnumeric> into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash&nbsp;flows from both designated and non-designated contracts are reported as operating activities&nbsp;in the Condensed Consolidated Statement of&nbsp;Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro, Japanese yen, British pound, Canadian dollar and Swiss franc. For exposures in developing country currencies, including the Chinese renminbi, the Company will enter into forward contracts to offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 13 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i46b181cf0fc34606b4b39e7c0e7f7eb8" continuedat="i0e0d3209edd84065a45befafb08d0160"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than <ix:nonnumeric contextref="ib23f5de2e6364aef8d294f417184975c_D20220101-20220331" name="us-gaap:DerivativeAverageRemainingMaturity1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfNDk3MQ_b6f254c4-17a9-4df6-895a-c3a03b70b2b8">one year</ix:nonnumeric>.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1Mzg_372d1bb8-355b-40a1-bd63-c8e6b6b2b919" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4bf5519b00f14ff5a470c47005b300d0_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNC0xLTEtMS01MjY5Mg_b1ec0b8d-ac8c-42ec-9a3b-fd72bad3c989">16</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i06ec6961ec5f401389c48e535ff46fb4_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNC0zLTEtMS01MjY5Mg_7473321e-36a7-4845-bd52-7ddc64186512">25</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i99c9a3d4ebfd426db78c80d3da415662_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNC05LTEtMS01MjY5Mg_2478db9e-964d-4fa4-9c71-381c8611bfe8">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i04c957f5468648da9ae763ce245aa7b3_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNC0xMS0xLTEtNTI2OTI_f0fe3fdc-7acf-4084-8cfb-85c7761557c1">4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ifd5cc35ac9c349e8b4c1ac63211fa54e_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNS0xLTEtMS01MjY5Mg_b668067e-4ecc-481b-a335-9a357e05da78">53</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ica54be2dee1b437d88bd886a3f2565d6_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNS0zLTEtMS01MjY5Mg_8eac09fb-6d7b-4e99-b19f-157e5d4e9d80">166</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2f50717d64cd4e5c81ae4cee1966eec7_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNS05LTEtMS01MjY5Mg_69366f92-8939-44a4-a463-474fd33ba0e6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id627fe4c400c40eca27607598ac180f5_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjJmNTAwMmQ3ZWEyNDQ1NzU4ZWM2MmYyYjBhMGYwMDM1L3RhYmxlcmFuZ2U6MmY1MDAyZDdlYTI0NDU3NThlYzYyZjJiMGEwZjAwMzVfNS0xMS0xLTEtNTI2OTI_c95296f4-5b84-41c6-bed6-b35ac97a5d75">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCL into income related to the sale of a subsidiary.</span></div></ix:nonnumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022,&nbsp;<ix:nonfraction unitref="interest_rate_swap" contextref="i6ceecbab094742dfa41de3ea9a97a557_I20220228" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfNzA0NQ_1feeacb0-c761-4260-ba0a-c38d03d19315">five</ix:nonfraction>&nbsp;interest rate swaps with a total notional amount of&nbsp;$<ix:nonfraction unitref="usd" contextref="i6ceecbab094742dfa41de3ea9a97a557_I20220228" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfNzEwMA_478a4cab-9110-4b1b-a974-66c746ecc590">1.25</ix:nonfraction> billion matured. These swaps effectively converted the Company’s&nbsp;$<ix:nonfraction unitref="usd" contextref="i6e0b94edb4164c418f9f13e185935729_I20220228" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfNzE2MA_04409052-4705-41b9-aae2-256e938373da">1.25</ix:nonfraction> billion,&nbsp;<ix:nonfraction unitref="number" contextref="i6e0b94edb4164c418f9f13e185935729_I20220228" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfNzE2NA_fd9dbdf1-20d7-4534-827d-f058f1b84213">2.350</ix:nonfraction>%&nbsp;fixed-rate notes due 2022 to variable rate debt.&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfInterestRateDerivativesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1NDI_344e1f6d-07fb-43dc-a186-207fb4f0bfc1" continuedat="ia7928d6630534b8dac69291887eeb736" escape="true">At March&nbsp;31, 2022, the Company was a party to <ix:nonfraction unitref="interest_rate_swap" contextref="i8615839501ea408fb7490e432802996e_I20220331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfNzI1MA_7b36dc00-1ffd-4a8d-83d9-000431a08f20">four</ix:nonfraction> pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</ix:nonnumeric></span></div><div style="margin-top:5pt"><ix:continuation id="ia7928d6630534b8dac69291887eeb736"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:58.695%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="number" contextref="i156e7362feab48919b4eac83c9ed17e5_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjYwNDA1ZTY2MjA0YTQ5NDg4ZDcxMGE2ZTZiZWEyNmY5L3RhYmxlcmFuZ2U6NjA0MDVlNjYyMDRhNDk0ODhkNzEwYTZlNmJlYTI2ZjlfMi0wLTEtMS01MjY5Mi90ZXh0cmVnaW9uOmYyMWI2MjU1MDU1MTQyOTRhYzU2YWEyYTlmYWZhOWJkXzQ_8c406cfd-9548-46f3-ad71-a75d492663cc">2.40</ix:nonfraction>% notes due 2022</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i156e7362feab48919b4eac83c9ed17e5_I20220331" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjYwNDA1ZTY2MjA0YTQ5NDg4ZDcxMGE2ZTZiZWEyNmY5L3RhYmxlcmFuZ2U6NjA0MDVlNjYyMDRhNDk0ODhkNzEwYTZlNmJlYTI2ZjlfMi0xLTEtMS01MjY5Mg_72118779-a522-4e7c-8d13-b837b431f4e0">1,000</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="interest_rate_swap" contextref="i156e7362feab48919b4eac83c9ed17e5_I20220331" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjYwNDA1ZTY2MjA0YTQ5NDg4ZDcxMGE2ZTZiZWEyNmY5L3RhYmxlcmFuZ2U6NjA0MDVlNjYyMDRhNDk0ODhkNzEwYTZlNmJlYTI2ZjlfMi0zLTEtMS01MjY5Mg_825625d7-c555-4a33-96e5-64c570796459">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i156e7362feab48919b4eac83c9ed17e5_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjYwNDA1ZTY2MjA0YTQ5NDg4ZDcxMGE2ZTZiZWEyNmY5L3RhYmxlcmFuZ2U6NjA0MDVlNjYyMDRhNDk0ODhkNzEwYTZlNmJlYTI2ZjlfMi01LTEtMS01MjY5Mg_83216f59-d283-4f00-9de2-01007a304941">1,000</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark LIBOR swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. See Note 1 for a discussion of the pending discontinuation of LIBOR as part of reference rate reform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 14 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i0e0d3209edd84065a45befafb08d0160" continuedat="i87eb2a41809542b9b550fcff70a3287b"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1MzM_9eaeea9c-c26f-4925-b6aa-52623a3c85ee" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Condensed Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tbody><tr><td style="width:1.0%"></td><td style="width:48.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.181%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic787f6bbc99f421884366f628bd5b20e_I20220331" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmM1NGFlMTI2MDg4NzRmODE4NGU3MzUxMTcyY2Q0ZDJiL3RhYmxlcmFuZ2U6YzU0YWUxMjYwODg3NGY4MTg0ZTczNTExNzJjZDRkMmJfMi0xLTEtMS01MjY5Mg_37a76d13-24b3-4e56-8255-97de801769ad">1,003</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i28d0c434076a41b7b58281c1421da539_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedge" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmM1NGFlMTI2MDg4NzRmODE4NGU3MzUxMTcyY2Q0ZDJiL3RhYmxlcmFuZ2U6YzU0YWUxMjYwODg3NGY4MTg0ZTczNTExNzJjZDRkMmJfMi0zLTEtMS01MjY5Mg_90ca3ead-622d-4dff-8c85-03f992a98557">2,263</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic787f6bbc99f421884366f628bd5b20e_I20220331" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmM1NGFlMTI2MDg4NzRmODE4NGU3MzUxMTcyY2Q0ZDJiL3RhYmxlcmFuZ2U6YzU0YWUxMjYwODg3NGY4MTg0ZTczNTExNzJjZDRkMmJfMi01LTEtMS01MjY5Mg_b8fd733e-38bc-4b36-a3af-0ac38955df76">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i28d0c434076a41b7b58281c1421da539_I20211231" decimals="-6" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmM1NGFlMTI2MDg4NzRmODE4NGU3MzUxMTcyY2Q0ZDJiL3RhYmxlcmFuZ2U6YzU0YWUxMjYwODg3NGY4MTg0ZTczNTExNzJjZDRkMmJfMi03LTEtMS01MjY5Mg_b6914922-748b-402d-86c1-0de082f925f9">13</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1MzU_e97661d5-d119-4a2c-a149-27356f1fcf5a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:19.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.241%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&nbsp;Value&nbsp;of&nbsp;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&nbsp;Dollar<br>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair&nbsp;Value&nbsp;of&nbsp;Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.&nbsp;Dollar<br>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i84df9ebcb6e249b19b8c65abf2f51afa_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNC0yLTEtMS01MjY5Mg_da796a81-6f1d-453b-a675-b8b6ccc5c3a2">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i84df9ebcb6e249b19b8c65abf2f51afa_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNC02LTEtMS01MjY5Mg_168976ec-bd84-4643-9d53-8a7b6f734a0b">1,000</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic80869c9916c4f3182f5f1350d321cb6_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNC04LTEtMS01MjY5Mg_dc19c774-d3db-4671-8504-00f5a05da5ce">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic80869c9916c4f3182f5f1350d321cb6_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNC0xMi0xLTEtNTI2OTI_3b01f104-dec0-4b40-b38a-ec06cb2b7440">2,250</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic58e613848c84850b802e16f2446e287_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNi0yLTEtMS01MjY5Mg_94c795c9-3622-4442-aca2-ebbc115b8612">341</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic58e613848c84850b802e16f2446e287_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNi02LTEtMS01MjY5Mg_728fdac0-264d-490d-98aa-ed8212f5f5fe">7,429</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifcf11f7d39174deb85575c3236863ed0_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNi04LTEtMS01MjY5Mg_e98de0b6-14c5-4798-b8dc-9d95cc11aa53">271</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifcf11f7d39174deb85575c3236863ed0_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNi0xMi0xLTEtNTI2OTI_988185f6-411a-42bb-ac9e-97c28c57cc9d">6,778</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf10bff6ef994f5390993e6748298938_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNy0yLTEtMS01MjY5Mg_10da9301-5a62-49d4-8dea-0db2aeeca548">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf10bff6ef994f5390993e6748298938_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNy02LTEtMS01MjY5Mg_0ebf590f-88ca-43a6-9fa5-ea76bb5ef825">1,595</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9b526e855cd94aae8975c28ab280e3b1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNy04LTEtMS01MjY5Mg_43f454ea-9ddf-4862-b776-0ae95772ac34">43</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9b526e855cd94aae8975c28ab280e3b1_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfNy0xMi0xLTEtNTI2OTI_c3751817-b1d8-4c60-9077-fd9e13cd5601">1,551</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3aa9308da6b34a0485af1842344b0316_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOC00LTEtMS01MjY5Mg_216910e0-3b28-470e-95ba-dad6877e33b0">21</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3aa9308da6b34a0485af1842344b0316_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOC02LTEtMS01MjY5Mg_3f0c564c-556d-4ec0-afd9-32cd9765035f">1,060</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b6bb899590e49088d607dbe3f6d0b39_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOC0xMC0xLTEtNTI2OTI_ad277c68-6e45-4a54-abc4-9439f702721e">24</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b6bb899590e49088d607dbe3f6d0b39_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOC0xMi0xLTEtNTI2OTI_1690e7a4-38d0-4e10-ae53-a3331eb8acd3">1,623</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib604f9403b4d4bf89b2a4adb03975da0_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOS00LTEtMS01MjY5Mg_0cf30d7d-4eb0-46d7-8a0e-1284072b576e">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib604f9403b4d4bf89b2a4adb03975da0_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOS02LTEtMS01MjY5Mg_c19d470d-c88a-4982-b5ce-e19da5d54bc7">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42b36a47629843b99a34c827ca9295e1_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOS0xMC0xLTEtNTI2OTI_551fa71f-a992-49d3-b0e1-837d4d1b49bd">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42b36a47629843b99a34c827ca9295e1_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfOS0xMi0xLTEtNTI2OTI_e9da6bad-5483-486e-aa22-1bf0e932894c">43</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i29d9a7e5941144369913a515e4e7bfc6_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTAtMi0xLTEtNTI2OTI_317a1573-39f4-47db-8a0b-7deb37051121">391</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i29d9a7e5941144369913a515e4e7bfc6_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTAtNC0xLTEtNTI2OTI_13dc5103-b6a0-43fd-99dc-145635737d09">22</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i29d9a7e5941144369913a515e4e7bfc6_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTAtNi0xLTEtNTI2OTI_49cb63f9-a2b2-47e4-a919-8068cedfebd5">11,093</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i168e76fe57954e69a56f509855769b31_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTAtOC0xLTEtNTI2OTI_2c7453a5-fbc2-4b43-9c4e-8a2b1de532b7">328</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i168e76fe57954e69a56f509855769b31_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTAtMTAtMS0xLTUyNjky_a8b2eb33-0d64-4b4e-949e-bd5081df50da">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i168e76fe57954e69a56f509855769b31_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTAtMTItMS0xLTUyNjky_0bd8d7e2-6881-4ea6-9944-13281df58804">12,245</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i376cb0cd1f4a49d39b22e1d7c29a4444_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTItMi0xLTEtNTI2OTI_5b13cda7-5fd1-4487-aab3-8df7b920d579">288</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i376cb0cd1f4a49d39b22e1d7c29a4444_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTItNi0xLTEtNTI2OTI_1ab8f860-d6de-42de-8303-af685c107806">12,466</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib6cd283e82c243c88676c6ae6dcb0ee7_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTItOC0xLTEtNTI2OTI_c5b367a7-d2a4-4fd8-a0b0-f1f3e5045e56">221</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib6cd283e82c243c88676c6ae6dcb0ee7_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTItMTItMS0xLTUyNjky_90913cc7-8260-4a90-9d40-d8e1e914db68">10,073</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16730a36e519417bb54981b32dbf2cb9_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTMtNC0xLTEtNTI2OTI_71a2aa65-361b-4c30-9f33-4c6cb0f32fbf">219</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16730a36e519417bb54981b32dbf2cb9_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTMtNi0xLTEtNTI2OTI_99b81c31-8e64-4eda-af8b-1a575c9a0409">7,700</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1c161bae8ad46a79a1341906268cb7f_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTMtMTAtMS0xLTUyNjky_0d604257-e966-48d2-a4f6-dbef57fcebda">96</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1c161bae8ad46a79a1341906268cb7f_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTMtMTItMS0xLTUyNjky_00687e80-6481-4fe9-9274-668e54cce84a">10,640</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8bddef458f3b4c5fb9672550af5f7a97_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTQtMi0xLTEtNTI2OTI_89ee794b-6a8f-4fbd-a079-5789c1aa7ec6">288</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8bddef458f3b4c5fb9672550af5f7a97_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTQtNC0xLTEtNTI2OTI_c2751289-0f7d-4ff1-a24d-df12ea8d107b">219</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8bddef458f3b4c5fb9672550af5f7a97_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTQtNi0xLTEtNTI2OTI_5ec01443-7a53-431f-8a9a-e1c98ffe21c9">20,166</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8b41770f9644bf59fb55850d5ceb2e0_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTQtOC0xLTEtNTI2OTI_757f34d3-252c-43cb-a4e4-b3c910e61467">221</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8b41770f9644bf59fb55850d5ceb2e0_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTQtMTAtMS0xLTUyNjky_cb7c8c3b-2bd4-42c1-938e-05e485fcc816">96</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id8b41770f9644bf59fb55850d5ceb2e0_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTQtMTItMS0xLTUyNjky_8ba02eae-a7e1-4805-bab7-d1db0172ecee">20,713</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTUtMi0xLTEtNTI2OTI_8cc545b0-c95c-49ad-9347-8878a648f01f">679</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTUtNC0xLTEtNTI2OTI_7d64f660-f589-4225-9727-4f76bdec4f79">241</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTUtNi0xLTEtNTI2OTI_e86e0c0e-65f6-4ac9-8a08-6b137cf627b3">31,259</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTUtOC0xLTEtNTI2OTI_99a7a233-b69d-4724-b0a0-f10e808f5617">549</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTUtMTAtMS0xLTUyNjky_9863f8f0-5753-4cce-8faa-9bafa9a6b905">121</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjgwYmExYWI5MmYyZDQ3MThiNWM4YTdhZTk3ZGZhOTBmL3RhYmxlcmFuZ2U6ODBiYTFhYjkyZjJkNDcxOGI1YzhhN2FlOTdkZmE5MGZfMTUtMTItMS0xLTUyNjky_5ae50d65-ceac-4db9-8da4-0fa4218c55a5">32,958</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). <ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="mrk:OffsettingAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1NDM_5bb89bcf-4c46-44e3-808d-ddc4677a8b08" continuedat="if846963564ef4d40be38d851ee528a25" escape="true">The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</ix:nonnumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="if846963564ef4d40be38d851ee528a25"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMi0xLTEtMS01MjY5Mg_c672c2db-47de-458d-b148-a351d088ec39">679</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMi0zLTEtMS01MjY5Mg_23c922e3-cf6d-4b7e-bce3-dc66b5d9ac3b">241</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMi01LTEtMS01MjY5Mg_67d79cf4-6acd-4ee4-8e1d-02cd90e1ea2b">549</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMi03LTEtMS01MjY5Mg_9df77a17-a8fa-44c4-b51f-b61f3b4c8967">121</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMy0xLTEtMS01MjY5Mg_0bda6122-a977-4f1a-b1d1-f28b1fe1c396">191</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMy0zLTEtMS01MjY5Mg_053ffeee-b700-4120-becd-d200f66d8de0">191</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMy01LTEtMS01MjY5Mg_ebd33a1c-9eca-4dae-bb30-6ffffbe6ef9d">110</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityNotOffsetPolicyElectionDeduction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfMy03LTEtMS01MjY5Mg_1c3082b7-8e2b-4c90-9cf7-ffc8d0148cc0">110</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNC0xLTEtMS01MjY5Mg_49000ffb-f56e-4cda-99b6-401aecbb895c">220</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNC0zLTEtMS01MjY5Mg_06d235a6-8c2d-4683-a553-d9d6b8ed63f6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNC01LTEtMS01MjY5Mg_c24ebbd6-6eea-4f80-8edd-47ddb89304da">164</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralRightToReclaimCash" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNC03LTEtMS01MjY5Mg_83fe9fde-32c3-4d61-8344-834345ff6ff6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNS0xLTEtMS01MjY5Mg_a32d943a-2e99-4922-be77-b94fce65f3ef">268</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNS0zLTEtMS01MjY5Mg_c4c0a549-daae-4c91-a226-a9ab1174d4a1">50</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNS01LTEtMS01MjY5Mg_5fb0a41e-e2d4-42bd-8226-686d55880924">275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmUwYjBiNGM3Njk3NzQ5OThiNDA5YzM1NmE2YjQxN2I3L3RhYmxlcmFuZ2U6ZTBiMGI0Yzc2OTc3NDk5OGI0MDljMzU2YTZiNDE3YjdfNS03LTEtMS01MjY5Mg_c13f538c-a49f-484f-923f-ebaa74f70980">11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:continuation></div></ix:continuation><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 15 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i87eb2a41809542b9b550fcff70a3287b" continuedat="i2c96f8ccf54f47769dd1df4348fcef69"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1NTk_e449125a-dd9f-40d8-8a07-83b70962257e" escape="true"><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax gains and losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow </span></div><div style="text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Hedges are Recorded</span></div></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMy0xLTEtMS01MjY5Mg_c0200447-8007-49b4-96c5-2c1bc744a7cb">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMy0zLTEtMS01MjY5Mg_bf666d7c-b66b-425c-abfa-4306342b791b">10,627</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMy01LTEtMS01MjY5Mg_57e85371-36e4-4905-a3a8-064eb352b79f">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMy03LTEtMS01MjY5Mg_00718ea2-9b44-40e6-99da-935ed54da7f3">455</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMy05LTEtMS01MjY5Mg_65ffcf41-acbb-457b-bf0c-b99b63be32d1">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMy0xMS0xLTEtNTI2OTI_d0a4cd95-23a9-45c4-9527-2eaee9b205ea">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife71d5c0fc5f4f848de0b11fdd67eea6_D20220101-20220331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfNi01LTEtMS01MjY5Mg_0ac59c94-947e-46e3-947f-20a044d45e93">10</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic1f02aeb9ea1476fb0c433f8859d06c4_D20210101-20210331" decimals="-6" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfNi03LTEtMS01MjY5Mg_3108ded3-a357-4ca2-a4dc-9487028fc5ce">11</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife71d5c0fc5f4f848de0b11fdd67eea6_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfNy01LTEtMS01MjY5Mg_b5e162fd-4f39-4798-b182-cc2dfa83ef36">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic1f02aeb9ea1476fb0c433f8859d06c4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfNy03LTEtMS01MjY5Mg_13ba519c-b916-408d-9b9f-2b5a30622d5f">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4bf5519b00f14ff5a470c47005b300d0_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTAtOS0xLTEtNTI2OTI_4ba3407c-055d-4b3d-8f24-2caee44772f2">148</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06ec6961ec5f401389c48e535ff46fb4_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTAtMTEtMS0xLTUyNjky_168689eb-3633-45f5-a3a8-d9f8102d9203">180</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic1d7d0b1ad9945b1a7ae596cacb65fda_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTEtMS0xLTEtNTI2OTI_2155cbb7-479c-4ebb-897b-8df49e316ebb">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2fd8e131edc14305952828bea95e6c14_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTEtMy0xLTEtNTI2OTI_0de5cc63-cb23-4970-a11d-df1d484a0e40">112</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4bf5519b00f14ff5a470c47005b300d0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTEtOS0xLTEtNTI2OTI_96ef3ef5-0a16-4113-ae6e-42c87bc81047">67</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06ec6961ec5f401389c48e535ff46fb4_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTEtMTEtMS0xLTUyNjky_fca7f5ac-25b6-44e6-83c5-37d68c7e2405">112</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ife71d5c0fc5f4f848de0b11fdd67eea6_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTMtNS0xLTEtNTI2OTI_9fbde6c4-8f31-4ab2-9224-f06e12289c98">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic1f02aeb9ea1476fb0c433f8859d06c4_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTMtNy0xLTEtNTI2OTI_a663be5c-2660-4331-93c2-f2fa97e91392">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i65bfaada786f453bb1ac34787c8e1216_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTQtOS0xLTEtNTI2OTI_8e500ae1-edeb-4f32-9857-7cb121bd8a58">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i61c1473d795f48b0b06a08146f9355ef_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjc4ZWMwYmViZTQyYzRiNWZiNTkwMjhmNTVjN2I1YjIyL3RhYmxlcmFuZ2U6NzhlYzBiZWJlNDJjNGI1ZmI1OTAyOGY1NWM3YjViMjJfMTQtMTEtMS0xLTUyNjky_ae3bac08-4fc8-4d6c-87e1-a5186034e07e">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div></ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1MjY_aa6b316d-d37e-4d30-b3d1-731ab0cf0874" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.283%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53aae0c518854acf83522df504d07e4c_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjM1M2ExMDIwYzY4ZjQ0YmNiOTNhNzBjNDAzYWUyY2QwL3RhYmxlcmFuZ2U6MzUzYTEwMjBjNjhmNDRiY2I5M2E3MGM0MDNhZTJjZDBfNC0zLTEtMS01MjY5Mg_146e1dcd-ffe4-44ce-8786-396804f5d7c9">28</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5256e90e8c7c488599f91eb12c5ca8a5_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjM1M2ExMDIwYzY4ZjQ0YmNiOTNhNzBjNDAzYWUyY2QwL3RhYmxlcmFuZ2U6MzUzYTEwMjBjNjhmNDRiY2I5M2E3MGM0MDNhZTJjZDBfNC01LTEtMS01MjY5Mg_d5dafe76-e109-4cb5-b14a-4049c8bcf976">50</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4a635a711e444518a5bc98f59d33afca_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjM1M2ExMDIwYzY4ZjQ0YmNiOTNhNzBjNDAzYWUyY2QwL3RhYmxlcmFuZ2U6MzUzYTEwMjBjNjhmNDRiY2I5M2E3MGM0MDNhZTJjZDBfNS0zLTEtMS01MjY5Mg_85ece249-c352-4c4a-8bd1-0973f35c5468">2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i86bb9e8cd0bc4d449fcb29e8666c0a9b_D20210101-20210331" decimals="-6" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjM1M2ExMDIwYzY4ZjQ0YmNiOTNhNzBjNDAzYWUyY2QwL3RhYmxlcmFuZ2U6MzUzYTEwMjBjNjhmNDRiY2I5M2E3MGM0MDNhZTJjZDBfNS01LTEtMS01MjY5Mg_2a6b4ca3-235b-4580-8bc3-9eb76478b6bb">4</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts primarily mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&nbsp;31, 2022, the Company estimates $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfOTkzNA_cec16497-373b-4995-9a90-b73851c7ef59">248</ix:nonfraction> million of pretax net unrealized gains on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div></ix:continuation><div style="margin-top:12pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 16 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i2c96f8ccf54f47769dd1df4348fcef69" continuedat="i50441c8bfdd5477ba61dea6ee25f33ad"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1NDQ_bb6e204b-61f8-456b-9da2-435b331b8e82" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:31.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&nbsp;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross&nbsp;Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i14e42ef5c15e4cc4b90826fe4fe87191_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xLTEtMS02NzQwMQ_92108047-e056-4e85-a6c5-1c40625dbe57">372</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i14e42ef5c15e4cc4b90826fe4fe87191_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0zLTEtMS02NzQwMQ_160b7105-0617-460c-a1a9-1ceba8702c6c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i14e42ef5c15e4cc4b90826fe4fe87191_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy01LTEtMS02NzQwMQ_f650ffcc-54d9-4f6c-bc6f-4af9b1baa149">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i14e42ef5c15e4cc4b90826fe4fe87191_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy03LTEtMS02NzQ5Mg_14f15c9a-7196-44cd-8355-0b88aa44642f">372</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2493ec10d2914f8882dd1f55bbe1cd74_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy05LTEtMS02NzQwOA_acff85bb-27f2-496d-9988-e888fbe1adba">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2493ec10d2914f8882dd1f55bbe1cd74_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xMS0xLTEtNjc0MDg_9c4cee03-5cad-4815-bc00-f6077fa75f4f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2493ec10d2914f8882dd1f55bbe1cd74_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xMy0xLTEtNjc0MDg_0b4b1a2b-b4de-477e-8101-3cddac69c8c2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2493ec10d2914f8882dd1f55bbe1cd74_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xNS0xLTEtNjc0OTI_daa5c2b1-8ca4-44a8-a362-e35716103a96">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44167d75dc2f4d418e6ddf1fd6751beb_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xLTEtMS01MjY5Mg_146a6b3a-c43b-4ba9-bde7-23e992fe68ba">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44167d75dc2f4d418e6ddf1fd6751beb_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0zLTEtMS01MjY5Mg_e202b41b-0009-476e-84a5-254a66252317">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44167d75dc2f4d418e6ddf1fd6751beb_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy01LTEtMS01MjY5Mg_61050019-8c01-4b00-a44d-bc4d959fc504">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44167d75dc2f4d418e6ddf1fd6751beb_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy03LTEtMS01MjY5Mg_f7bb8d6d-fb74-43d3-9173-fb6712d31adb">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44ce7d8d13ba48ae8a571e69a7f54ce9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy05LTEtMS01MjY5Mg_c95e02b5-721a-4159-8905-aab179f329e1">80</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44ce7d8d13ba48ae8a571e69a7f54ce9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xMS0xLTEtNTI2OTI_4c545081-2f97-48f9-bb38-6209cb69d8af">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44ce7d8d13ba48ae8a571e69a7f54ce9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xMy0xLTEtNTI2OTI_91b07b77-d926-4190-9312-af353d1ef692">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i44ce7d8d13ba48ae8a571e69a7f54ce9_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfMy0xNS0xLTEtNTI2OTI_ade5af70-f242-427b-9e36-d75dbadf75ce">80</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bf4a45e94534529ac1947bcc0b3a138_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC0xLTEtMS01MjY5Mg_71570f72-06f9-4d75-93cd-145c328d7d81">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bf4a45e94534529ac1947bcc0b3a138_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC0zLTEtMS01MjY5Mg_a1523b78-fb00-4b35-9844-aa78f1b6e309">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bf4a45e94534529ac1947bcc0b3a138_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC01LTEtMS01MjY5Mg_62ef4cb8-15d9-4610-8965-d853f2750775">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bf4a45e94534529ac1947bcc0b3a138_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC03LTEtMS01MjY5Mg_425e86ee-76b2-42a1-b9f7-4ad78f65b00e">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0d747a14a1549afafa300095b8cbf00_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC05LTEtMS01MjY5Mg_e0d32b79-fa63-4540-8695-df3635d16065">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0d747a14a1549afafa300095b8cbf00_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC0xMS0xLTEtNTI2OTI_a48b8f19-9203-4ecc-925a-5de3b41f0632">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0d747a14a1549afafa300095b8cbf00_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC0xMy0xLTEtNTI2OTI_d77d19fd-cf11-4d77-b2ec-874a7dba7833">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib0d747a14a1549afafa300095b8cbf00_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNC0xNS0xLTEtNTI2OTI_24a676fe-7554-447c-b936-c8711e671876">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bfae8729b2f40538fdad12a6f09ee7c_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS0xLTEtMS01MjY5Mg_2566887a-0399-4b60-8254-90fdc24c585b">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bfae8729b2f40538fdad12a6f09ee7c_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS0zLTEtMS01MjY5Mg_853a3a6d-fa3e-4595-b509-e3f412923f5d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bfae8729b2f40538fdad12a6f09ee7c_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS01LTEtMS01MjY5Mg_be1ace65-c501-44ac-8d0f-9a37730f086f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bfae8729b2f40538fdad12a6f09ee7c_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS03LTEtMS01MjY5Mg_121e8168-72e7-4c8d-b922-11489d485379">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2215a71340744b95b2bfd090a9c51f79_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS05LTEtMS01MjY5Mg_4d94c30b-d93f-43fa-9f29-51b01271b362">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2215a71340744b95b2bfd090a9c51f79_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS0xMS0xLTEtNTI2OTI_7b6faac1-05cf-46f7-a6a0-19ce818d66a0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2215a71340744b95b2bfd090a9c51f79_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS0xMy0xLTEtNTI2OTI_5116ed2e-9793-4e07-bd2d-31080cdda192">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2215a71340744b95b2bfd090a9c51f79_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNS0xNS0xLTEtNTI2OTI_742d8d29-d694-47bc-b385-e951e9fa5cb5">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi0xLTEtMS01MjY5Mg_f756b041-9dbd-4d6e-ba33-04657a4e34a1">454</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi0zLTEtMS01MjY5Mg_f6a251dd-7e50-47a2-bf39-bea0eb001699">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi01LTEtMS01MjY5Mg_47122b39-2b8f-489f-acd1-1aec64a3b85d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi03LTEtMS01MjY5Mg_403e3299-ef69-49ac-ac3c-e2c26ec0908b">454</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi05LTEtMS01MjY5Mg_0ad34099-17d3-44ec-8ce8-e0217819f0f5">86</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi0xMS0xLTEtNTI2OTI_1f87ecbe-afbe-47fc-9a48-14d4155679ef">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi0xMy0xLTEtNTI2OTI_223d1677-f1a4-4778-86be-f3c61779b7ec">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNi0xNS0xLTEtNTI2OTI_19acc7fb-4a62-4aeb-8dea-22c9c4404418">86</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNy03LTEtMS01MjY5Mg_fee13fba-a930-4b26-93b2-d51b17f046ec">1,397</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfNy0xNS0xLTEtNTI2OTI_12d9c8e6-3245-4448-8817-32a5bf728180">1,647</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfOC03LTEtMS01MjY5Mg_4374b01b-ccee-4b97-ab2b-4caebc816310">1,851</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="mrk:DebtSecuritiesandEquitySecuritiesFVNI" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOmJjNDcyZTc0YWFjMTRmNTFiMTY5YTExNTk2MzRhM2E3L3RhYmxlcmFuZ2U6YmM0NzJlNzRhYWMxNGY1MWIxNjlhMTE1OTYzNGEzYTdfOC0xNS0xLTEtNTI2OTI_4b2166ae-cc9c-4f4c-8065-0af520611968">1,733</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net losses of $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTA0ODQ_f5ba26f7-1c1a-4be5-af20-1ea3762570da">225</ix:nonfraction>&nbsp;million were recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at March&nbsp;31, 2022 in the first quarter of 2022. Unrealized net losses recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at March&nbsp;31, 2021 were $<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTA3MzM_09a4570e-2349-434a-b826-dc6af24bbc31">181</ix:nonfraction> million in the first quarter of 2021.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March&nbsp;31, 2022 and March&nbsp;31, 2021, the Company also had $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTA4Mzc_6be353fc-10b7-4282-a368-2d0b55fca6e3">643</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTA4NDQ_429f8d6f-4c91-408c-bb02-7ae28131ab00">651</ix:nonfraction> million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company records unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and records unrealized losses based on unfavorable observable price changes, which are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the first quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTEyODc_8bc9c4a5-6711-4bfc-8308-e1fd7b427a23">14</ix:nonfraction> million related to certain of these equity investments still held at March&nbsp;31, 2022. During the first quarter</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the Company recorded unrealized gains of $<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTE0NzI_7d845629-7ea8-43cb-8234-b00935ecffc6">33</ix:nonfraction>&nbsp;million related to certain of these investments still held at March&nbsp;31, 2021. Cumulative unrealized gains and cumulative unrealized losses based on observable price changes for investments in equity investments without readily determinable fair values still held at March&nbsp;31, 2022 were $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTE3Nzk_b4502b6b-ba37-4edd-a6f4-c806ce2224b6">248</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTE3ODY_31a58eae-0ddd-4a87-907f-bc51e0526a03">7</ix:nonfraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2022 and 2021, the Company also had $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-8" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMjE5OTAyMzI3NjI5Nw_67bea5f9-18a6-41b9-a681-d20987257a27">1.2</ix:nonfraction>&nbsp;billion and $<ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:EquitySecuritiesFVNINoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMjE5OTAyMzI3NjMxMQ_d72cf001-7dcc-479f-99d3-4f5fc62faae2">884</ix:nonfraction>&nbsp;million, respectively, recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for equity securities held through ownership interests in investment funds. Losses (gains) recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relating to these investment funds were $<ix:nonfraction unitref="usd" contextref="ief69ef50aac84d68859ca7c590a9fefd_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMjE5OTAyMzI3NjM2NA_34ecbf65-8e84-4df4-8182-a31661b007b7">509</ix:nonfraction>&nbsp;million and $(<ix:nonfraction unitref="usd" contextref="ie9a0d28cc055444882014830f4dc1e4f_D20210101-20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMjE5OTAyMzI3NjM4MA_9e3013e3-a2cd-49ef-a926-1efcab674f79">264</ix:nonfraction>)&nbsp;million for the first quarter of 2022 and 2021, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level&nbsp;1 having the highest priority and Level 3 having the lowest: </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div></ix:continuation><div style="margin-top:6pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 17 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i50441c8bfdd5477ba61dea6ee25f33ad" continuedat="i9562afe5a9ea4a8b816ed67ad13ede38"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1NDk_af612290-1f12-45a1-967a-222d72a59a1f" escape="true"><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:25.654%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i19fd8267373c484eb4577b24d021f871_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xLTEtMS02NzU1MQ_535a2542-c40f-43d5-80e8-e2da806691e6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6b3ac36ac61e4e30a59026ba389c4521_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0zLTEtMS02NzU1MQ_7b773c92-120f-4fb2-8326-6a78125ed80e">372</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78c97e839a044ceca9dc4c6d46a7e30e_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS01LTEtMS02NzU1MQ_d6c48912-16c0-4dec-afe6-7b206b56afb1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icad87ec0429c4aafa2367208cc9a35bb_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS03LTEtMS02NzU1MQ_d0df716f-d8df-44f7-9dcb-e47e252d06f8">372</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i058b744e350e4d37b18173eed07706c6_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS05LTEtMS02NzU1MQ_8d2261ce-8250-48ec-b836-482a5d692276">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00be2778a35042578ac5940ad025a162_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xMS0xLTEtNjc1NTE_f91c5762-7b8b-40fa-92ba-e5ccb804030c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e2dd8c1250d42feb61783187b40b51a_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xMy0xLTEtNjc1NTE_3235b8fe-0e8e-4990-8467-d8294b6c74eb">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3ac5eca5208c42ca9da3f2e492e3f7ac_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xNS0xLTEtNjc1NTE_5d6b811c-3d28-495e-bd6a-a6f678e506a2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia1ba976024d048e59f4225613ee1e674_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xLTEtMS01MjY5Mg_bb89ddb2-6efc-4a2c-9241-94ed584bdb76">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11037a410e5649299700d6b8f3a0432d_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0zLTEtMS01MjY5Mg_c2c1568b-3f7a-4b9d-9786-bf9e89733df4">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i508c444df6354c518af0b243171959de_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS01LTEtMS01MjY5Mg_974bcd4c-5c89-4c64-a6f0-b79b9aa7bbe2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i85a617267a104bfc851fbebc1558cd54_I20220331" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS03LTEtMS01MjY5Mg_c97a7a29-c070-4746-8c0b-c5200cacef9a">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5afe9754eff748e086f47c6c114acb74_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS05LTEtMS01MjY5Mg_e7f0c36c-1a0a-46cb-990f-32d6cab52794">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2016debe972145bc98c3c25f1aa41b87_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xMS0xLTEtNTI2OTI_ecc3ee16-0882-4b38-9f13-d9362cd3a170">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i06f313ec9d8a4dc1a75bccac7278fd22_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xMy0xLTEtNTI2OTI_9b025be2-7346-4370-a3d1-8e0e89cd62e0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i24c3193be6a042d0af52807bce70ecda_I20211231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNS0xNS0xLTEtNTI2OTI_fe6523a6-7a8b-40cb-b0eb-003cdd0df1f1">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8cbb3082e2644156843c8824062a7557_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi0xLTEtMS01MjY5Mg_1e7a3624-db05-4dba-853e-e3087be76f98">313</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if85d5119138f46fb8cdbf0fe1efaf24b_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi0zLTEtMS01MjY5Mg_b9499d57-9bad-43c9-b301-c949e6bcf790">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5781272ef99e4f83bbe40ea807776a10_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi01LTEtMS01MjY5Mg_a59a89eb-464e-4c1e-8233-d68248796ed5">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72fc65d345c746a6ada52bf9d2e84f7c_I20220331" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi03LTEtMS01MjY5Mg_121c7e2a-d20c-484e-bb51-e1b46ae3477d">313</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e8ba41deb584dc59a7bba3cc7ae5669_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi05LTEtMS01MjY5Mg_f1ceac7e-73df-4700-944a-310c87f80187">368</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89063d17a7524107aa093d098e3dc3a2_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi0xMS0xLTEtNTI2OTI_884df0b1-ec06-4d5d-90e4-56c8ba231eb8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4526b0eac0744eccbf73718ad53e4f2c_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi0xMy0xLTEtNTI2OTI_5f892d70-93f6-4cfe-95f4-1b573b0fe751">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c311677e06141488580cf4163bb8dee_I20211231" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNi0xNS0xLTEtNTI2OTI_2a73e9f6-fdff-43aa-b0dd-86d65148dc10">368</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy0xLTEtMS01MjY5Mg_c193f5cc-b17f-4f14-af8b-1410dd1a44ee">313</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy0zLTEtMS01MjY5Mg_74b42114-f26c-49ae-87a7-d9f7a77803f1">375</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy01LTEtMS01MjY5Mg_29c8ffb8-0e1e-45ea-aa02-38b3c279816d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy03LTEtMS01MjY5Mg_2ad0ee42-1618-4881-a673-bf574da01562">688</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy05LTEtMS01MjY5Mg_4b202213-dccf-4b66-9180-f8e989168966">368</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy0xMS0xLTEtNTI2OTI_4be89c50-21fe-4451-9ff6-59c6a8dad66f">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:TradingSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy0xMy0xLTEtNTI2OTI_423bd218-d5b3-46de-9491-a0f6b5535aef">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:TradingSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfNy0xNS0xLTEtNTI2OTI_6966c9ef-8f5b-414e-a8fa-d32fa6da20c0">370</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i873b5a8d74304ec7b4354dec1d9f90d7_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS0xLTEtMS01MjY5Mg_1862f351-84b5-46e1-880e-b70a7267b2f9">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f6ff63ba5be4b52aabecb169fa52722_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS0zLTEtMS01MjY5Mg_d97a850c-2918-4467-9d28-9da02705f52c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3a5be3a3163942b98163c1596faa6f6c_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS01LTEtMS01MjY5Mg_e628f3fc-d878-4aff-b9aa-598bed9d5f17">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4e360316d573495ebc4756cad1721c2b_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS03LTEtMS01MjY5Mg_49ce0c9d-063e-4a21-9ad6-35441aa7b7ac">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i506d5cfd75cf461da8ce1b0b5a919a4d_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS05LTEtMS01MjY5Mg_4a19660a-2ba3-4352-9f93-7a2bd0f3ca27">80</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i03f146fa9b2349669cba9352f1d8e8b1_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS0xMS0xLTEtNTI2OTI_7ebacb98-527f-4987-92ae-df59823b2dc0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iff1a794b0e884fb2b74ec29d1b022c8a_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS0xMy0xLTEtNTI2OTI_838aadf6-ee8a-4f91-80f6-8d71c7d83286">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54f72cb1f8564c60979721b97816a447_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfOS0xNS0xLTEtNTI2OTI_1e932d63-f0c2-4d53-89f4-7da2f2a8b901">80</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i462a05784a5d4fb390f1ce1698ae9d59_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtMS0xLTEtNTI2OTI_7d5b84f6-2726-41d3-9542-1e8b956ac7f0">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ae92003c3ca44eaac051a7ccb801cd9_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtMy0xLTEtNTI2OTI_2bc4907b-4bfa-4525-a070-dae5253e4bd7">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i781fe021baea49cbbbadd17d2d3c23c9_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtNS0xLTEtNTI2OTI_096af3ae-1f46-43e7-8f69-ae6fd5dc03aa">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i821128012d944b9b89e26d92f448187f_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtNy0xLTEtNTI2OTI_11a48c93-0a66-4eba-8211-f41ff50510be">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4cf90f5f8b4f465a9b2f2a812adeb5d4_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtOS0xLTEtNTI2OTI_8ad7f237-1616-44eb-b928-d7105f17ab51">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5bc703e9ac74452693a59794f39a39fd_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtMTEtMS0xLTUyNjky_e4a2cc99-2734-488c-aa83-4d77f5c69c0f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia33e3ebe6ac44bf380de57dedb6df3c6_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtMTMtMS0xLTUyNjky_6705d690-e586-4805-bd60-73d4c8ccbb21">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iec8f14e1d6d3489c9e2345c77d66d5a6_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTAtMTUtMS0xLTUyNjky_d32b07b0-a7a6-47b6-9724-3598dfde39b7">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8cbb3082e2644156843c8824062a7557_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtMS0xLTEtNTI2OTI_8768f12a-1d1c-4df7-9b3a-8135997d30a5">1,084</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if85d5119138f46fb8cdbf0fe1efaf24b_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtMy0xLTEtNTI2OTI_fb5ae013-df32-4d20-8e06-9ecde0d74c84">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5781272ef99e4f83bbe40ea807776a10_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtNS0xLTEtNTI2OTI_a973df9c-9e6b-41ec-8ad6-b9fc5af1f223">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72fc65d345c746a6ada52bf9d2e84f7c_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtNy0xLTEtNTI2OTI_8dd6c523-6215-4c4c-a030-87e10d7a3991">1,084</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e8ba41deb584dc59a7bba3cc7ae5669_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtOS0xLTEtNTI2OTI_dcc5ad83-b37a-4ecb-b4aa-a6be10d99f5e">1,279</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i89063d17a7524107aa093d098e3dc3a2_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtMTEtMS0xLTUyNjky_0848b952-e079-4075-ab49-8875db4158b6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4526b0eac0744eccbf73718ad53e4f2c_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtMTMtMS0xLTUyNjky_8cfc98b2-c270-4366-83f6-a8fee765b69f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c311677e06141488580cf4163bb8dee_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTEtMTUtMS0xLTUyNjky_890b842b-a764-458d-8de9-edc9731e1b99">1,279</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItMS0xLTEtNTI2OTI_ceecab91-7c6d-4ff9-8a19-458ad41c155e">1,163</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItMy0xLTEtNTI2OTI_2677b27c-44ba-4615-90a5-335149b0aed4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItNS0xLTEtNTI2OTI_838bdff1-1593-4f16-910a-0a0331c475da">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItNy0xLTEtNTI2OTI_47cd8214-6d12-4ee4-a03f-a6bea00f87f7">1,163</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItOS0xLTEtNTI2OTI_30340d7d-add7-499f-9559-f0f67f545c6d">1,363</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItMTEtMS0xLTUyNjky_0722efd2-ac12-4745-9edd-d1920d81450d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItMTMtMS0xLTUyNjky_bd6bd906-953b-4b55-80b6-bfa01685d1f6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTItMTUtMS0xLTUyNjky_29b86371-53ec-4b70-867e-4f06a44ac3c9">1,363</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a894e3c7de94746bb7076620527450b_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtMS0xLTEtNTI2OTI_185bc8df-b04a-426b-85f0-288297b9ef9e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b749683577344bb9d612ab4ee18010f_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtMy0xLTEtNTI2OTI_92633dfd-42a1-40cf-9b2f-225ca79a20ac">433</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia68f391c66714b649ad9f46eca9223d1_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtNS0xLTEtNTI2OTI_53736c9e-779c-46af-b655-27d7e16b4c2e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i90699b79bf61454d8bff5340c54d3eb2_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtNy0xLTEtNTI2OTI_01a1d9d7-3b2d-40bb-9847-b8a64770e33b">433</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib191c3745a5b437abb310a27c2b61de8_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtOS0xLTEtNTI2OTI_45efbd7d-d0ca-4216-8628-5c65af0d5b18">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i56f64528a30f499f8acb3e5e48ddc37d_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtMTEtMS0xLTUyNjky_4c4b9d54-8f4d-4825-826b-8fc703170d9d">351</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ideda08d68af841649ba8a54a96663719_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtMTMtMS0xLTUyNjky_4fdc7ccd-6a64-46ef-94ed-87c23b8dfbb3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09c83e8675a247d08046df72a466fccf_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTQtMTUtMS0xLTUyNjky_43d3d426-b1a0-4485-a8d1-af9c1982bafd">351</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iafd08e88c9f249c0a805905dc35016e3_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtMS0xLTEtNTI2OTI_5af5bae8-f0ed-4b3a-a801-3e22cf2f9e34">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1167fc16115840aa8ffc6b3af27b7649_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtMy0xLTEtNTI2OTI_52fb5e51-e297-462b-9cdb-78b083641f1a">242</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8198a8617a6e479ebc1b1e733a86998d_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtNS0xLTEtNTI2OTI_a26e7899-b772-43da-872c-bfe5cbeb55fd">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2dc3737f560d4ebe92d5e7eb5cfd7d0c_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtNy0xLTEtNTI2OTI_848e1b21-f7d0-4122-8c6b-2144f52130d4">242</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45a789d9da35420fbfe7638ebd042627_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtOS0xLTEtNTI2OTI_6af28632-fc9e-42d8-8ea2-2ff08dc3ace0">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i77789de03f614d58b866b84ba8a0f6cb_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtMTEtMS0xLTUyNjky_89ea8cd0-9c7b-4915-9600-b6f7716f15a9">184</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a47b1e009574aa3aaa91a70d30a5858_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtMTMtMS0xLTUyNjky_c56676bb-a7ad-4e6c-b732-8390ed9ad323">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3fd373a74d74951a1e4cd3e326cddf0_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTUtMTUtMS0xLTUyNjky_555f1811-7c53-4095-8a71-5a0f8e83bf96">184</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id9e748a24f084da795c60693831ed5fc_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtMS0xLTEtNTI2OTI_583f4049-e45c-40e7-85d1-43c75e144772">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i008adb89e343430489011984e43b69e8_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtMy0xLTEtNTI2OTI_0de5743e-87f9-408e-a3f7-fff8a1d49915">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia84cc74eab5647dd968209fa6a792fb2_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtNS0xLTEtNTI2OTI_3cade388-4d47-478c-ad8d-210d18710936">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cfa215068fd4942971b106029db9040_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtNy0xLTEtNTI2OTI_7bb5d61f-0e08-4e9a-8bde-17e4fb424234">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaec951ec4b5e4261a5ab63f0bcbe89a1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtOS0xLTEtNTI2OTI_59b8fe02-56f9-45cf-8ee0-630b23c7c7e2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0759b405a04a4443951e4f30e3abd266_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtMTEtMS0xLTUyNjky_b39d8704-9c9e-4a7f-9460-04a207873ab5">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i136dd348c81a454c8124ea6791b9afa1_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtMTMtMS0xLTUyNjky_91ee538c-0b03-436c-b42c-06f87e8445b3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6aadef6c3c7b4eff8169224531cfd935_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTYtMTUtMS0xLTUyNjky_4afe4b42-828b-4b18-a75c-0bb9e6d9aa19">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctMS0xLTEtNTI2OTI_2ca55d7c-2fa4-402b-b858-e574eb8fb770">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctMy0xLTEtNTI2OTI_72018085-233c-467d-81af-37a6785b1d64">679</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctNS0xLTEtNTI2OTI_fcf42794-d748-4724-a93e-5e3903b8b3c2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctNy0xLTEtNTI2OTI_00645c6b-29a2-4c04-b830-82dc4d892842">679</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctOS0xLTEtNTI2OTI_b5617272-1c56-4f65-a8c5-f4e8181631ab">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctMTEtMS0xLTUyNjky_f45bd326-76a0-4503-a16d-d5f4a02fe934">549</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctMTMtMS0xLTUyNjky_beb7ade5-2e11-41aa-aa27-cc5adbc44981">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTctMTUtMS0xLTUyNjky_ccf6cc47-ebf1-41b6-a10d-05bdf364e654">549</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtMS0xLTEtNTI2OTI_04556856-91bd-42cc-9cfe-12a451652484">1,476</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtMy0xLTEtNTI2OTI_907df334-a52a-4be5-8f76-e5ad2a69974f">1,054</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtNS0xLTEtNTI2OTI_e460d68f-1979-46af-b1b2-869c812679db">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtNy0xLTEtNTI2OTI_a1d967ce-61f5-407b-ba6e-0fc823a413e2">2,530</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtOS0xLTEtNTI2OTI_682b5554-c919-4773-bf8f-e82522168900">1,731</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtMTEtMS0xLTUyNjky_71eb263d-4c37-4adb-9dfd-47a694fe1d16">551</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtMTMtMS0xLTUyNjky_26baa4e6-bb7a-41c9-9cb8-fa3e7e093fc7">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMTgtMTUtMS0xLTUyNjky_285b3a16-3e25-424d-93bc-0ec498193336">2,282</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtMS0xLTEtNTI2OTI_bbd9eba7-534e-4e2a-b272-27bab7b82c6f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtMy0xLTEtNTI2OTI_8a1862ec-75ce-4898-85c3-d4a82796ce66">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtNS0xLTEtNTI2OTI_2c922e4e-b115-41b7-89d6-eb5a9e0f55e9">572</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtNy0xLTEtNTI2OTI_0056a446-14f4-416e-a8be-a3d299969c58">572</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtOS0xLTEtNTI2OTI_ca8c322b-5ca1-443c-84f0-30954b3b84dc">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtMTEtMS0xLTUyNjky_8b87c2f0-809d-4fcc-8982-7b9ea9337e76">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtMTMtMS0xLTUyNjky_23ed9b87-b38c-441e-a426-eb758ae79402">777</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjEtMTUtMS0xLTUyNjky_6134b4ee-05e8-4a56-9e22-42763016f41d">777</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a894e3c7de94746bb7076620527450b_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtMS0xLTEtNTI2OTI_5300bc32-1e1c-4fb3-b842-cd89e077d7ae">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b749683577344bb9d612ab4ee18010f_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtMy0xLTEtNTI2OTI_e7f11279-721c-4e31-87ba-5f5d6897dce8">240</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia68f391c66714b649ad9f46eca9223d1_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtNS0xLTEtNTI2OTI_5f03e423-7848-4e7d-a837-544ea2dd8c9f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i90699b79bf61454d8bff5340c54d3eb2_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtNy0xLTEtNTI2OTI_78bb16a7-4e7d-4072-91dc-72f1ea3618d9">240</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib191c3745a5b437abb310a27c2b61de8_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtOS0xLTEtNTI2OTI_2c906286-401e-41b1-afa6-916c54a58756">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i56f64528a30f499f8acb3e5e48ddc37d_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtMTEtMS0xLTUyNjky_2eae269d-643f-4e21-b1b7-f379af6457ff">120</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ideda08d68af841649ba8a54a96663719_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtMTMtMS0xLTUyNjky_4013a84e-2a1d-4c01-aa90-3734ae4d3010">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09c83e8675a247d08046df72a466fccf_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjMtMTUtMS0xLTUyNjky_a5e9de7a-24b7-4834-8ec6-f74623ef29ac">120</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iafd08e88c9f249c0a805905dc35016e3_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtMS0xLTEtNTI2OTI_c9187610-7b65-47e2-a712-c260038eac2c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1167fc16115840aa8ffc6b3af27b7649_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtMy0xLTEtNTI2OTI_28e451ba-8ff5-439c-8abf-2450d91259cc">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8198a8617a6e479ebc1b1e733a86998d_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtNS0xLTEtNTI2OTI_0e6a6d8d-953a-495f-82d2-05293807408b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2dc3737f560d4ebe92d5e7eb5cfd7d0c_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtNy0xLTEtNTI2OTI_e641943e-22ad-4f0b-9b55-a38c7fdd35bc">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i45a789d9da35420fbfe7638ebd042627_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtOS0xLTEtNTI2OTI_a29110a9-10ca-4886-bdfc-e3848cec5f85">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i77789de03f614d58b866b84ba8a0f6cb_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtMTEtMS0xLTUyNjky_ee6e6ae7-b07b-43a3-829d-1f0a94cc6047">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a47b1e009574aa3aaa91a70d30a5858_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtMTMtMS0xLTUyNjky_f64b7e9c-d205-461b-a387-cbd3c34fa07c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3fd373a74d74951a1e4cd3e326cddf0_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjQtMTUtMS0xLTUyNjky_eb1e17e4-b221-48eb-9388-ffc295fb1980">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtMS0xLTEtNTI2OTI_f33db5cd-70c7-46f1-98b5-6c9de0bcf1b8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtMy0xLTEtNTI2OTI_2bc8424e-0be5-4594-9c04-58ab8a03a626">241</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtNS0xLTEtNTI2OTI_494ad595-41e6-4d4c-888a-580db8deee5e">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtNy0xLTEtNTI2OTI_4c1a3dcb-2326-4a07-a8f9-ef771c63516c">241</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtOS0xLTEtNTI2OTI_25c45f38-5f74-42cb-89b7-8bf37a43445f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtMTEtMS0xLTUyNjky_c8937c1b-d314-4d70-856f-3bfaa51511c3">121</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtMTMtMS0xLTUyNjky_73a380e1-0154-4b36-acd6-fd76154dc051">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjUtMTUtMS0xLTUyNjky_9d844b8f-2bf1-4403-8242-e97939a6d4e1">121</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0c153486b35548988b8e854138265838_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtMS0xLTEtNTI2OTI_e049d0b0-d70f-4a61-a6ca-f00c42d7ecf3">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifd6b28e99a3d4ed49e0a37e6a821749e_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtMy0xLTEtNTI2OTI_58e38e4d-42af-41b6-8e24-b4378d483c7f">241</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d4ffa81ccfe4709b9e617c24c1886ff_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtNS0xLTEtNTI2OTI_0a727017-09d6-4ead-b889-5cdce5d25a02">572</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb91aa4006a4ea8a9a7acfb0a724522_I20220331" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtNy0xLTEtNTI2OTI_12407636-5250-4f7d-bf9c-6bb5b19a65df">813</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaedbd4bdda9646cab4a985f1707ec76b_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtOS0xLTEtNTI2OTI_c6c9540f-9a1f-484f-986d-a3e1cc407fb2">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7ba131d09314cdc8ecd3b07bf530589_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtMTEtMS0xLTUyNjky_8b201f05-3803-437b-bf46-b7e80d54e78d">121</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if030bfa28e754701848677a020bbae82_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtMTMtMS0xLTUyNjky_98bd1a0d-6e90-44c7-b102-d2644e37c3e4">777</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i595357f3962a47df94dfc2693b9fbcb6_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjcwZDE3ZDllNWNhYTQxNTg5YjQ3OTEzYTJlNjhmZDVmL3RhYmxlcmFuZ2U6NzBkMTdkOWU1Y2FhNDE1ODliNDc5MTNhMmU2OGZkNWZfMjYtMTUtMS0xLTUyNjky_96c652cc-2d21-4032-8fc2-78aaec28abfc">898</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt"> Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022 and December&nbsp;31, 2021, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $<ix:nonfraction unitref="usd" contextref="i5cc8c4747c7c48f3a46c864d8d719810_I20220331" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTM5NDE_f94dae2e-6803-40f3-a7ea-95ffa3a636fe">7.4</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="idc764995a38e4fb386a52f5427d915bf_I20211231" decimals="-8" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTM5NDg_30ec0845-6af9-481d-b5b0-d54a94f8ac48">6.8</ix:nonfraction> billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTg1Njc_ab52bef5-ebe6-4448-a891-b10a38d77843" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in the fair value of liabilities for contingent consideration associated with business combinations is as follows:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.846%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfMi0xLTEtMS01MjY5Mg_3b39bfc3-1bcd-4444-a94e-4046cdbc907d">777</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i866b60422112474194bfe1e56bc43a8a_I20201231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfMi0zLTEtMS01MjY5Mg_fc1d7b15-b101-44cc-b232-7137443aca5f">841</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNC0xLTEtMS01MjY5Mg_63477322-b654-4d98-9306-8572067e12b1">84</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNC0zLTEtMS01MjY5Mg_08f1f309-3e01-4a3c-8ce2-3bc7b3a0bc92">13</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNS0xLTEtMS01MjY5Mg_cb801ba9-5821-472a-b17c-4f9535ce9b63">119</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNS0zLTEtMS01MjY5Mg_d1424d18-a1ff-4390-9b5a-239b68f799b5">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNi0xLTEtMS01MjY5Mg_dc809d53-de82-47b4-a601-79e6c3e0f5a8">2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="mrk:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNi0zLTEtMS01MjY5Mg_5874646a-21fb-486c-aebb-99619daedcbb">12</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value March 31 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNy0xLTEtMS01MjY5Mg_4cbef99c-7c64-46ec-823f-c7d555d29251">572</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RhYmxlOjkxNmQ4MmI0OWI5ZTRmMDNhYjk1NTRjZmM1MWRlNDdjL3RhYmxlcmFuZ2U6OTE2ZDgyYjQ5YjllNGYwM2FiOTU1NGNmYzUxZGU0N2NfNy0zLTEtMS01MjY5Mg_3c6d397c-084f-4013-be01-136f0219df24">816</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Balance at March&nbsp;31, 2022 includes $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTQ0MDc_cec62466-0581-42f0-ac59-ccc27569ecaf">149</ix:nonfraction> million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At March&nbsp;31, 2022 and December&nbsp;31, 2021, $<ix:nonfraction unitref="usd" contextref="i4e3c4a0d9dc842b0b896df5bdbf8f9c3_I20220331" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTQ1MTk_66a45776-010e-460a-824b-1aac88136dc5">439</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i296c894765054ec796a8893e029f09e0_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTQ1MjY_cc8f2192-f94d-4d0c-9ff6-5ba753b1afb7">620</ix:nonfraction> million, respectively, of the liabilities relate to the termination of the Sanofi Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of <ix:nonfraction unitref="number" contextref="i4e3c4a0d9dc842b0b896df5bdbf8f9c3_I20220331" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTQ3MzU_0853e9f9-a324-462d-8147-ed9739f988b8">11.5</ix:nonfraction>% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of <ix:nonfraction unitref="number" contextref="i5bcd093a311846d483b85ff16cb11e50_I20220331" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTQ5OTk_79ef8146-9e5e-45fa-b9ce-508e7a38bd87">8</ix:nonfraction>% to present value the cash flows.</span></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The payments of contingent consideration in 2022 relate to the Sanofi-Pasteur MSD liabilities described above.</span></div></ix:continuation><div style="margin-top:9pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 18 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i9562afe5a9ea4a8b816ed67ad13ede38" continuedat="i124e7c2ffbb140da944908c7eb993cdb"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at March&nbsp;31, 2022, was $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTU2NTE_f6fef82b-21f6-4a51-86be-e31f17c10f44">31.7</ix:nonfraction> billion compared with a carrying value of $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTU2ODg_8b3b2b35-7c80-4326-8943-6743613e416d">31.8</ix:nonfraction> billion and at December&nbsp;31, 2021, was $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-8" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTU3MDY_4287a8b1-c999-44a2-aae5-e9d6b2368e2e">35.7</ix:nonfraction> billion compared with a carrying value of $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-8" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTU3NDM_672bfcad-ebdf-41fe-9a11-e7b07506a8a7">33.1</ix:nonfraction> billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the U.S., Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers.&nbsp;The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTcxMzQ_4a9c7aaf-4be8-4433-a8f9-5577da2493e5">2.2</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i9074269624d0486f958a02678eecdb2f_D20211001-20211231" decimals="-8" name="us-gaap:AccountsReceivableSale" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTcxNDE_a2b1021f-9567-485a-8526-70eefa8bf712">2.8</ix:nonfraction> billion of accounts receivable as of March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. As of March&nbsp;31, 2022 and December&nbsp;31, 2021, the Company had collected $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMjE5OTAyMzI3ODU1Mw_5bb10cd2-9a8c-4706-af25-452f0a651e78">31</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMjE5OTAyMzI3ODUzOQ_c0f075f3-db63-4929-b2f9-fde4556a5dbd">62</ix:nonfraction>&nbsp;million, respectively, on behalf of the financial institutions, which is reflected as restricted cash in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other current assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the related obligation to remit the cash within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company remitted the cash to the financial institutions in April 2022 and January 2022, respectively. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><ix:continuation id="i124e7c2ffbb140da944908c7eb993cdb" continuedat="if3710b7edef84df48c32cdb846a1eebc"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTgzMzg_dbd056c6-8b95-4bf8-9fd0-a88b238679b9">220</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:DerivativeCollateralObligationToReturnCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl80OS9mcmFnOmQ4OTdkMjUzOGM3NTQxNGJiN2QxYWIzZmVjZjBlZTVjL3RleHRyZWdpb246ZDg5N2QyNTM4Yzc1NDE0YmI3ZDFhYjNmZWNmMGVlNWNfMTA5OTUxMTY1MTk0Mw_81fc439d-b844-443f-ac71-75e360f85bdc">164</ix:nonfraction>&nbsp;million at March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if3710b7edef84df48c32cdb846a1eebc">.</ix:continuation> </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_52"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RleHRyZWdpb246ZjkxNzRjMWY3MGEyNGRmZDkzMDY5YTNhNjBjYjMwOTJfNDMw_9a25f2a5-6952-4a95-9820-d7e76292a68e" continuedat="i3bb197d335f84450aa72de1a9a6cec76" escape="true">Inventories</ix:nonnumeric></span></div><ix:continuation id="i3bb197d335f84450aa72de1a9a6cec76" continuedat="i00e53fc9be324a1c9947afa06f72b27a"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RleHRyZWdpb246ZjkxNzRjMWY3MGEyNGRmZDkzMDY5YTNhNjBjYjMwOTJfNDMz_ceef4532-146d-48c2-a62b-54841ea5e5a5" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfMS0xLTEtMS01MjY5Mg_97732146-b087-45ef-b08f-2c9d1ce1ce61">1,772</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfMS0zLTEtMS01MjY5Mg_362d05ed-23c3-433c-8154-c62db2886207">1,747</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfMi0xLTEtMS01MjY5Mg_69891709-924f-49e7-9131-16c48bf16c51">6,365</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryWorkInProcessAndRawMaterials" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfMi0zLTEtMS01MjY5Mg_ff0d2936-1bb3-43ee-8298-5ca6f184a9ef">6,220</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfMy0xLTEtMS01MjY5Mg_64d8465e-0c80-48af-85e0-636c1beb13bb">209</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:OtherInventorySupplies" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfMy0zLTEtMS01MjY5Mg_4eee22ba-8726-4d80-86c0-4e32aff6f609">196</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfNC0xLTEtMS01MjY5Mg_86e1d08a-111e-4dd4-8031-6166584165e1">8,346</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfNC0zLTEtMS01MjY5Mg_f651aa51-8b1e-4994-adb5-074670750c5b">8,163</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfNS0xLTEtMS01MjY5Mg_9cc3b615-a5a9-4361-821e-ef7a53ceaa52">77</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryLIFOReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfNS0zLTEtMS01MjY5Mg_30821b39-7213-4a8d-991e-07f02b51f830">16</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfNi0xLTEtMS01MjY5Mg_9e0eba04-5fdd-4bdd-a352-c9992ccfb574">8,269</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="mrk:InventoryNetAndInventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfNi0zLTEtMS01MjY5Mg_bcb1f895-4745-4edd-9581-24c240833d73">8,147</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfOC0xLTEtMS01MjY5Mg_0a79f352-7d87-4b93-bedc-018c11d453d2">5,774</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfOC0zLTEtMS01MjY5Mg_307693c7-46c5-4e54-b3bb-5e7530f94ccd">5,953</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfOS0xLTEtMS01MjY5Mg_370e8a7f-3353-4648-85bb-b505814c7ede">2,495</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RhYmxlOjY2NjExMjdhMzk5OTQ2ZGViYTM1NGQ2ZDE0MjBhZGUxL3RhYmxlcmFuZ2U6NjY2MTEyN2EzOTk5NDZkZWJhMzU0ZDZkMTQyMGFkZTFfOS0zLTEtMS01MjY5Mg_8d78062d-48f6-43f1-bee4-c3c986e6f9f2">2,194</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At March&nbsp;31, 2022 and December&nbsp;31, 2021, these amounts included $<ix:nonfraction unitref="usd" contextref="i33f0265719e0496eb57d78b92ca47991_I20220331" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RleHRyZWdpb246ZjkxNzRjMWY3MGEyNGRmZDkzMDY5YTNhNjBjYjMwOTJfMjAw_bd95f207-100f-4989-9b2c-310a39b973ea">2.1</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i2ab33cb07df549d893db0991189976f4_I20211231" decimals="-8" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RleHRyZWdpb246ZjkxNzRjMWY3MGEyNGRmZDkzMDY5YTNhNjBjYjMwOTJfMjA3_1c461bae-df07-4d16-893b-45bade9c6f0c">1.9</ix:nonfraction> billion, respectively, of inventories </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 19 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i00e53fc9be324a1c9947afa06f72b27a">not expected to be sold within one year. In addition, these amounts included $<ix:nonfraction unitref="usd" contextref="i303c573a9967470a927cfd2797389b32_I20220331" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RleHRyZWdpb246ZjkxNzRjMWY3MGEyNGRmZDkzMDY5YTNhNjBjYjMwOTJfMzE3_6d0dbfb2-5863-4d7d-a183-35af86a4cac8">327</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i1748811c5bee4a9d8c37844a62128658_I20211231" decimals="-6" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81Mi9mcmFnOmY5MTc0YzFmNzBhMjRkZmQ5MzA2OWEzYTYwY2IzMDkyL3RleHRyZWdpb246ZjkxNzRjMWY3MGEyNGRmZDkzMDY5YTNhNjBjYjMwOTJfMzI0_5091f11d-42c9-4370-b18f-7d668a577097">256</ix:nonfraction> million at March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively, of inventories produced in preparation for product launches.</ix:continuation></span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_58"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMjI5OTc_916bffc2-92ed-4cd1-9b8c-e2db7aa5836b" continuedat="ic045f2d0382b4b558a898eb7a81830a9" escape="true">Contingencies</ix:nonnumeric></span></div><ix:continuation id="ic045f2d0382b4b558a898eb7a81830a9" continuedat="i04b3c5e92755468ab379e7690984fe73"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i)&nbsp;what claims, if any, will survive dispositive motion practice, (ii)&nbsp;the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii)&nbsp;how the discovery process will affect the litigation, (iv)&nbsp;the settlement posture of the other parties to the litigation and (v)&nbsp;any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. <ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:LegalCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMjMwMTI_b3027a30-0057-4d2b-9914-8eb788f485b2" escape="true">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</ix:nonnumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving Fosamax (alendronate sodium) (Fosamax Litigation). As of March&nbsp;31, 2022, approximately <ix:nonfraction unitref="case" contextref="icf694a8cdad74109872af987bd236b31_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMjQyNQ_f912e8f0-c3ad-4b32-84e1-269e120eda3a">3,460</ix:nonfraction> cases are pending against Merck in either a federal multidistrict litigation (Femur Fracture MDL) or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2014, the Femur Fracture MDL court dismissed with prejudice approximately <ix:nonfraction unitref="case" contextref="idee85c8998654d22829a19bfaa792815_D20140301-20140331" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMTA5OTUxMTY1MDc5OA_4d32c77c-aaae-48a5-9a42-27244006b563">650</ix:nonfraction> cases on preemption grounds. Plaintiffs in approximately <ix:nonfraction unitref="case" contextref="idee85c8998654d22829a19bfaa792815_D20140301-20140331" decimals="0" name="mrk:LossContingencyClaimsonAppealNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMjg3MA_4024c9ee-2d53-4ca2-b1c4-e1fd69f62629">515</ix:nonfraction> of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. On March 23, 2022, the District Court granted Merck’s motion and ruled that plaintiffs’ failure to warn claims are preempted as a matter of law to the extent they assert that Merck should have added a warning or precaution regarding atypical femur fractures prior to September 2010. Whether the plaintiffs will attempt to move forward on other claims or seek to appeal the District Court’s ruling is not yet known.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL. As part of the spin-off of Organon, Organon is required to indemnify Merck for all liabilities relating to, arising from, or resulting from the Fosamax Litigation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the U.S. involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl). As of March&nbsp;31, 2022, Merck is aware of approximately <ix:nonfraction unitref="claim" contextref="i0c5975a461004aefa1f84879bc18ca78_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfNDMxNQ_b92f19d5-0bdc-4f6e-aabd-90f42f14e00f">660</ix:nonfraction> product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). On March 9, 2021, the MDL Court issued an omnibus order granting defendants’ summary judgment </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 20 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i04b3c5e92755468ab379e7690984fe73" continuedat="idb4a056bd89b4febabfb2410c1af825b"><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motions based on preemption and failure to establish general causation, as well as granting defendants’ motions to exclude plaintiffs’ expert witnesses. The plaintiffs appealed that order. Since that time, more than half of these claims have been dismissed with prejudice as to Merck, and on October 5, 2021, the U.S. Court of Appeals for the Ninth Circuit dismissed the appeal as to Merck and two of its codefendants.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). On April 6, 2021, the court in California issued an omnibus order granting defendants’ summary judgment motions and also granting defendants’ motions to exclude plaintiffs’ expert witnesses.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&nbsp;31, 2022, <ix:nonfraction unitref="claim" contextref="ic249d5f64be94c4ba42d8e0d08f01af1_I20220331" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfNTQ1Nw_c21e6d3a-5403-4847-bafc-4cc98914e63f">six</ix:nonfraction> product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the Fosamax matter discussed above). Merck filed the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court. In May 2020, the Illinois Appellate Court issued a mandate to the state trial court, which, as of March 31, 2022, had not scheduled a case management conference or otherwise taken action.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately <ix:nonfraction unitref="claim" contextref="i5ce78d919a424343b550fe2aa711ab67_I20220331" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfNjgxMg_8c196aa0-c578-4e6b-8b1b-7178e6104e6f">50</ix:nonfraction> additional claims. The Company intends to continue defending against any remaining lawsuits.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company’s subsidiaries in China receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the U.S. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Antitrust Litigation</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck, MSD, Schering Corporation, Schering-Plough Corporation, and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia (ezetimibe) alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. In August 2020, the district court granted in part the direct purchasers’ motion for class certification and certified a class of <ix:nonfraction unitref="claim" contextref="i3eebc9efbe164eca98287ede312ba518_I20200831" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfOTk0NA_c9df0ad8-7617-4a68-b9d5-ad89039e461b">35</ix:nonfraction> direct purchasers. In August 2021, the Fourth Circuit vacated the district court’s class certification order and remanded for further proceedings consistent with the court’s ruling. In September 2021, the direct purchaser plaintiffs filed a renewed motion for class certification. On January 25, 2022, the magistrate judge recommended that the district court deny the motion for class certification. On February 8, 2022, the direct purchaser plaintiffs filed objections to the recommendation. On April 13, 2022, the district court overruled the direct purchaser plaintiffs’ objections, adopted the magistrate judge’s recommendation, and denied the direct purchaser plaintiffs’ renewed motion for class certification.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court has heard </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 21 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="idb4a056bd89b4febabfb2410c1af825b" continuedat="i9fe54fdf2690439682117706d1623c6d"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">argument on certain of the motions. The court granted partial summary judgment to the plaintiffs on issues of market definition. Defendants Glenmark Pharmaceuticals Ltd. and Glenmark Pharmaceuticals Inc., USA (collectively, the Glenmark Defendants) filed a motion to certify the court’s decision for interlocutory appeal on March 28, 2022. This motion is fully briefed and awaiting decision. The court may hold additional hearings on the summary judgment and other motions that remain undecided. Trial in this matter has been adjourned.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in August 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. In August 2021, the district court granted certification of a class of indirect purchasers. In September 2021, the Merck Defendants petitioned to appeal the class certification decision to the Fourth Circuit. The Fourth Circuit denied that petition on September 30, 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, United Healthcare Services, Inc. filed a lawsuit in the U.S. District Court for the District of Minnesota against the Merck Defendants and others (the UHC Action). The UHC Action makes similar allegations as those made in the Zetia class action as well as allegations about Vytorin. In September 2020, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, Humana Inc. filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against Merck and others, alleging defendants violated state antitrust laws in multiple states. Also, in December 2020, Centene Corporation and others filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana. Both lawsuits allege similar anticompetitive acts to those alleged in the Zetia class action. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Kaiser Foundation Health Plan, Inc. similarly filed a lawsuit in the Superior Court of the State of California, County of San Francisco, against the same defendants as Humana and Centene. The Kaiser lawsuit alleges similar anticompetitive acts to those alleged in the Zetia class action. The Kaiser action was removed to the U.S. District Court for the Northern District of California on July 16, 2021. In September 2021, the U.S. Judicial Panel on Multidistrict Litigation transferred the case to the Eastern District of Virginia to proceed with the multidistrict Zetia litigation already in progress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 2021, all of the insurer plaintiffs (Kaiser, Humana, and Centene) are part of the multidistrict Zetia litigation, and are proceeding with discovery in that action. On February 9, 2022, United Healthcare, Kaiser, and Humana each filed an amended complaint. On March 2, 2022, the Merck Defendants, jointly with other defendants, moved to dismiss certain aspects of the insurer plaintiffs’ complaints, including any claims for Vytorin damages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rotavirus Vaccines Antitrust Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, MSD is a defendant in putative class action lawsuits filed in 2018 on behalf of direct purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">q</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Rotavirus Vaccine, Live, Oral, Pentavalent), alleging violations of federal antitrust laws. The cases were consolidated in the Eastern District of Pennsylvania. In January 2019, the court denied MSD’s motions to compel arbitration and to dismiss the consolidated complaint. In February 2019, MSD appealed the court’s order on arbitration to the Third Circuit. In October 2019, the Third Circuit vacated the district court’s order and remanded for limited discovery on the issue of arbitrability. On July 6, 2020, MSD filed a renewed motion to compel arbitration, and plaintiffs filed a cross motion for summary judgment as to arbitrability. On November 20, 2020, the district court denied MSD’s motion and granted plaintiffs’ motion. On December 4, 2020, MSD filed a notice of appeal to the Third Circuit. On March 21, 2022, the Third Circuit reversed the order of the district court and remanded with the instruction that the court grant MSD’s motion to compel arbitration. On April 4, 2022, plaintiffs filed a petition for panel rehearing or rehearing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">en banc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions accounted for as business combinations, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, between January and November 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection.&nbsp;In March, April and December 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies.&nbsp;All actions in the District of New </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 22 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i9fe54fdf2690439682117706d1623c6d" continuedat="i6491526f1c1f4f4da81712d5c6ac141a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jersey have been consolidated. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier. The U.S. District Court for the District of New Jersey has set a bench trial in this matter beginning on October 12, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with <ix:nonfraction unitref="case" contextref="i3b4e06253e024eeebe9194651ea94b81_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMTYzNjA_580176cc-b7ba-4e73-89b5-5ac2925cf0de">four</ix:nonfraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in January 2026 (which may be delayed by any applicable pediatric exclusivity) or earlier under certain circumstances. The Company has agreed to stay the lawsuit filed against two generic companies, which in exchange agreed to be bound by a judgment on the merits of the consolidated action in the District of New Jersey. One of the generic companies in the consolidated action requested dismissal of the action against it and the Company did not oppose this request, which was subsequently granted by the court. The Company does not expect this company to bring its generic version of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the market before January 2026 or later, depending on any applicable pediatric exclusivity, unless the Company receives an adverse court decision.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — As previously disclosed, the FDA has granted pediatric exclusivity with respect to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and J</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">anumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl extended-release), which provides a further six months of exclusivity in the U.S. beyond the expiration of all patents listed in the FDA’s Orange Book. Adding this exclusivity to the term of the key patent protection extends exclusivity on these products to January 2023. The Company currently anticipates that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. will decline significantly after this date. However, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> contain sitagliptin phosphate monohydrate and the Company has another patent covering certain phosphate salt and polymorphic forms of sitagliptin (2027 salt/polymorph patent), which, if determined to be valid, would preclude generic manufacturers from making sitagliptin phosphate salt and polymorphic forms until 2027 with the expiration of that patent, plus pediatric exclusivity. In 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of the 2027 salt/polymorph patent. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection, but prior to the expiration of the 2027 salt/polymorph patent, and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation where its term plus the pediatric exclusivity ends in 2029. The Company also filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel on Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the beginning of the scheduled October 2021 trial in the U.S. District Court for the District of Delaware on invalidity issues, the Company settled with all defendants scheduled to participate in that trial. In the Company’s case against Mylan, a bench trial was held in December 2021 in the U.S. District Court for the Northern District of West Virginia, and the closing arguments were held on April 13, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company has settled with <ix:nonfraction unitref="case" contextref="iec7ed14666dd45dcb45d6638db9a83a0_D20220101-20220331" decimals="INF" name="us-gaap:LossContingencyClaimsSettledNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMTkwNTY_ed850db8-97f5-4ebd-90a0-6206a3236679">21</ix:nonfraction> generic companies providing that these generic companies can bring their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in May 2026 or earlier under certain circumstances, and their generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to the market in July 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Review (IPR) at the U.S. Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2027 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial was held in February 2021 and a final decision was rendered in May 2021, holding that all of the challenged claims were not invalid. Mylan has appealed the USPTO’s decision to the U.S. Court of Appeals for the Federal Circuit.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc., and Cadila Healthcare Ltd. (collectively, Zydus). In that lawsuit, the Company alleged infringement of the 2027 salt/polymorph patent based on the filing of Zydus’s application seeking approval of its sitagliptin tablets. The U.S. District Court for the District of Delaware has set a three-day bench trial in this matter beginning on October 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic companies have sought revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the following European countries: Austria, Czech Republic, Finland, France, Hungary, Italy, Portugal, Romania, Slovakia, and Sweden. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> could lose market exclusivity in these countries at the same time as the expiry of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> pediatric market exclusivity in September 2022. In February 2022, a Finnish court referred certain questions to the European Court of Justice that could determine the validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPCs in Europe. In June 2021, a </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 23 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i6491526f1c1f4f4da81712d5c6ac141a"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">German court decided that the SPC for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is invalid, which decision the Company has appealed. The validity of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SPC was upheld in the Czech Republic in March 2022 in a first instance decision.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of March&nbsp;31, 2022 and December&nbsp;31, 2021 of approximately $<ix:nonfraction unitref="usd" contextref="i44e0eaee7a8f4256a0faf20e53fff644_I20220331" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMjIzNzA_15ab61e9-aeee-42e4-b7b8-7071af3de7b4">235</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="ia6f5d387d9334baaaacde5a04c3a0c51_I20211231" decimals="-6" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl81OC9mcmFnOjVjZWJiNzAxMzVjMDQyODhhNWVlYzExMTI0NmY3ODJkL3RleHRyZWdpb246NWNlYmI3MDEzNWMwNDI4OGE1ZWVjMTExMjQ2Zjc4MmRfMjIzNzc_041d6d20-77a2-4a6d-94a2-8559daf6289e">230</ix:nonfraction> million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div></ix:continuation><div id="ia10991337ee64bfe975ff621c73a0ff6_61"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RleHRyZWdpb246NzAwNGE0NWRjOWMwNGQ2YzhjZDQxMGZiODhjMzhhMTBfMzM_0c81a6e1-2b88-46ea-b954-fe104bc97a36" continuedat="i460544b55f6946fda5d2ae5787092516" escape="true">Equity</ix:nonnumeric></span></div><div style="margin-top:5pt"><ix:continuation id="i460544b55f6946fda5d2ae5787092516"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfStockholdersEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RleHRyZWdpb246NzAwNGE0NWRjOWMwNGQ2YzhjZDQxMGZiODhjMzhhMTBfMzY_48511af9-f891-4912-8b78-9b4ed2990a66" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tbody><tr><td style="width:1.0%"></td><td style="width:29.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br>Paid-In<br>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br>Other<br>Comprehensive<br>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br>controlling<br>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par&nbsp;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ide2da8218e1c4af4825a176997cbbcbd_I20201231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy0xLTEtMS01MjY5Mg_5188bd03-c311-495c-8473-3020c48d5bba">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide2da8218e1c4af4825a176997cbbcbd_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy0yLTEtMS01MjY5Mg_b2f7fb42-8201-4b96-88ea-52d515acf972">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1443f0f0b960439dab747f16cc5bc588_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy0zLTEtMS01MjY5Mg_e4e063eb-0ef6-405d-871f-4387233e6670">39,588</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i49237e599c524d95ab14bbe9d7c419f6_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy00LTEtMS01MjY5Mg_d166499b-d7ea-450a-9a74-d91a7d8878c7">47,362</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iab28075d402e4ad9ac4ac4c3641fdf1d_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy01LTEtMS01MjY5Mg_994c85ae-9820-44d6-9cf6-a7b97122df9e">6,634</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i5cb2adf38d934a58bb760e95785409a5_I20201231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy02LTEtMS01MjY5Mg_3dbe7841-d5ef-4097-8d6d-04f4c4bdcc55">1,047</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5cb2adf38d934a58bb760e95785409a5_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy03LTEtMS01MjY5Mg_789e1c9d-8498-496f-90bd-8f6a5f944aad">56,787</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42a93558d82f406f9ad4a89f27edcd96_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy04LTEtMS01MjY5Mg_d3579c28-8080-4c8f-9edb-de4e6b17d638">87</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i866b60422112474194bfe1e56bc43a8a_I20201231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMy05LTEtMS01MjY5Mg_464279fa-e2f8-4a57-9568-cfdb6d9d81ae">25,404</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ied574a7294fb41989cbb70d3122b883a_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNC00LTEtMS01MjY5Mg_d96d1f32-f4f2-4730-91ef-01af5d77c967">3,179</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNC05LTEtMS01MjY5Mg_3b705a63-1e31-4ec6-8e73-4d5a7d8fa5e6">3,179</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8ad697e3368343c7919b7dd3273b3410_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNS01LTEtMS01MjY5Mg_8c417f38-4b38-46bf-afd6-8c42a9410f9b">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNS05LTEtMS01MjY5Mg_b1d3df90-1d08-46cf-87d2-ca5a2fd92744">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNi0wLTEtMS01MjY5Mi90ZXh0cmVnaW9uOjgwOWJjZWRlOTRkYTQ4MzE4YWJlOTZjNDRhNGQ0Njg2XzQ1_3feaf48a-8b71-423c-af10-cc340695e537">0.65</ix:nonfraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ied574a7294fb41989cbb70d3122b883a_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNi00LTEtMS01MjY5Mg_d4b133c1-1afe-491c-96de-9968b8b3e486">1,653</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNi05LTEtMS01MjY5Mg_e03ed57c-af5f-4fc7-b950-80ccbcbda1f4">1,653</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iad37d7d7a2e348e2bd3eda54cebe4097_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNy0zLTEtMS01MjY5Mg_82be1a23-b654-4ec3-b6b4-7bab859832a9">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="shares" contextref="i514acae560c54b4bb8231d1ce5dcd76f_D20210101-20210331" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNy02LTEtMS01MjY5Mg_48675da3-3716-4131-bd10-03c7981e4eb3">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i514acae560c54b4bb8231d1ce5dcd76f_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNy03LTEtMS01MjY5Mg_7aed01a5-5e21-4e06-8869-55c29eb67246">65</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfNy05LTEtMS01MjY5Mg_54364025-398f-45de-a82b-9cad6447ee51">90</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifb57492bab6e48b7836070385115bfa0_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfOC04LTEtMS01MjY5Mg_0a7fac06-77e6-4dd6-aef8-c4ef39057ddd">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfOC05LTEtMS01MjY5Mg_9ff01507-0065-465a-8862-9a0780cdfce3">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i53a0a89ea3b54892a65055ce371fb98e_I20210331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtMS0xLTEtNTI2OTI_f0dcdbe9-edb4-416c-ae68-eb41bf4ca167">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53a0a89ea3b54892a65055ce371fb98e_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtMi0xLTEtNTI2OTI_fd7eae90-4438-4557-837d-11df07b11224">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib14867d580e04b399eb725d467bc805d_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtMy0xLTEtNTI2OTI_f0bb5c5b-10bc-415e-99e6-1fc2bd1ad78f">39,613</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42b8a21f43da47c1ade213512e51477f_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtNC0xLTEtNTI2OTI_6da4ab20-daab-47c9-8003-01d98e7e2903">48,888</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i68676726a1254cd4845299523b924c36_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtNS0xLTEtNTI2OTI_31662114-4a88-416f-94e2-01707e770c8f">6,622</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="ie684996ed0954f7e97d7fee6bbde21b1_I20210331" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtNi0xLTEtNTI2OTI_a2bf24bc-37d9-4e93-9080-e5bbbe213b04">1,046</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie684996ed0954f7e97d7fee6bbde21b1_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtNy0xLTEtNTI2OTI_549f5cc8-c456-4d5d-8541-9e2362eac29b">56,722</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idfa93baa9609499080ad1e1f74dc86ed_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtOC0xLTEtNTI2OTI_cec2b203-ddfb-4074-88bf-d206d68c5f31">94</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5d6e28b8146e48e58a44f95cd279905a_I20210331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTAtOS0xLTEtNTI2OTI_ff3b9892-91e4-42d1-977c-eecbf8b3cb35">27,039</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="if84b4767925647209c5222bd0a0dbe6e_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtMS0xLTEtNTI2OTI_c527bfb5-ff9d-462d-a97c-634ee8ea14ee">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if84b4767925647209c5222bd0a0dbe6e_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtMi0xLTEtNTI2OTI_5e241bb8-072f-4a8f-871d-9a6b553d6ea8">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1531c1718983403c863b19ea7f471a60_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtMy0xLTEtNTI2OTI_c6718942-b0cb-4cef-9e4c-4dd1d84b4c54">44,238</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if84b5a70a078433ea9402fc49b7c46a8_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtNC0xLTEtNTI2OTI_e36e8a4d-21b6-47af-bbc0-fcf1f089cd53">53,696</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia3887784c2224aad9004e572def3ab66_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtNS0xLTEtNTI2OTI_f9daf6f0-be6a-4074-8e79-3eeaecf1c0a5">4,429</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i3ce2e4b1a08045b6b19059f506912c04_I20211231" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtNi0xLTEtNTI2OTI_a40aa514-dfe6-4c46-8bb8-bfa360343681">1,049</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3ce2e4b1a08045b6b19059f506912c04_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtNy0xLTEtNTI2OTI_e83a9502-dae7-4698-9d04-f58f90efb1f1">57,109</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia466e356c7ac4d43b134063092b70bec_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtOC0xLTEtNTI2OTI_06fde21e-66a6-4fa0-ba4f-e1e48c8fd0d1">73</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18adaae581f9469896445184e25ae852_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTEtOS0xLTEtNTI2OTI_43cdf511-9db1-4450-9731-af7def4fca86">38,257</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie136701fb9f24134ae604f5b6f0c1970_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTItNC0xLTEtNTI2OTI_a0a76a20-eaf6-40c2-aec4-6c4ccbf5c9c6">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTItOS0xLTEtNTI2OTI_841f1fa6-52dc-4cb9-bc54-9546a0d5f790">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifbc101a99c394b61a87e53e12bd2c43d_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTMtNS0xLTEtNTI2OTI_77527149-902d-4a90-bb5e-654218f35010">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTMtOS0xLTEtNTI2OTI_913cbb20-7e05-448e-8bb5-213eb3652b8a">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($<ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTQtMC0xLTEtNTI2OTIvdGV4dHJlZ2lvbjo3NjRkMjllN2JjZjk0NDkxOTA2MzFjZTM1NTYyM2ZmOV80NQ_86f91e1f-5aa4-4f9d-8a97-a9eb7645a69f">0.69</ix:nonfraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie136701fb9f24134ae604f5b6f0c1970_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTQtNC0xLTEtNTI2OTI_7c95df05-d25a-4514-88a4-5926eabb3b68">1,754</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTQtOS0xLTEtNTI2OTI_4979d7c6-7dea-44d7-b297-012095e06f27">1,754</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93f7b31f62a84d71bd2d076d745e615a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTYtMy0xLTEtNTI2OTI_57fa113d-8171-4f67-a19a-430d5d743ae3">37</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i6522f7a5335d4e668aa0f115930308e9_D20220101-20220331" decimals="-6" name="us-gaap:StockholdersEquityOtherShares" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTYtNi0xLTEtNTI2OTI_f627efb5-c194-43e6-9557-8efbbd0d4293">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6522f7a5335d4e668aa0f115930308e9_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTYtNy0xLTEtNTI2OTI_a2e97ce1-aaee-44f8-8ca0-06fd558e85a0">46</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTYtOS0xLTEtNTI2OTI_3500fbd2-7d17-4004-95a8-96b7961e92c8">83</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic95aad46020143b09177438a9c4b2837_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTctOC0xLTEtNTI2OTI_18487b55-d4e9-448a-ac4e-31b6ef70a9ad">3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTctOS0xLTEtNTI2OTI_fb787540-5dd4-49cd-8f7f-f101b0675096">3</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i569ec33f48d74348bdd4d6f901790fb0_I20220331" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktMS0xLTEtNTI2OTI_9d017021-9e08-4b5a-ba0b-d7217f9a552d">3,577</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i569ec33f48d74348bdd4d6f901790fb0_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktMi0xLTEtNTI2OTI_e2a07a8e-fdcb-4f20-a571-6031dfedadb3">1,788</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i20619e693d1542d58ca14d0e7360873c_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktMy0xLTEtNTI2OTI_b376fa99-0f36-41a3-91e8-b412ae0e5fc8">44,275</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i62ddfa6cfc2540b09aab7403b62c4afe_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktNC0xLTEtNTI2OTI_1c79a3f7-31d0-43ca-97e8-ff961ce5572e">56,252</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic8b43a3143c447289f9e943f75e08163_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktNS0xLTEtNTI2OTI_3dc65f41-477d-4cbb-9e6a-17b9d654912a">4,369</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i4c0732fd93fb42dd939a8a10b16cb8ec_I20220331" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktNi0xLTEtNTI2OTI_efbcdc14-83a4-43e3-bf6a-53aea382ce83">1,049</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4c0732fd93fb42dd939a8a10b16cb8ec_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktNy0xLTEtNTI2OTI_367c86f4-e6ef-4d75-b65b-e7e3ff89fd6e">57,063</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia13b37526517428c88988a9ca38929b0_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktOC0xLTEtNTI2OTI_1e097d45-2fe9-4980-959d-e01392756a71">70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6a111b75f22542d9a20b9262e2295716_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82MS9mcmFnOjcwMDRhNDVkYzljMDRkNmM4Y2Q0MTBmYjg4YzM4YTEwL3RhYmxlOjg3M2EzYzQwZDVmZTRlMDA5MTI3MDkxN2UxODNmMGNlL3RhYmxlcmFuZ2U6ODczYTNjNDBkNWZlNGUwMDkxMjcwOTE3ZTE4M2YwY2VfMTktOS0xLTEtNTI2OTI_d8346986-74df-47ba-b7de-48e4f199a5c5">40,953</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></ix:nonnumeric></ix:continuation></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:0.584%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div id="ia10991337ee64bfe975ff621c73a0ff6_64"></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 24 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RleHRyZWdpb246YTA1YTEyMmUwOGI2NDI2MTg1MDc5NWY3NDViOGFjYWNfMjczMg_943d59d2-a8db-4f60-8a99-26a6f79486e0" continuedat="i9a53d706c6424683ad8d348e813e1923" escape="true">Pension and Other Postretirement Benefit Plans</ix:nonnumeric></span></div><ix:continuation id="i9a53d706c6424683ad8d348e813e1923"><ix:nonnumeric contextref="i8cb2f0fd7de9416c874ac85ecf17441a_D20220101-20220331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RleHRyZWdpb246YTA1YTEyMmUwOGI2NDI2MTg1MDc5NWY3NDViOGFjYWNfMjc0MQ_1239e790-3d0b-46b8-992d-04a6468d524a" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the U.S. and in certain of its international subsidiaries. The net periodic benefit cost of such plans (including certain costs reported as part of discontinued operations in the first quarter of 2021) consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.091%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMy0xLTEtMS01MjY5Mg_700eb357-9ddf-4c9b-b1e5-7d2130c7bac3">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMy0zLTEtMS01MjY5Mg_2e1b754e-4930-483c-812f-ffda9c1c7118">75</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMy01LTEtMS01MjY5Mg_56398afe-fc57-458e-bee9-27cacff1ae24">100</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMy03LTEtMS01MjY5Mg_4b32026e-2e8e-4cc1-8508-7aacf0cb3d9b">92</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNC0xLTEtMS01MjY5Mg_420a1628-7ca9-49fa-a37c-2de1551d4c83">103</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNC0zLTEtMS01MjY5Mg_4dc930f2-ce17-4fab-8956-74f89284a56c">38</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNC01LTEtMS01MjY5Mg_1e33943e-a057-442b-b69f-2b496e315e6f">96</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNC03LTEtMS01MjY5Mg_18fd4f7f-6123-412c-8067-803fef5ae8ce">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNS0xLTEtMS01MjY5Mg_54bfc240-ee39-4a27-9447-705b7e552146">196</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNS0zLTEtMS01MjY5Mg_f0b98ec8-b0e8-41ce-85a3-64e04d3db4e3">101</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNS01LTEtMS01MjY5Mg_4a6927f9-593b-49b4-bd71-a52b9b2a4620">188</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNS03LTEtMS01MjY5Mg_e94411cf-d301-4765-a087-13125db50a77">104</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNi0xLTEtMS01MjY5Mg_54e02b9c-3016-42b1-b958-d1a9918c91ec">8</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNi0zLTEtMS01MjY5Mg_e6e41a66-ffe4-4297-bda4-3f1d461ba208">4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNi01LTEtMS01MjY5Mg_f2002ddc-53ef-4f35-9404-162d76ab1229">10</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNi03LTEtMS01MjY5Mg_65e800a0-97e4-4b03-a262-b12235483f97">4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNy0xLTEtMS01MjY5Mg_77d26ea8-779d-4f6a-80af-743a8dae3ad9">56</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNy0zLTEtMS01MjY5Mg_61024bd5-c070-4320-af0c-b21e7ddb76fc">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNy01LTEtMS01MjY5Mg_02a5ce80-c318-4594-8ade-c127d1a2b806">85</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfNy03LTEtMS01MjY5Mg_885fca49-e516-46d0-bb9e-c273eccfbc98">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOC0xLTEtMS01MjY5Mg_227f081e-d1de-4ea2-8e7c-9b0d3147078a">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOC0zLTEtMS01MjY5Mg_a05c315b-8a47-4833-8e99-7a8ed549efe5">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOC01LTEtMS01MjY5Mg_ca8a72c3-3501-4fa8-954e-04cd3af3fc89">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOC03LTEtMS01MjY5Mg_438d1dee-7dff-4901-bd55-882289eeea6b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOS0xLTEtMS01MjY5Mg_b975d991-e2cd-4947-97d1-15d6895beb62">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOS0zLTEtMS01MjY5Mg_7451709a-65e1-4c53-ad93-eaf511dfc5e9">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOS01LTEtMS01MjY5Mg_44a091d1-3928-4d43-bdfe-d9359eb75186">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfOS03LTEtMS01MjY5Mg_8027fbb3-6f4b-40ac-a641-bfedc726e14c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTAtMS0xLTEtNTI2OTI_12232e9e-47e4-403c-8402-e5164ac18b64">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTAtMy0xLTEtNTI2OTI_919d34c5-92d8-4f23-8c03-d8e356c95ada">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTAtNS0xLTEtNTI2OTI_4f4e435a-da4d-4f6a-a625-d67f38dc8ab4">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTAtNy0xLTEtNTI2OTI_5fbaa4dd-0bfd-4edc-90b9-f7c78ac40d50">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia2a29800f66240688de941c099b47bd0_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTEtMS0xLTEtNTI2OTI_89576af0-0520-4084-9af1-e045db73448c">58</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id579b8c1bb934264940d6cf79d30c998_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTEtMy0xLTEtNTI2OTI_cee7283a-b7ed-4f23-ab56-fe5660c685e2">33</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3dfcff0a152f434c9f51870421d4f7cf_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTEtNS0xLTEtNTI2OTI_49565884-04c0-4198-a39a-ee05fff3138f">91</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieff37403743248c6b0412f84a58b886b_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjBmOThjMTc3ZTFhMDRkOGRhZGFhNmJhMDM4NjMxODRjL3RhYmxlcmFuZ2U6MGY5OGMxNzdlMWEwNGQ4ZGFkYWE2YmEwMzg2MzE4NGNfMTEtNy0xLTEtNTI2OTI_53feb76a-d7cf-474b-b1e9-9c0c2830f969">54</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><ix:nonnumeric contextref="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RleHRyZWdpb246YTA1YTEyMmUwOGI2NDI2MTg1MDc5NWY3NDViOGFjYWNfMjc1Mw_4da356dd-e590-4209-be8d-e6aeaa43d876" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:82.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.943%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfMi0xLTEtMS01MjY5Mg_a7027f8d-88fd-4b76-92f6-e028e5fc9b20">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4997b6e3663c4f838b0a7631c305249c_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfMi0zLTEtMS01MjY5Mg_d14aa973-8e6c-47b8-aa16-8c85f1fe1993">13</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfMy0xLTEtMS01MjY5Mg_b2c3a702-e4e6-464c-b828-0d691afd867c">11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4997b6e3663c4f838b0a7631c305249c_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfMy0zLTEtMS01MjY5Mg_a0def3fc-6d0a-44ad-85b4-ba8616fadec5">11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfNC0xLTEtMS01MjY5Mg_005f7aff-87ef-4162-bba0-a63f290d9380">21</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4997b6e3663c4f838b0a7631c305249c_D20210101-20210331" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfNC0zLTEtMS01MjY5Mg_ed955734-d0eb-46db-8d2f-26b2d8bccff5">20</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfNS0xLTEtMS01MjY5Mg_3bf9ab56-0d51-4a69-af9f-926613c87046">25</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4997b6e3663c4f838b0a7631c305249c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfNS0zLTEtMS01MjY5Mg_d6fb9fe6-1998-4dec-812b-82723ce838dc">25</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ieb4ca1e071a54d64a442cef319f87c0c_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfOS0xLTEtMS01MjY5Mg_1400d69c-dadb-4aef-a114-a03276098250">23</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4997b6e3663c4f838b0a7631c305249c_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82NC9mcmFnOmEwNWExMjJlMDhiNjQyNjE4NTA3OTVmNzQ1YjhhY2FjL3RhYmxlOjNmODFhOTM0NWU1OTRiMGNhYTMzODM0NzE2YmZhZTE4L3RhYmxlcmFuZ2U6M2Y4MWE5MzQ1ZTU5NGIwY2FhMzM4MzQ3MTZiZmFlMThfOS0zLTEtMS01MjY5Mg_349b4d87-6c0f-4608-b10d-ef4df087de63">21</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;padding-left:4.5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 5), termination charges were recorded on pension plans related to expanded eligibility for certain employees e</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iting Merck. Also, in connection with these restructuring activities, curtailments and settlements were recorded on certain pension plans. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 11), with the exception of certain amounts for termination benefits, curtailments and settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions.</span></div></ix:continuation><div id="ia10991337ee64bfe975ff621c73a0ff6_67"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RleHRyZWdpb246MzMwNzFmOWEyNDUyNDlmZDlkYWVjMjZhYWYyNDU4ZTJfNjk1_721d2603-50bc-4472-9f37-36549b007b51" continuedat="iaba0412306be4164951f87f3377b709a" escape="true">Other (Income) Expense, Net</ix:nonnumeric></span></div><ix:continuation id="iaba0412306be4164951f87f3377b709a" continuedat="i70114a8ef50a40f1baee2d3af99866d2"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RleHRyZWdpb246MzMwNzFmOWEyNDUyNDlmZDlkYWVjMjZhYWYyNDU4ZTJfNjg3_18020fe5-b85a-4fae-8d53-ddae365ed942" continuedat="i4d68410414da425c9832db1aa57bab76" escape="true"><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.821%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfMi0xLTEtMS01MjY5Mg_fd9009ae-2099-48f2-8a30-aa7002bdf6a3">7</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfMi0zLTEtMS01MjY5Mg_6346a573-5f02-4b3c-af74-7cbc20a89415">11</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfMy0xLTEtMS01MjY5Mg_08638aeb-1320-4579-b7a9-25ce4cca1d1e">243</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfMy0zLTEtMS01MjY5Mg_8bfabc04-cf85-4c3e-acfc-b5b47f715dec">200</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNC0xLTEtMS01MjY5Mg_ef988eaf-2bdf-4b1b-84d5-7edf3f3e884b">39</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNC0zLTEtMS01MjY5Mg_d6581de7-3031-4b4b-b651-b4ba9d817d10">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNS0xLTEtMS01MjY5Mg_cfc7d255-5b09-402b-92f1-c26b4ba24ff4">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNS0zLTEtMS01MjY5Mg_f4418ddf-601a-48ab-8f22-4cd6bf92e9ed">574</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNi0xLTEtMS01MjY5Mg_a66d2c1c-fa03-4a39-81b8-8611490d3a18">121</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNi0zLTEtMS01MjY5Mg_159ad39c-6410-4b79-a56f-b1bd77f1ba77">89</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNy0xLTEtMS01MjY5Mg_060965ab-fb85-42f0-b276-ece7f7668619">154</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="mrk:OtherNonoperatingIncomeExpenseOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfNy0zLTEtMS01MjY5Mg_faaeb1c1-eccf-4483-8f91-8019193825fc">22</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfOC0xLTEtMS01MjY5Mg_98cef226-ddb2-428d-bfe4-c52d38efaf16">708</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RhYmxlOmVmYWZjMDhiYzBmYjQyYWFhNzY2MDFhMjM3M2U3OGQxL3RhYmxlcmFuZ2U6ZWZhZmMwOGJjMGZiNDJhYWE3NjYwMWEyMzczZTc4ZDFfOC0zLTEtMS01MjY5Mg_d885065a-d31b-427a-96ec-f50a21ca4d34">455</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"><ix:continuation id="i4d68410414da425c9832db1aa57bab76" continuedat="iff6eb252bfa64627a9cf7932a94a64be">(1)&nbsp;&nbsp;&nbsp;&nbsp;</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="iff6eb252bfa64627a9cf7932a94a64be">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while gains and losses from ownership interests in investment funds are accounted for on a one quarter lag. The Company estimates that losses of approximately $<ix:nonfraction unitref="usd" contextref="i1a0cf1b8de8d4747b40955501b90028d_D20220401-20220630" decimals="-6" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RleHRyZWdpb246MzMwNzFmOWEyNDUyNDlmZDlkYWVjMjZhYWYyNDU4ZTJfNTA5_1d131e40-3a5d-43f6-9963-9ce6d296ca97">300</ix:nonfraction>&nbsp;million will be recorded in the second quarter of 2022 from ownership interests in investment funds.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 25 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i70114a8ef50a40f1baee2d3af99866d2">Interest paid for the three months ended March&nbsp;31, 2022 and 2021 was $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RleHRyZWdpb246MzMwNzFmOWEyNDUyNDlmZDlkYWVjMjZhYWYyNDU4ZTJfNjU5_e1776f4f-4e9a-4342-8aaa-405c2020f41f">211</ix:nonfraction> million and $<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl82Ny9mcmFnOjMzMDcxZjlhMjQ1MjQ5ZmQ5ZGFlYzI2YWFmMjQ1OGUyL3RleHRyZWdpb246MzMwNzFmOWEyNDUyNDlmZDlkYWVjMjZhYWYyNDU4ZTJfNjY2_3fa2e233-d5ac-46a6-a3be-0f6afcaf0c70">217</ix:nonfraction> million, respectively.</ix:continuation></span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_70"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfMTU0MA_9ce0f789-b1a3-4a02-adba-b1e66faaf86e" continuedat="ibc0673c975a047279389e9408c12064a" escape="true">Taxes on Income</ix:nonnumeric></span></div><ix:continuation id="ibc0673c975a047279389e9408c12064a"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were <ix:nonfraction unitref="number" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfODg_afc30b97-d528-4bfe-8543-29c9000f9edc">11.4</ix:nonfraction>% and <ix:nonfraction unitref="number" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfOTU_f7d481a6-bfc7-4d8f-bf91-26acdd4f7592">8.0</ix:nonfraction>% for the first quarter of 2022 and 2021, respectively, which reflect the beneficial impact of foreign earnings. The effective income tax rate from continuing operations in the first quarter of 2022 also includes the impact of lower U.S. income reflecting net unrealized losses from investments in equity securities. The effective income tax rate from continuing operations for the first quarter of 2021 also reflects a net tax benefit of $<ix:nonfraction unitref="usd" contextref="i5545d6274b6d4e7ebf69a25bbe09d26c_D20210101-20210331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfNjIz_3e7f8b1e-4096-4399-90c9-e53310e29ab2">208</ix:nonfraction>&nbsp;million related to the settlement of certain federal income tax matters as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $<ix:nonfraction unitref="usd" contextref="i722194ef527244e7a0dbe92e91b2d199_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfOTE2_54ed4160-3937-41bc-8be8-b7dd7a9ffc1f">190</ix:nonfraction>&nbsp;million (of which $<ix:nonfraction unitref="usd" contextref="i5545d6274b6d4e7ebf69a25bbe09d26c_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfOTI5_fc2c7352-e361-424c-b19b-ef35f23720fd">172</ix:nonfraction>&nbsp;million related to continuing operations and $<ix:nonfraction unitref="usd" contextref="i5f59125c6bbe48bb88c3cfe119fec9de_D20210101-20210331" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfOTc1_e455e593-2e51-404d-be57-e583a73df272">18</ix:nonfraction>&nbsp;million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $<ix:nonfraction unitref="usd" contextref="i722194ef527244e7a0dbe92e91b2d199_D20210101-20210331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfMTIwNg_16c660b1-ce2d-4ea7-ac36-21ab340657fc">237</ix:nonfraction>&nbsp;million net tax benefit in the first quarter of 2021 (of which $<ix:nonfraction unitref="usd" contextref="i5545d6274b6d4e7ebf69a25bbe09d26c_D20210101-20210331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfMTI2Ng_3e7f8b1e-4096-4399-90c9-e53310e29ab2">208</ix:nonfraction>&nbsp;million related to continuing operations and $<ix:nonfraction unitref="usd" contextref="i5f59125c6bbe48bb88c3cfe119fec9de_D20210101-20210331" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83MC9mcmFnOjEwMWVmYmFlYzBjMzQ4ZjA4ZDU0MmVjMDNhMDBhZWIwL3RleHRyZWdpb246MTAxZWZiYWVjMGMzNDhmMDhkNTQyZWMwM2EwMGFlYjBfMTMxMg_159a9b7f-0755-4ba0-aaaf-c50a6d7f0f92">29</ix:nonfraction>&nbsp;million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div></ix:continuation><div id="ia10991337ee64bfe975ff621c73a0ff6_73"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RleHRyZWdpb246ZjM2ZDFjNjM2OGIyNDBiZTgwNjVjOGI0Y2YwZmI3NzBfNDYz_83707755-0443-4cfd-ad24-ee2f1fec315a" continuedat="id34ff9df3fd2406badfa9ab55a7aef7c" escape="true">Earnings Per Share</ix:nonnumeric></span></div><ix:continuation id="id34ff9df3fd2406badfa9ab55a7aef7c" continuedat="id07b85d3aafb4b0182087e321b71017e"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RleHRyZWdpb246ZjM2ZDFjNjM2OGIyNDBiZTgwNjVjOGI0Y2YwZmI3NzBfNDY2_9d084694-6c64-4f37-8d4b-bafb0cac0e71" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:81.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.236%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income from Continuing Operations Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMi0xLTEtMS01MjY5Mg_25f94374-9239-418b-a988-0b2245185486">4,310</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMi0zLTEtMS01MjY5Mg_0ff066a6-4e7c-4187-ba31-5bea8cfa780b">2,745</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMy0xLTEtMS01MjY5Mg_3d202955-84f1-4df7-bded-16cf7e48d858">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMy0zLTEtMS01MjY5Mg_895d2fbf-2966-4c34-85ac-242c5100c122">434</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income Attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNC0xLTEtMS01MjY5Mg_9da1ade8-6924-4d07-a02d-fc8c9c7ad6a0"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNC0xLTEtMS01MjY5Mg_fd0cc116-94d3-46c0-862a-06060d97f902">4,310</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNC0zLTEtMS01MjY5Mg_9a1b69fe-75ab-47af-a586-4137cb2eee77"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNC0zLTEtMS01MjY5Mg_a2337ec1-85d6-46d4-ae6f-8767979f8f6c">3,179</ix:nonfraction></ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNS0xLTEtMS01MjY5Mg_59bd39ee-0bf6-4fa0-8a0d-9e8ed73b56a5">2,528</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNS0zLTEtMS01MjY5Mg_400fb675-c1ae-483d-b333-94b97421b277">2,531</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNi0xLTEtMS01MjY5Mg_6b77bf0b-53a7-400d-8073-852ef5bb5009">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNi0zLTEtMS01MjY5Mg_62f225a1-8ea5-45d8-8786-fc290c163320">10</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNy0xLTEtMS01MjY5Mg_21018785-52b9-4fd8-a1bb-6ef648e3c74f">2,537</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="shares" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfNy0zLTEtMS01MjY5Mg_2247b880-f146-4b63-982b-483182f4bb00">2,541</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic Earnings per Common Share Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfOS0xLTEtMS01MjY5Mg_70335c48-3082-4d0f-bce4-8336ec7f5175">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfOS0zLTEtMS01MjY5Mg_b3c4b338-fb68-4ef1-aade-746f33897f71">1.08</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTAtMS0xLTEtNTI2OTI_d636b759-d862-42f2-a6f2-5f0c6d740c5d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTAtMy0xLTEtNTI2OTI_f5a77b57-9a96-4ce1-819d-b2368311cfbb">0.17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTEtMS0xLTEtNTI2OTI_37073fbe-7816-4434-85f3-a8e0b4a9bcde">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTEtMy0xLTEtNTI2OTI_08e945a7-7e41-41e2-ae35-1e8873dc1403">1.26</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per Common Share Assuming Dilution Attributable to Merck &amp; Co., Inc. Common Shareholders:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTMtMS0xLTEtNTI2OTI_6c5ca56b-8f0a-4239-8de1-6a6e0b6b4715">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTMtMy0xLTEtNTI2OTI_11c4cc90-db79-4bbc-8789-8b6c17495801">1.08</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Discontinued Operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTQtMS0xLTEtNTI2OTI_a6027045-a896-4e2c-88a7-ab127673026c">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTQtMy0xLTEtNTI2OTI_ef4c54f9-7d99-4db2-9dc8-79fbbb89ee16">0.17</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTUtMS0xLTEtNTI2OTI_0f72f3a9-997c-4fd4-b756-b79692de5d50">1.70</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usdPerShare" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RhYmxlOjE4NGJjM2ZkNmFhODQzYzk5ZWM4OWIzZDJiYTc1ZWY2L3RhYmxlcmFuZ2U6MTg0YmMzZmQ2YWE4NDNjOTllYzg5YjNkMmJhNzVlZjZfMTUtMy0xLTEtNTI2OTI_953c1749-f388-4b03-8af3-eeb2f47a08c5">1.25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div></ix:nonnumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id07b85d3aafb4b0182087e321b71017e">For the first quarter of 2022 and 2021, <ix:nonfraction unitref="shares" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RleHRyZWdpb246ZjM2ZDFjNjM2OGIyNDBiZTgwNjVjOGI0Y2YwZmI3NzBfMTc2_28c30216-1fe6-4a07-834d-8191f0458fae">7</ix:nonfraction> million and <ix:nonfraction unitref="shares" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83My9mcmFnOmYzNmQxYzYzNjhiMjQwYmU4MDY1YzhiNGNmMGZiNzcwL3RleHRyZWdpb246ZjM2ZDFjNjM2OGIyNDBiZTgwNjVjOGI0Y2YwZmI3NzBfMTgz_a16d9652-1cb7-4066-87c6-5693ee507ad8">14</ix:nonfraction> million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.</ix:continuation> </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_76"></div><div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 26 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RleHRyZWdpb246NjVlNDU0ZTA1MzY4NGViNWI1MWQ3ZTdhMDk4MzI2OTlfNTM4_a3fb991d-6a4f-4e30-b5d4-0ed8ba9e2d5d" continuedat="i831eb21efe2d4eb7a1985ad1bcfabc7f" escape="true">Other Comprehensive Income (Loss)</ix:nonnumeric></span></div><ix:continuation id="i831eb21efe2d4eb7a1985ad1bcfabc7f"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RleHRyZWdpb246NjVlNDU0ZTA1MzY4NGViNWI1MWQ3ZTdhMDk4MzI2OTlfNTM5_79b29114-be64-40dc-b55f-252922b8bb16" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in each component of other comprehensive income (loss) are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br>Benefit<br>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Currency<br>Translation<br>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br>Comprehensive<br>Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id61a3e58809341d7a4d794616833beb7_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMi0xLTEtMS01MjY5Mg_7bc957c5-d04a-4277-8a39-3f15fbd7d659">266</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iedb28ff42f1b4f8e9eaa37f6e70aee28_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMi01LTEtMS01MjY5Mg_001eb803-b0f5-4849-8eee-1c081fdaae57">4,540</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i18d94e3476884c45be0248c4ec69fd85_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMi03LTEtMS01MjY5Mg_d1690e02-41a3-4acf-aa2e-597ddb4d9030">1,828</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="iab28075d402e4ad9ac4ac4c3641fdf1d_I20201231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMi05LTEtMS01MjY5Mg_07b5f778-0fd1-4b80-8897-98ad6c45d96d">6,634</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMy0xLTEtMS01MjY5Mg_3e2d17ae-e269-46e1-99b4-96cfa7b11961">180</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMy01LTEtMS01MjY5Mg_d622e086-bf9d-4705-964f-9ec6cebdc012">4</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMy03LTEtMS01MjY5Mg_8507f466-46ea-453a-aaba-899472b78aa2">211</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMy05LTEtMS01MjY5Mg_d2a8773d-3f25-40c4-94ec-1237c01cceaf">35</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNC0xLTEtMS01MjY5Mg_b12f0d58-195e-43fb-a781-36d66a1dbe0d">38</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNC01LTEtMS01MjY5Mg_b1fbfcc7-b8a9-4e92-af7b-ecab1377b40a">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNC03LTEtMS01MjY5Mg_dca65662-14af-42ab-9986-021adad4e925">88</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNC05LTEtMS01MjY5Mg_9061a113-a987-43fc-8894-a331f6e8578c">127</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNS0xLTEtMS01MjY5Mg_2c46f56f-39d2-43c5-a3a0-8dd7069508f7">142</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNS01LTEtMS01MjY5Mg_3ef9fa1d-fc5e-493b-967c-e45d47bf1929">5</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNS03LTEtMS01MjY5Mg_0b790f5f-5010-49f3-89c6-ef18640856dd">299</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNS05LTEtMS01MjY5Mg_ea04bd6c-4f6f-4b68-8b9b-0af870e45b3a">162</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNi0xLTEtMS01MjY5Mg_43d55bbb-aea8-4651-98f0-5fb07b7f2664">111</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNi01LTEtMS01MjY5Mg_f25b35dd-51d9-4b6a-a5c4-6263df5f3c5d">87</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNi03LTEtMS01MjY5Mg_d73998f5-4f28-483c-9ff1-1cab8894dd5f">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNi05LTEtMS01MjY5Mg_180f0310-414c-40cd-952b-590bb77e4f52">198</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNy0xLTEtMS01MjY5Mg_e32db71e-67ac-433d-92fe-8b4bf07471a8">23</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNy01LTEtMS01MjY5Mg_c27ebbf0-2dd0-45f6-b158-fd868c7e45d9">1</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNy03LTEtMS01MjY5Mg_4705e077-d4bb-47fe-86b6-fa7ba221f2a6">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfNy05LTEtMS01MjY5Mg_e1dd6aff-165e-4e76-af3b-1089d4a19335">24</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOC0xLTEtMS01MjY5Mg_c3324e2a-57c7-4cc6-aebc-35f2cf948a13">88</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOC01LTEtMS01MjY5Mg_5d7b5915-2a4e-4e92-aed7-f6fa99f32bc1">86</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOC03LTEtMS01MjY5Mg_2b40c11d-222a-4ab2-b996-336444a69160">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOC05LTEtMS01MjY5Mg_9ccd0b5a-2297-41b7-8dfb-7dcea8fc5b12">174</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib250fc704cb74117b1e045c8f7569c73_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOS0xLTEtMS01MjY5Mg_70d62e30-5fc0-4df6-930a-87efa9103625">230</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2ca6bf37e31f4ed5927bbdff88eef38e_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOS01LTEtMS01MjY5Mg_8e1bec71-1d9a-4b10-886b-e0a589cb5e6f">81</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i357fc697f3854534a3ea09fa5fc006a3_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOS03LTEtMS01MjY5Mg_2b903fc9-ee7b-41bc-ab09-da8de554e016">299</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfOS05LTEtMS01MjY5Mg_82cc17c8-4f50-4cbf-bf84-e70f5ff3f848">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2021, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ie3b973ff519747f085a3dc65ff1c1d1e_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTAtMS0xLTEtNTI2OTI_0e4e2906-cc4a-43bb-a2ab-c722ff688923">36</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i40b4346129b5496b92f90d13a2ab678c_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTAtNS0xLTEtNTI2OTI_75e236e4-9743-49a1-8bed-aaf8099353de">4,459</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i98eb42d0251f4537a6f17d79aa48cb2e_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTAtNy0xLTEtNTI2OTI_87032652-af95-438e-8bff-aba2b172d847">2,127</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i68676726a1254cd4845299523b924c36_I20210331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTAtOS0xLTEtNTI2OTI_c9c14c38-a470-44a1-879e-4133e9e621d3">6,622</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i60156c387cf345abb90a9ef946ec3248_I20211231" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTEtMS0xLTEtNTI2OTI_3bb779bd-4c53-4903-bf03-699e16df40dc">144</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i44a102637a5141308efca9ba686f71c6_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTEtNS0xLTEtNTI2OTI_310e61b9-0359-4e83-a658-7a02a1e521bb">2,743</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i4ca2053e683b45e3b6831b4ef691041f_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTEtNy0xLTEtNTI2OTI_9d0fc991-eb15-4499-b285-82f40169d6d4">1,830</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia3887784c2224aad9004e572def3ab66_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTEtOS0xLTEtNTI2OTI_74197df1-b762-416e-bfda-d6ab45cd70da">4,429</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTItMS0xLTEtNTI2OTI_8aef646e-56ca-46c6-a436-ac0ec6564f8d">148</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTItNS0xLTEtNTI2OTI_2b9c1fb3-5c9d-4feb-9974-d3a30f7ee4b4">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTItNy0xLTEtNTI2OTI_42b1984e-cbc3-49bd-994e-33cadc0e0980">18</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTItOS0xLTEtNTI2OTI_c10c7d76-4439-42e5-8bea-ed6d2deb75f0">131</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTMtMS0xLTEtNTI2OTI_121cb00e-90f4-49a7-8831-17ca36122396">31</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTMtNS0xLTEtNTI2OTI_3d8a7a64-68bd-454c-888b-4baf7b7c5ed7">2</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTMtNy0xLTEtNTI2OTI_18da58d7-035d-4e24-ab6e-2216bf8b05ad">17</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTMtOS0xLTEtNTI2OTI_6bf1462b-1e34-45e5-ba75-017e54052366">50</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTQtMS0xLTEtNTI2OTI_8dde33e6-f135-48c5-8971-97ae83173287">117</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTQtNS0xLTEtNTI2OTI_5a9152ad-dd23-4e32-979d-15ed53418182">1</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTQtNy0xLTEtNTI2OTI_0f6fe029-9ca8-4e8f-9530-f1137453ea7b">35</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTQtOS0xLTEtNTI2OTI_0a204ff4-5ca3-4d93-8485-d343d4b8d0ad">81</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTUtMS0xLTEtNTI2OTI_8665b1cc-1ca4-4c5a-bbb7-f0f5177730d8">68</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTUtNS0xLTEtNTI2OTI_401df703-eb0d-40bd-923e-782548de7a67">45</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTUtNy0xLTEtNTI2OTI_6e69582a-6983-4193-b1d8-52840492bcc8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTUtOS0xLTEtNTI2OTI_422219cb-7d28-4be9-a7b9-55b9e699c840">23</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTYtMS0xLTEtNTI2OTI_e9fa0762-35cb-4893-8615-5cc6572e8ec1">14</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTYtNS0xLTEtNTI2OTI_46184069-9143-45a6-81d2-450606d258b4">12</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTYtNy0xLTEtNTI2OTI_f00cb29f-7412-48a3-ae6d-0864f03db2b8">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTYtOS0xLTEtNTI2OTI_64be4216-56a6-4ae2-909f-61cd9b83c459">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTctMS0xLTEtNTI2OTI_33e1340a-ac3e-4e70-948f-bfff424beedc">54</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTctNS0xLTEtNTI2OTI_a37f574e-49d0-4e61-8296-5cf1f97cc6b8">33</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTctNy0xLTEtNTI2OTI_a552b58f-fb7c-4b71-b6e1-f40346f00603">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTctOS0xLTEtNTI2OTI_b42256cb-819e-40bb-b548-ffcfb25eb521">21</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7e4d384e6f4c464096c853592f42d620_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTgtMS0xLTEtNTI2OTI_7254aef6-55ab-4a62-8400-248329b5ccb1">63</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09175a8f6a794c40abb43b76ae7d3c77_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTgtNS0xLTEtNTI2OTI_82619560-40f3-48e8-8362-d2af5bbc7880">32</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5f608f49f8744395b6a65c12d44b498a_D20220101-20220331" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTgtNy0xLTEtNTI2OTI_9c686cdd-8391-4858-b8a7-aa49f2a9c297">35</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTgtOS0xLTEtNTI2OTI_a63b7579-5e25-4fca-833f-3ff7e1dee0b4">60</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance March 31, 2022, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i54569a21dcd945d3a0ccd5c1fa57a69d_I20220331" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTktMS0xLTEtNTI2OTI_ad3cd9cf-bc78-4970-8cba-64bc172a65d1">207</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ia60c4136abf045e5b267ba9a6119f8a1_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTktNS0xLTEtNTI2OTI_9283286b-a096-4b9f-8b07-8f46a5194411">2,711</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5af03731af2e458f94fb496c82505c6a_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTktNy0xLTEtNTI2OTI_0c6df359-c30b-46fa-b8d2-96a6b8add320">1,865</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic8b43a3143c447289f9e943f75e08163_I20220331" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83Ni9mcmFnOjY1ZTQ1NGUwNTM2ODRlYjViNTFkN2U3YTA5ODMyNjk5L3RhYmxlOjE1MmI5YWRmZjY0MjQ4NTlhMmRiMTAyODg1MThjOWQwL3RhYmxlcmFuZ2U6MTUyYjlhZGZmNjQyNDg1OWEyZGIxMDI4ODUxOGM5ZDBfMTktOS0xLTEtNTI2OTI_b81986af-2d8f-4a08-8d29-576a60700a3b">4,369</ix:nonfraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></tbody></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Primarily relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 10).</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:3.362%"><tbody><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric></ix:continuation><div><span><br></span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_79"></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&nbsp;&nbsp;&nbsp;&nbsp;<ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfNTgwMQ_80ae8504-536f-49a6-8af5-b3f177a6e219" continuedat="i0baef8ee29714098ab2cc82e4396933f" escape="true">Segment Reporting</ix:nonnumeric></span></div><ix:continuation id="i0baef8ee29714098ab2cc82e4396933f" continuedat="i19b832f366ab469bbe46be62a5d430fe"><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a product basis and include <ix:nonfraction unitref="segment" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfMTA4_3b5258c5-db92-4f37-aaea-5b66dd988c89">two</ix:nonfraction> operating segments, which are the Pharmaceutical and Animal Health segments, both of which are reportable segments. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S.&nbsp;Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.</span></div></ix:continuation><div style="text-indent:24.75pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 27 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i19b832f366ab469bbe46be62a5d430fe" continuedat="i61358273d7df40b6b470a6f6c2400491"><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfNTc5OA_b6efd5ce-431e-4082-8a2b-3d5ee5e54ef0" escape="true"><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.608%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">&nbsp;($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e20d7ab5de543189c7cf8412b527d91_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNS0xLTEtMS01MjY5Mg_39ed9407-836d-43c1-849b-57a0596df613">2,779</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5c74c81f5c5848f7b6e0d02515994746_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNS0zLTEtMS01MjY5Mg_4104c292-d086-4db6-8fc2-cbc7b189a0e3">2,030</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i59f0a1b106fb4080ab3a1f36cf82f84e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNS01LTEtMS01MjY5Mg_8a80619f-79ac-45b4-aa35-1ee54feb626e">4,809</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2a397fcb3142441ab06e1baf08c9a722_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNS03LTEtMS01MjY5Mg_deb652e9-e346-4c21-b145-d757982f3078">2,181</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6cef69b39c01439c999f212fce44ae46_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNS05LTEtMS01MjY5Mg_87c07bfd-e527-485a-a343-d028a3dce469">1,718</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8eb7b724f079410499ef45133c491127_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNS0xMS0xLTEtNTI2OTI_5dfc4599-3be5-4b72-bddf-4f16ca56ceb5">3,899</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1378f05e1d974c3ca238effcc1061478_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNi0xLTEtMS01MjY5Mg_087b993e-5c9f-4db7-8c47-dfbf3b4d64d3">141</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8f1bdc3bdf3b4a73bd66b0c8de1a282c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNi0zLTEtMS01MjY5Mg_6e636b27-8db6-4af1-880d-ba70fe97e70c">125</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d3b992d66c145ee9b4de5a44211145a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNi01LTEtMS01MjY5Mg_d7a1c3cd-16ff-40fc-ba5b-290d07e96fcf">266</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2304d957e48c4123ba09bda499b2d23e_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNi03LTEtMS01MjY5Mg_21022691-2956-4c70-83f2-fdd91bd3947c">118</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic70d2ca596904f71a73677ba284cc40d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNi05LTEtMS01MjY5Mg_ef062ad6-d1c9-4a1e-9b9f-80429412d187">110</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ad1b075422749bda5cab7e535626e43_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNi0xMS0xLTEtNTI2OTI_dbbcabf2-c0ff-4b87-aefe-2db92eca52ff">228</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie39cf686456342a2a5b66bcf8844e2e7_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNy0xLTEtMS01MjY5Mg_0d92cb92-1aa2-4108-ae02-b60905c7d479">156</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie59504a27285489990a160f7597466ba_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNy0zLTEtMS01MjY5Mg_58c69130-6263-45d5-9753-7a19a8403252">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i10c8790583e745e5884414f13c237f59_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNy01LTEtMS01MjY5Mg_d7c4a080-cc79-4a87-bd0a-a8c6729db505">227</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d85c438f0794b93b403a542b9f547e9_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNy03LTEtMS01MjY5Mg_8f93e1e5-3af7-49be-bda7-219799c39534">85</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icdb3340ce88447fb8ec56ddedb0a9613_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNy05LTEtMS01MjY5Mg_928271b6-6026-44af-8507-91a9f5b12389">44</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2777ab5df4a04c53943c51b99e654204_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNy0xMS0xLTEtNTI2OTI_0455ab61-b245-491f-b087-b5fbb0149adc">130</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i430607cc58d54dae9f78ee68eb170d71_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOC0xLTEtMS02MjY3Mg_fb620aea-0a4a-42d4-8486-585117596a30">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba955f563da04b5bab9409f14b1489c9_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOC0zLTEtMS02MjY3Mg_408e13f4-3174-4efc-a938-821ef5a147f2">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9866070ee97e4d06bf9db13bdb8d5c38_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOC01LTEtMS02MjY3Mg_64615d7d-3f3c-4bff-9b1d-f4a1783745ea">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4c2ade46f88949858cb25d24064a3022_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOC03LTEtMS02MjY3Mg_42e57828-03ac-49ee-9de3-25379953262b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1755d070f6e64a8c815d655fa303d6a7_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOC05LTEtMS02MjY3Mg_e1f9e462-c6d9-4123-8425-87dca7c5e51b">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if66aeae0bba947d1a8fd303f4cd0fb33_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOC0xMS0xLTEtNjI2NzI_87379845-db42-4250-ad13-6fd23f9c0329">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3c128862bc5343b087e092c74da567c1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOS0xLTEtMS01MjY5Mg_aca03ea3-2455-4c54-99fb-8e3f55dfd6cb">418</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3504a83c127d4e359c262077a8ad4937_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOS0zLTEtMS01MjY5Mg_9d0b1335-8d78-4b8b-83ac-227e15040399">1,042</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibe365a7ec2da4ab3ba5739bdcc1d5b43_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOS01LTEtMS01MjY5Mg_36af73b2-b802-4d9a-8511-12c62d14cb3c">1,460</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c48e69a260a47678c638d3f0443574e_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOS03LTEtMS01MjY5Mg_447f4906-f872-4064-953e-362dc0b29a1d">313</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5ddb3fa9a42640bf8f91ebf091b18bb2_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOS05LTEtMS01MjY5Mg_18ec293f-1924-40c7-b959-91ab54aa9eb7">604</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i838bf6dbbb1441a38d01e394886cd47e_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfOS0xMS0xLTEtNTI2OTI_14355ec6-2762-4b7a-8e21-2b11e2d5c3ac">917</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia95362eebb4d4129b5da0bfea68690b7_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTAtMS0xLTEtNTI2OTI_4df7436a-d8b4-4901-b42d-afd35a1e0879">371</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i388d1c7fcb724149afdcbc135beb7bf1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTAtMy0xLTEtNTI2OTI_3d15a0bc-e9e1-489c-8dd0-b0b880b04ab3">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic287bd3ac4174f009f5fff050055d549_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTAtNS0xLTEtNTI2OTI_cd6f705c-026e-4ca8-b2b3-5ab582e1db6e">470</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i53447d9d3c8f4921905c3f995cfa0af1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTAtNy0xLTEtNTI2OTI_45f91e68-910f-4772-83e8-b6c2f223811d">333</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4d1c72d338764cd9b5c9993a8d7dc13a_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTAtOS0xLTEtNTI2OTI_26f55ed1-6292-42e7-a92c-2ba88c8c6849">117</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0eea09aa7ba84aec98f08abd7dbb2d78_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTAtMTEtMS0xLTUyNjky_95b9cffb-f342-48a8-b0d2-40f9a38d41e9">449</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idd18a522fe054206a57830a86c371f89_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTItMS0xLTEtNjYwMjk_2fc2d215-7954-452a-ac6b-b7d219cd7b21">175</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5834efb4cd2f49a98240297687acd797_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTItMy0xLTEtNjYwMjk_4fa1e061-561a-457e-b087-fbb5851cf896">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8aae9208f3d8457e9b21275c1d73198d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTItNS0xLTEtNjYwMjk_dc0b1961-043e-4f4e-92b9-836b1d485b3c">216</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1fed20a2ab2c48cbac68fbcc8bd07eed_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTItNy0xLTEtNjYwMjk_8a3f9821-1a0f-422e-8be9-5f362c42739b">118</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic9d2a7af1b184d2ea6dc8cbc5e01096c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTItOS0xLTEtNjYwMjk_d48b585b-2f65-4c12-988c-71fb715bb25c">41</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7ee9e5e8e731421fbf23451888573a74_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTItMTEtMS0xLTY2MDI5_b6d9bff6-82bd-4185-8b01-07f8f8bc951c">158</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b676ade4f634770a2257c0bb201fdf8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTEtMS0xLTEtNTI2OTI_59803ec0-6e1c-4cd7-aaef-50f27b4aebac">118</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i83aac4908f344299afbc6ae433a1f0af_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTEtMy0xLTEtNTI2OTI_d4bd34bf-1bd9-49d1-867d-6392e3c25b38">55</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icb46708dbe9746aba6e4befe3b17efb8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTEtNS0xLTEtNTI2OTI_2c40fd0c-a820-41bd-b048-27fb8584b72c">173</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22eafc9339474ccfa21087916f78f6b4_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTEtNy0xLTEtNTI2OTI_3aaba925-bdc5-443e-9d14-bf562946e3eb">73</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0dcdd3046920429498dad4bae9f17593_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTEtOS0xLTEtNTI2OTI_77141419-b967-4b32-84ce-8eb7d04b00e4">99</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab0182afac194a5fb81a1c96977cddcf_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTEtMTEtMS0xLTUyNjky_e93ba6fd-13e2-41f3-822f-c223e449d5a5">171</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8052b0b3db74426782acc8b83c74328f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTMtMS0xLTEtNTI2OTI_675d5029-18ae-4ba0-b44b-fca6d0c70222">29</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1864645c4d0744b0ab18f7faf2df55a3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTMtMy0xLTEtNTI2OTI_d21e2335-17c1-4c2b-bab0-77a42aef9214">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib212bb0719a14f2a8f94c612a65306bd_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTMtNS0xLTEtNTI2OTI_d35dab1f-b763-41df-8ab8-398894cda2dc">36</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i33fbbd3074a14a4093926946d00bf9ce_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTMtNy0xLTEtNTI2OTI_4cc67ab5-823e-4e27-9cd7-c9301cdf36f9">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia43e0b0a29cf46f6aa2e4a25f68539b2_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTMtOS0xLTEtNTI2OTI_9b89d655-9664-4c6c-8393-ac143f8c3e65">9</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4fae42aaa56041e698ffba39abde1724_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTMtMTEtMS0xLTUyNjky_ca6722a7-a347-430f-8f74-868960d02b27">34</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9caf3514be7245078400fd569244bc9e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTUtMS0xLTEtNTI2OTI_3fd258eb-7400-4ce4-8634-17b70954e354">195</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0c98d3de72a46189d71d82351a42f04_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTUtMy0xLTEtNTI2OTI_bcee9883-e85a-4214-8739-7c982e689e47">199</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8dd109f470494dd1bb8437978682a1e0_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTUtNS0xLTEtNTI2OTI_41376585-3c95-4639-8e2a-b8ba24b973fc">395</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i857899174bd6427390552a84e60057af_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTUtNy0xLTEtNTI2OTI_edd39d18-1e83-4631-b364-8028306a0015">167</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4b6eed4d805a4aeebc6c7f0360690d12_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTUtOS0xLTEtNTI2OTI_7f968755-8a93-4b8f-86d3-7a3e3af02c6b">173</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia7871d0715f34b86a8252114d3825cf7_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTUtMTEtMS0xLTUyNjky_26e98bef-8f66-49c2-9100-e33657d3b3d2">340</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0912660964c148c5ac628105e11a43de_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTYtMS0xLTEtNTI2OTI_b57f188b-ce3d-4a7f-8c11-1dbc7df8c178">40</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b6cbff393cd412cb163a3c1d00ddf02_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTYtMy0xLTEtNTI2OTI_3a42f951-bfa7-4e3f-9661-5050bca934af">54</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="idf506a2ad624416f8c885812d21a79e5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTYtNS0xLTEtNTI2OTI_f8605c4f-d87c-4690-9f28-8c12efd8dfd3">94</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia8f26fbda981444bb87c932a8c8b22a0_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTYtNy0xLTEtNTI2OTI_be1f5f18-6597-4503-8f32-297a6f8602e9">35</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic581eb34f89d4cc88fef686876979dac_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTYtOS0xLTEtNTI2OTI_32a21333-4a8f-4e19-8b63-d0dbf5fb1486">47</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic29d1c42753f4a70a8e0bfec27c982dd_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTYtMTEtMS0xLTUyNjky_54c5d17e-0b3a-4e8f-b0c6-72e478afdedb">82</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibb6bcf16d7634857b3a41025fc1e5a48_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtMS0xLTEtNjU5MzM_db875c24-f798-4c85-ac19-7fa730b1fc12">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i31ef62147d294376ad3e6b572d5fa670_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtMy0xLTEtNjU5MzM_7fe859f3-4934-4ebc-aa97-a094096e67d2">58</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i11d11267dbc74238ae8ca79161f06bbd_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtNS0xLTEtNjU5MzM_5d992361-720a-43b4-a1cc-fe43d497f3f5">58</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i22d9aa0f9b2b44c38916d0502515d3aa_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtNy0xLTEtNjU5MzM_c0589dfc-7f5c-4626-8618-1a957109b5aa">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i42e26677453249db9ead107c4de5b019_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtOS0xLTEtNjU5MzM_44f40478-1ee9-4cac-8217-c9267075dacf">65</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i04e6e1b20ab942b0a2f7ae504b7566d5_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtMTEtMS0xLTY1OTMz_144d298a-7472-4e14-9ce6-334797aaf24f">65</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3bb775fc2a5449b4a22e2aa06c800df6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTctMS0xLTEtNTI2OTI_71464b45-5c46-4a88-bd23-aff96eb22886">10</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e65bdf4cd884592969b00480a8f084d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTctMy0xLTEtNTI2OTI_1a913537-d094-4e3c-a707-c46df714d22d">48</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib7c4d6b47ddc45aba6614bd2d7dbb95e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTctNS0xLTEtNTI2OTI_993de82a-026b-46fa-99ab-f727fa29f435">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia0154b7a75a64b6288d5772b8f5d2e96_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTctNy0xLTEtNTI2OTI_4c88c892-1fca-4125-9b30-f93135e97615">15</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if1bf26dd8e8f4dd3b9c1aa19e216657b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTctOS0xLTEtNTI2OTI_2ac9ee7f-d367-48d4-b673-b9e78e6e1c6d">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i55fcdef6d50641ada8cbf2dc6e04923d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTctMTEtMS0xLTUyNjky_776dd1d9-a084-4934-9d26-a9f9462330be">67</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6c302287c10d4bbba92104de6015674b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtMS0xLTEtNTI2OTI_fef512af-913c-479e-ab15-f9f1e1b30285">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i51625423201f4036aaaa3448bc46e451_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtMy0xLTEtNTI2OTI_acdaad20-9cb8-4f78-b792-c619105e27fd">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8a92cf715e5748528d2cbf3f4e939a8c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtNS0xLTEtNTI2OTI_e617e0a0-6802-440a-9d7f-25262a2248be">53</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8845af6d649d47a1b15777a446d60622_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtNy0xLTEtNTI2OTI_78701166-1d9c-4bb3-9e70-b84af71ae443">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia67d0514f105435b8cc5eb4a4d139459_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtOS0xLTEtNTI2OTI_987b5439-33bc-4586-946e-55ee3676e417">55</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i294a9a3d373d43c8b9c22d4ae6652cd8_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMTgtMTEtMS0xLTUyNjky_f6351a16-9f8f-4380-94ab-e43122f3c9ae">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Dificid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iede1c9ca1a5f402baa8b5a1a52d8b34a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtMS0xLTEtNjU0MjU_c7e13cb2-4ea3-4828-b628-807eb7c96a34">49</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i250fe35362a1407db2b756c0a0b8e38d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtMy0xLTEtNjU0MjU_912698bd-5b4e-4334-abd1-611969813211">3</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaff416e85bc6431ea58ec7f72f7bfa35_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtNS0xLTEtNjU0MjU_01a75312-61dd-43b5-bb7b-82867c821089">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic0ab75e20bb74c62a2e6a8161dc8aa74_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtNy0xLTEtNjU0MjU_1d476d75-5c58-4948-9189-8f6c0a323699">25</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ife864b353c764785a4fd4b6d6c5d4cd8_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtOS0xLTEtNjU0MjU_e9fc70b5-8b5a-45d9-afe9-bbfed3e7ddd1">2</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iab2ab04147f14d6b82d4eb4e2db69840_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtMTEtMS0xLTY1NDI1_2d870754-bc65-4758-bee5-9980f6cb3eea">27</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id890b7eb85fb4ec5adaedafb87a577d6_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjAtMS0xLTEtNTI2OTI_41c2273d-5095-47db-bfc3-2520b3631e1f">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i27cce489f4214d679226b5c1a2f29002_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjAtMy0xLTEtNTI2OTI_61d7177e-e650-41d6-a0b9-82843a3889e9">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if23e2963b2b24cf38e3d3a0273e7ff8a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjAtNS0xLTEtNTI2OTI_eb4cb199-0de2-417a-974b-e4682fed5592">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i386e1dee7980403d90579134e5a034ad_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjAtNy0xLTEtNTI2OTI_5de6f08a-6b42-4a97-be74-4af26a51aedd">4</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i98871de672bc4cf9a2f9c2893864dba2_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjAtOS0xLTEtNTI2OTI_3b11d13f-4d07-45aa-a77f-75b266ecbf68">52</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0daa1a20926f47dba8e3f9d6f3ccdec6_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjAtMTEtMS0xLTUyNjky_4176d022-3e32-4e1e-ad44-afb494411cf6">57</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ieb0e057b94c24ec7ad57d18b99d50040_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtMS0xLTEtNTI2OTI_632fe25f-39b4-41a3-84f6-45228a916b51">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1fda497fd81c49d1ac2ea34d0e8d89e7_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtMy0xLTEtNTI2OTI_299e79da-e32b-4bd8-8cdf-e830ea19a6d9">12</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice5a78f7e33447faa37a77afb681e64f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtNS0xLTEtNTI2OTI_bfab77f4-1b12-41b4-99fa-757fbb9b5713">30</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i221d9f3c2d7d4781a89faee3f94a7786_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtNy0xLTEtNTI2OTI_58965725-a0c3-47ef-ac16-c94a2c99e899">2</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="ic3078484ed0d409abf5fde684285c4fd_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtOS0xLTEtNTI2OTI_f0ccd181-f38b-45a0-b393-03d49754b334">6</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i87e8d96cd86641c9a2bbceab6b5e3885_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjEtMTEtMS0xLTUyNjky_02b956c8-c4ad-424a-82cc-a198cd8be9cb">8</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas/Verquvo </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4576e4055fd34ac8b561387532885764_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjQtMS0xLTEtNjM3MTQ_842a35c3-5d5a-4d78-9c3f-1670d297ee37">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id77091160deb4ea3a554852c67d0f417_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjQtMy0xLTEtNjM3MTQ_bbb31c84-0fe8-48f0-b3fe-3946622110f4">1</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id52fdebd7d444eb8b2fada047216591c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjQtNS0xLTEtNjM3MTQ_6df9d5a2-e4a3-4cd2-a631-37a93f56438a">72</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2fccec8055c748b59514bf2db4c364e6_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjQtNy0xLTEtNjM3MTQ_447c1e79-3251-4d09-b5fd-fdd87f01a2a7">68</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia34189615c3f44f5a67d7c54dbd83e5e_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjQtOS0xLTEtNjM3MTQ_0ae5d9c8-23bf-446e-b30a-1039de588453">6</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i466f7808cc7f4c93822461872f46cac8_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjQtMTEtMS0xLTYzNzE0_3230b54c-bd15-4ad1-b2c1-db2583a4efc6">74</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib6af84104ab04015bbc4e6c75ac1eee5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjUtMS0xLTEtNjM3MTQ_39aa6890-a976-4521-b39d-ab12a4edab32">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78a96cf136e54d65b5505ce4b6553f59_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjUtMy0xLTEtNjM3MTQ_5da1026a-2494-471c-ab8b-5cb72054df97">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i3acadbfd1b374d1c95fab2bf669d36e3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjUtNS0xLTEtNjM3MTQ_a6ce79e4-ccb1-4589-bfa3-193dda902ffd">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i144ca4b663ce43abb161ecdb7289738b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjUtNy0xLTEtNjM3MTQ_8899846c-6774-4af4-a211-9d5b35dc51d1">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i78e605930642452d843e15d0458f5b45_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjUtOS0xLTEtNjM3MTQ_46e1ca73-4863-4a9a-9eef-fbfd6514b749">55</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i389b83ea828049f79aa3b7472a1ab6e6_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjUtMTEtMS0xLTYzNzE0_f42f3c36-10cf-4420-8f8d-b7717f897173">55</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93120915ebaf4bd0bc59ae2b3fd1221f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtMS0xLTEtNTY5OTI_d58eae3d-7eda-45f8-88c2-ec90d192ba21">1,523</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i202ece257bc745d0ab5d95dd1197149b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtMy0xLTEtNTY5OTI_07717e1f-7ea7-47da-9fcc-3c5b15f7fa19">1,723</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if54e2cbb0b6b4117bc02076df5389b97_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtNS0xLTEtNTY5OTI_2fe93408-4839-4ccc-a243-1b9987603eb4">3,247</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if7bc6d405a2c43e1a20d5f9ee6f9a891_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtNy0xLTEtNTY5OTI_8b4c9f4d-dd89-4201-80cb-f5e525114958">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib80cf6ef4ac0422cb4934b1f3b2e55de_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtOS0xLTEtNTY5OTI_a4050179-53dc-4662-b571-89030db8ab70">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0483b507af3f43039ee3bb2e5e4fd59f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtMTEtMS0xLTU2OTky_407d64d8-c5e4-447d-ad3d-d67c77203042">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iae02871fbc134bf98ef610b495a82e89_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtMS0xLTEtNTI2OTI_734609fb-2c01-4444-90bd-d154ff41cd03">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i16f81d66fdb946b193eda2ce7dd938e1_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtMy0xLTEtNTI2OTI_2294da2c-c827-4790-aa9e-ab826239214c">97</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ice1929e1a7514fe6a29683f034c9675b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtNS0xLTEtNTI2OTI_face85ee-a5b3-427a-b9e4-5363b3cc2337">158</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i639c1fa4f7e8493c8567be263134699d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtNy0xLTEtNTI2OTI_84bea8e9-848e-445a-83fc-a1fe1d3e87b6">71</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i880fd33cce254b1680f267ef07d64b3b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtOS0xLTEtNTI2OTI_0096f56c-0351-4742-8e9d-b8dd92f6ef05">138</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13bfa8c23a6c456b80ecc1b51a699afe_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMjgtMTEtMS0xLTUyNjky_c01dc340-df8f-4c80-b96a-a89351626e01">209</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id12d23aaa8b2478d8967537b0f69ce0e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtMS0xLTEtNjM4NTQ_581847a9-9e98-4b5d-9087-b25203e558a9">20</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i00401343fcb744118f01cc535f510acd_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtMy0xLTEtNjM4NTQ_73237482-59f4-4ad6-b797-b9fd8f1f73e7">48</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i845ed8a825cd41168120c2947d015353_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtNS0xLTEtNjM4NTQ_16847481-6895-493e-95fa-a4ce3d421f99">69</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib91461efd77540f090cbb84ba6705b1a_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtNy0xLTEtNjM4NTQ_e0b4f9cc-7d90-476a-8c08-c5fbe1309bf5">18</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i384a11b2f6834b88925abd09a13e8d5d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtOS0xLTEtNjM4NTQ_1adf65e0-cf33-4279-be94-b1e1ecec475c">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i17c934d811824b10a26f34f53efcf99e_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtMTEtMS0xLTYzODU0_14dc5755-6f8e-4a9e-a181-439df10d887d">79</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2c3e534d81884c479a27f2b7c59fcca5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtMS0xLTEtNjM4NDM_9a36f1a4-7ee1-49dc-82e0-acee5e31b04d">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13292a2df1a34e39b930bab123f399a9_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtMy0xLTEtNjM4NDM_bd6f4d23-1c36-4e82-95bb-9cb1f1f5222a">186</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iaa2af135a2604c0e94c271eedca94076_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtNS0xLTEtNjM4NDM_93f9b52f-dbc5-4d20-a7d9-bcb9eac871ca">186</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i46aa67a564c54ba58235e0dae468d04b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtNy0xLTEtNjM4NDM_93d76a52-9a03-4eba-8ab2-459c6889ecac">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if534ef43448248289888c3900c05a79c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtOS0xLTEtNjM4NDM_628681cf-c253-4fdd-bd45-effd9f3ed5d5">214</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icbfc0c60922645e7bf0f37a55452ecf4_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtMTEtMS0xLTYzODQz_ec215fdd-ad4d-4ccf-9846-4fea1486073c">214</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if5614b02cb16456ab7e83ce0861710b4_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktMS0xLTEtNjM4NDM_bdddbf55-524c-4dc5-a6d3-89919239d628">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if9a7dfd597324f94ae1e71b3f6af49de_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktMy0xLTEtNjM4NDM_6f606ebf-895f-4af6-996a-9351b64ac59c">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7f6b9edb8b8e4f949c9afac42a3ac8ad_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktNS0xLTEtNjM4NDM_22578446-0334-4479-8667-6d1a2c6282c0">61</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5298bb50d64a41048da6da4a04a1980b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktNy0xLTEtNjM4NDM_64ff5067-e49c-438d-82e4-0de347675e17">—</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2b1f8f65e7884ecea84ef1dd35dfe143_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktOS0xLTEtNjM4NDM_22c33fb7-1f9f-4def-9ae1-0ec862d28971">85</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1d2d623551394f889c8c888bf7f2b9d9_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktMTEtMS0xLTYzODQz_dbdd0bb3-a30f-46fb-85a3-6b056ece8af1">85</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i212ddd8af81949fd8cd393de736a7f6c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzMtMS0xLTEtNTI2OTI_84ee7603-f135-49df-b676-8fa083c938e8">325</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i687695b299054f1981462e305070aab7_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzMtMy0xLTEtNTI2OTI_7f136bba-dd6c-4953-96eb-bacf91bfd86f">454</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia96f98391f8b48db8fe6d5484e8e1bec_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzMtNS0xLTEtNTI2OTI_93d0d999-b483-4e31-a18f-d256d12373f6">779</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i5405f7e963764f13b153ed1803e7a5d2_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzMtNy0xLTEtNTI2OTI_57723557-d09c-4933-99f2-ca6017b1dae0">348</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i72b4065eae864dfd93bda2580923b71d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzMtOS0xLTEtNTI2OTI_2d2fd211-aa0c-4e93-b022-fdcf4db08bb8">461</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie3f68079a3f040028ea0bdc9d042eeeb_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzMtMTEtMS0xLTUyNjky_22e45407-c30d-415a-9c70-50132e5a0b3b">809</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b3b0ce0ab3b4f41a451e06195d62a3d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzQtMS0xLTEtNTI2OTI_9362d472-146f-41d4-a440-9c7c794c0a84">63</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4c716dc1fa514d2f993c196fe3d53e44_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzQtMy0xLTEtNTI2OTI_a79c6985-708d-48eb-a5f4-ccafe33a7aaf">391</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3e23ddc07914e189538f083e1ad125d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzQtNS0xLTEtNTI2OTI_a45076dd-5882-492c-ab8d-ddc1b702d7ae">454</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i61536937a0ac42c491620f652f2dbaca_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzQtNy0xLTEtNTI2OTI_35c11329-11d2-4df7-9e38-9ba0a7197e17">84</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8973bcd961044a5281efec8e23f6e50c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzQtOS0xLTEtNTI2OTI_3d4c8656-d87a-4e99-8fb0-7c89b4c1ebac">401</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icf5ab1d2973f456ba487a84f6954b05c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzQtMTEtMS0xLTUyNjky_56d4e16f-1a70-4c42-b363-e67e8c5d3f06">486</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie2c39a6aeaa14a958580471dfc51ee3c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtMS0xLTEtNTI2OTI_472ace4b-ad04-45b7-b0fd-8718aafe8134">181</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8535a1c06ba548a6b73396107ebec8a0_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtMy0xLTEtNTI2OTI_58752c3a-3da0-4b96-8b2f-87f2bb3a26ea">339</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7076d79036d14c0faafccd118812554e_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtNS0xLTEtNTI2OTI_c2fd217a-61d5-4674-82b6-e3f0a0a6fd9b">520</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia1d7ced6b9324fa2991b658827fd9316_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtNy0xLTEtNTI2OTI_cce9f39b-7ce7-4a57-ba23-0f06eafff9af">212</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i003b720f4b71442888b2d1e2aa744677_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtOS0xLTEtNTI2OTI_cf1a625c-3c4d-44d7-9aae-52ca60aeac71">341</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9fe330b8315c4a97bc08fdd8a66f169d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzUtMTEtMS0xLTUyNjky_afe852a4-2ea0-4024-a410-4d7934730bde">554</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1f85bc45c38440e7921d6dcc8810ca98_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzYtMS0xLTEtNTI2OTI_026b5d4b-875d-470a-9057-0311d6e3065b">6,773</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if83bee032b3b42e8ae62bfee1e18669a_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzYtMy0xLTEtNTI2OTI_0cdbb4d3-4e3d-4aba-ac3f-4198cfcfb383">7,334</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide544608790948358cf81ce72951b721_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzYtNS0xLTEtNTI2OTI_3fbe4f8d-7620-46f8-9e6b-6bf5b8eceea9">14,107</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ie597c94174af4d3080b24040f97f6fcd_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzYtNy0xLTEtNTI2OTI_d16a8c7f-c325-44fd-970b-076a9ad6860f">4,294</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i940a565e481444658f371bb6280b4a5b_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzYtOS0xLTEtNTI2OTI_a1cc2544-b7b1-4576-ba80-e2747babe9bc">4,944</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3e3bb9ecf1a4310bad6d9416ca7a442_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzYtMTEtMS0xLTUyNjky_9367ffc7-e829-4767-ae7a-4b30c32c638a">9,238</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icfd78e52591248fca78b77b79c337185_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtMS0xLTEtNTI2OTI_fc5be792-f99e-42d0-87f0-8fb6fcd9bb2b">171</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib318698f0b26449eaba9aebb81c2af09_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtMy0xLTEtNTI2OTI_d6fe2a15-9ab1-4f45-b7b6-e45235c14194">661</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9f60150344394470aafbfa1fa5034ae8_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtNS0xLTEtNTI2OTI_3d513e63-9a49-41a6-9924-0d0682eabb1f">832</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1b6a806ead72464c82b3623135bc8567_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtNy0xLTEtNTI2OTI_685617ae-1654-4ab8-8dbc-f3da8f4e7bd1">157</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i18383af3d15545d7be0cf119645ba24f_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtOS0xLTEtNTI2OTI_dfcc11b3-f1e3-4ff0-9ce9-d695856abf77">662</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i689f14e1dd0a414baaf55098628f39ef_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzgtMTEtMS0xLTUyNjky_d797cb69-8edf-468c-96a2-d9ce04c7dc72">819</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i919eda4a1c0042eba0c03bbf7a6753f7_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktMS0xLTEtNTI2OTI_644e62c4-5c93-46c8-b3c6-a5eb92f5db1a">302</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0587557c686b4a04bbbcc0624c6f30b5_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktMy0xLTEtNTI2OTI_62899497-1ce4-48d3-b44b-8706eb4053b2">348</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i0ed6c1a8ab034ca38bf825b813b3d1d3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktNS0xLTEtNTI2OTI_0b588d44-1a8f-400c-9ee5-f6f187507d45">650</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib31f6a3b25304b2b933451ed454c2e2c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktNy0xLTEtNTI2OTI_148f7230-ff77-46e9-babb-6570ec921b01">280</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ib26ae74a9cf34f3a8fe2534f4f3d8978_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktOS0xLTEtNTI2OTI_65b6286c-ae66-4290-aa4e-9411a4ae2382">319</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia4932b41093243e09414fa51871cd517_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfMzktMTEtMS0xLTUyNjky_b8ec62c1-e6f0-4f78-8268-560e21e1d67f">599</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7c38a413632b48d9bbc9b9e2167e547d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDAtMS0xLTEtNTI2OTI_5b267094-d2dc-4083-b277-c9bf0d8625e4">473</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="iba4aa5e714cd445db9dc73c878ec26d3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDAtMy0xLTEtNTI2OTI_2883d67a-3408-4c9c-8762-0b4b011dd5ef">1,009</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i832f6c2312634b0c8efe98724d677a4f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDAtNS0xLTEtNTI2OTI_ddac32bc-64a5-47fc-a0ce-d00a10783137">1,482</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id1ade9e4ea4e44a4a02621381fe81567_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDAtNy0xLTEtNTI2OTI_da632e13-58be-4b44-86b9-ca9e56779819">437</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i38114a565eee42cfb3866c874b66eb26_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDAtOS0xLTEtNTI2OTI_8493d095-3f07-43ba-9d23-90d64bab2780">981</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i36cc3bf951424ddd9bd95a8877f34254_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDAtMTEtMS0xLTUyNjky_6578f505-72af-4763-a8f5-db441f0c2916">1,418</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i7b4419b653b14e8ba56a856ed72eac11_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDItMS0xLTEtNTI2OTI_05d6a830-dd2b-4171-b8e1-7c60da99e878">7,246</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="icec5a3da921945199b8a928157f0653d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDItMy0xLTEtNTI2OTI_fc698a61-66f8-418c-b56c-b6284fc0bf31">8,343</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia017ccd654a14a9a9e1beb2f5bd9307f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDItNS0xLTEtNTI2OTI_f7206b64-6626-499a-a026-e89de4dcb66d">15,589</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ic43c11130efe4612b952e3280ff31240_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDItNy0xLTEtNTI2OTI_e262117d-322e-4e54-b09f-4b0bea504146">4,731</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i903b19cdc2174d5aa6f83e1099ddd056_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDItOS0xLTEtNTI2OTI_4e68551f-8c22-48e5-8890-cde60fb84fbc">5,925</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i69a378a7cacf4454a96200e18d69ff63_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDItMTEtMS0xLTUyNjky_05d0ae19-904c-4a55-9210-b6a9e674edf7">10,656</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i13dc1a7cc27b48ae966d1fbdc9d497d0_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDMtMS0xLTEtNTI2OTI_45f5c383-c9da-42a7-ae9e-5d366d13bec4">93</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ifc5a92bedff6472d86337c9ad9998d7f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDMtMy0xLTEtNTI2OTI_e153bb0d-1c25-4064-9419-87ba326a560b">220</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39edcaf7f9b94ecbbcadf2eb6aaa704c_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDMtNS0xLTEtNTI2OTI_8da39e14-e1d3-4665-b78d-22ff3db82ff7">312</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia5e3212388de4741bfbf8ede7fd7715d_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDMtNy0xLTEtNTI2OTI_bc7bfbdb-5911-405d-9119-4b4482650c06">59</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i67837cf6ae1f432bb479a5d818e4d8c7_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDMtOS0xLTEtNTI2OTI_88b0ed88-bdac-46be-a330-c9f4bdbc31e4">88</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5fe49c5e8275436c9c48915ae0beb1b1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDMtMTEtMS0xLTUyNjky_10adcd87-d8f1-4abd-a274-2448b40d230f">29</ix:nonfraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8370199418d341dfa57f78fc76f97e5b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDQtMS0xLTEtNTI2OTI_121ee500-e205-41ae-9fe8-32f0fdcabf2a">7,339</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i09120a7cb50145928e2cceb69ce5563d_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDQtMy0xLTEtNTI2OTI_86b15b22-d336-4f5d-a661-77229b6ac0d4">8,563</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDQtNS0xLTEtNTI2OTI_268cb669-ca79-4254-b8fa-15b113d4d718">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i457eb00986ce4537a0b974a2ae7dbefe_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDQtNy0xLTEtNTI2OTI_f71e8d13-b016-4d0d-8d12-c938f5e6a797">4,790</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia44515344512485e8df76049ac18fb59_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDQtOS0xLTEtNTI2OTI_8302062f-105f-4193-aa21-2886b08b2512">5,837</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmQ3YjZhZGQ3YjQ3YjRhZTk5Nzg0MWNjYTNiYWE1OTJhL3RhYmxlcmFuZ2U6ZDdiNmFkZDdiNDdiNGFlOTk3ODQxY2NhM2JhYTU5MmFfNDQtMTEtMS0xLTUyNjky_64396ff8-3363-479d-ab62-5c1e8519127d">10,627</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Lynparza and Lenvima represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Reblozyl</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> represents royalties and a payment received related to the achievement of a regulatory milestone (see Note 4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue for Adempas/Verquvo represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note&nbsp;4).</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(5)&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales (including sales to Organon). Other for the three months ended March&nbsp;31, 2022 and 2021 also includes $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfMzEwNA_1d4bc958-0b26-405f-bcc5-c5dbb965d904">114</ix:nonfraction>&nbsp;million and $<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfMzExMQ_21e8c8a6-bf08-42aa-9473-c6969d505c34">56</ix:nonfraction>&nbsp;million, respectively, related to upfront and contingent milestone payments received by Merck for out-licensing arrangements.</span></div></ix:nonnumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 28 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notes to Condensed Consolidated Financial Statements (unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (continued)</span></div></div><ix:continuation id="i61358273d7df40b6b470a6f6c2400491"><div style="margin-top:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $<ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfMzc3OA_3be4258a-ff99-4400-9e09-694fba7710c9">2.9</ix:nonfraction> billion and $<ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-8" name="mrk:SalesDiscounts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfMzc4NQ_f313c533-3bc1-4032-9e85-535745897c27">2.8</ix:nonfraction> billion for the three months ended March&nbsp;31, 2022 and 2021, respectively. </span></div><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfNTgwNQ_4e8eb567-cf32-4ad7-983e-50ae29aeab1c" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.674%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8370199418d341dfa57f78fc76f97e5b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfMi0xLTEtMS01MjY5Mg_e419b1fe-6c76-489d-bff3-b420faeab412">7,339</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i457eb00986ce4537a0b974a2ae7dbefe_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfMi0zLTEtMS01MjY5Mg_6b53be0f-6790-43da-890a-f589169e3af9">4,790</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i4f5ff3fcb89d427498588b0678cfdcd0_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfMy0xLTEtMS01MjY5Mg_b51484fd-64e0-4159-aae5-5e3a29ac14a0">4,359</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9fdba45d4cc24dd2b4ce2b0668b04cb3_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfMy0zLTEtMS01MjY5Mg_a58a0edf-d9f9-4ea5-a5f8-d66c55d54675">3,237</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i175ececc8f324759bce16a986b23197b_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNC0xLTEtMS01MjY5Mg_cf485caf-17e0-4453-af74-e55052209801">1,143</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i12cbfa0800eb4e0daf5239e28d6a0fb1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNC0zLTEtMS01MjY5Mg_399fe14f-4547-4fd9-a120-5a33efd8b00d">721</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i823435b3705e4f13ba33400ed97666e3_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNS0xLTEtMS01MjY5Mg_e32d7e6b-cf09-4952-a803-4c519b0897ce">989</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i091a65baf09e4e87b90261585534d803_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNS0zLTEtMS01MjY5Mg_59ebebec-bd4e-445e-8da3-568a3fa53015">629</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i1e5059094caf46cb86bcb13fb9c7d58f_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNi0xLTEtMS01MjY5Mg_3bd243f9-cd25-417a-b505-1ce4366f8fd4">930</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6f280dd8028c47a1a0b553f2d503416c_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNi0zLTEtMS01MjY5Mg_1e28e41d-436e-412b-8219-38f7dca7d663">575</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id7deb17350664f0a98fe1efcec5a5c64_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNy0xLTEtMS01MjY5Mg_4b50e7ae-4d3a-4a57-90fe-88c2896f1189">607</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i6de9ef09922d477c812801d4a0d1a6e8_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfNy0zLTEtMS01MjY5Mg_5b0d4a01-1dc7-44c5-bdc8-c17837b16463">500</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ibcaace6f2a59466b9a8e4608f6f4c6a2_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfOC0xLTEtMS01MjY5Mg_7f870099-18df-498a-8073-a5719dac3519">534</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i2e850ef397c144d3b7ca0fb1a8463120_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfOC0zLTEtMS01MjY5Mg_170773f2-e0af-4cd3-afad-40301abf9272">175</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfOS0xLTEtMS01MjY5Mg_cfee8d0c-8c90-43c0-9b6e-09dcada5eab6">15,901</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOmU3YzYyMGMyZjE2MDRhZGU4NmZlZGUxMzExODYxYzY5L3RhYmxlcmFuZ2U6ZTdjNjIwYzJmMTYwNGFkZTg2ZmVkZTEzMTE4NjFjNjlfOS0zLTEtMS01MjY5Mg_04742d40-9671-409f-bd22-866986f1b23a">10,627</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><ix:nonnumeric contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RleHRyZWdpb246NTViZjRkZjBlNTFhNDQxOTljZmFhYmZmNTU2NTQ1NjZfNTgxOA_b6560b74-7d8a-4c75-b66a-78165da960c9" escape="true"><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Continuing Operations Before Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:80.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.528%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ide544608790948358cf81ce72951b721_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMy0xLTEtMS01MjY5Mg_137bf834-409b-4ba9-a0d4-9f972d74ffa9">9,501</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="if3e3bb9ecf1a4310bad6d9416ca7a442_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMy0zLTEtMS01MjY5Mg_43b2e6c3-b77e-4e3d-848a-6767f7d7cf28">6,589</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i832f6c2312634b0c8efe98724d677a4f_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfNC0xLTEtMS01MjY5Mg_909baf76-f1fa-4464-ac50-7dcaee722123">585</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i36cc3bf951424ddd9bd95a8877f34254_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfNC0zLTEtMS01MjY5Mg_6c0355a4-cdcc-4de2-90f5-ea54fe842f2c">572</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="ia017ccd654a14a9a9e1beb2f5bd9307f_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfNi0xLTEtMS01MjY5Mg_316d4b6d-12e9-4ecd-bcc7-411c10a07a56">10,086</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i69a378a7cacf4454a96200e18d69ff63_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfNi0zLTEtMS01MjY5Mg_08e4b25d-3856-4ac0-be6c-33a446b8dcd5">7,161</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i39edcaf7f9b94ecbbcadf2eb6aaa704c_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfNy0xLTEtMS01MjY5Mg_ccee7b58-276e-4f6e-ad8d-4061229449f4">194</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i5fe49c5e8275436c9c48915ae0beb1b1_D20210101-20210331" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfNy0zLTEtMS01MjY5Mg_4426fa6a-5cfd-4e1c-a632-85fe56b300e2">50</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfOS0xLTEtMS01MjY5Mg_2232f7cf-ab3b-462b-8e5a-68e2bdd41373">7</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfOS0zLTEtMS01MjY5Mg_52723c68-35fa-421f-b4a1-50d02c38d591">11</ix:nonfraction>&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTAtMS0xLTEtNTI2OTI_afd8845b-da0e-4aee-92ac-c27eade7825e">243</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTAtMy0xLTEtNTI2OTI_c18f2c00-6b96-4951-ac99-aa99fa5bbd54">200</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTEtMS0xLTEtNTI2OTI_71d973af-236f-4a10-9e89-d97b11c7b041">699</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTEtMy0xLTEtNTI2OTI_587a577c-137b-45cc-9f1b-acc5553b508f">514</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTItMS0xLTEtNTI2OTI_ef613f67-cc57-49cd-bdfb-df803ceb2af5">378</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTItMy0xLTEtNTI2OTI_ffbded45-e319-49c0-9b68-23c8999528fd">340</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTMtMS0xLTEtNTI2OTI_2cea2034-3e01-433b-bba4-7c9c4957a72d">2,446</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTMtMy0xLTEtNTI2OTI_7cd6c968-0e03-446e-9c5b-a55919a902f4">2,305</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTQtMS0xLTEtNTI2OTI_df2903eb-cc89-4a59-af3d-260f307cf271">53</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTQtMy0xLTEtNTI2OTI_0b099d79-6ecd-40c0-8d29-17ab84db8230">297</ix:nonfraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="i8dd1a64575ba4abbb740cc985be830c0_D20220101-20220331" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTUtMS0xLTEtNTI2OTI_29446ed1-9cea-4348-9715-fb9f18af5c90">1,607</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonfraction unitref="usd" contextref="id6af44f428ac434eb778fbb4be560afb_D20210101-20210331" decimals="-6" name="mrk:SegmentReportingUnallocatedOtherExpensesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTUtMy0xLTEtNTI2OTI_541a79dc-7dba-4918-96f4-26dcc274a566">479</ix:nonfraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i93cb35679f4842c6ac883425f8ed1d71_D20220101-20220331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTYtMS0xLTEtNTI2OTI_5ea0c597-628a-40c2-b530-ceaa2e70872d">4,861</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonfraction unitref="usd" contextref="i9bd6dcee6745436cab3b2c6748c3c2a1_D20210101-20210331" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmExMDk5MTMzN2VlNjRiZmU5NzVmZjYyMWM3M2EwZmY2L3NlYzphMTA5OTEzMzdlZTY0YmZlOTc1ZmY2MjFjNzNhMGZmNl83OS9mcmFnOjU1YmY0ZGYwZTUxYTQ0MTk5Y2ZhYWJmZjU1NjU0NTY2L3RhYmxlOjA5OGU0MTBkZTQyODQxMTk4ZGRlMDdmNzBjYjYxYWIzL3RhYmxlcmFuZ2U6MDk4ZTQxMGRlNDI4NDExOThkZGUwN2Y3MGNiNjFhYjNfMTYtMy0xLTEtNTI2OTI_931da624-e282-4ed0-b02e-5b82f76882b5">2,987</ix:nonfraction>&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div></ix:nonnumeric><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of intangible assets and purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 29 -</span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_82"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_85"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Spin-Off of Organon &amp; Co.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2 to the condensed consolidated financial statements).</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Developments</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">War in Ukraine</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Russia invaded Ukraine. The Company’s primary concerns are the safety and well-being of its employees and ensuring patients and customers have continued access to medicines and vaccines needed for patient and public health. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck’s supply chain, operations and clinical trials. For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with evolving international sanctions. Merck plans to donate profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. The financial impacts of the war were immaterial to the Company’s consolidated financial statements for the first quarter of 2022. Combined sales to Russia and Ukraine were approximately 1% of total Merck consolidated sales for the full year of 2021.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combination of the Russian government’s invasion of Ukraine, as well as the resultant economic sanctions imposed by the U.S., the European Union (EU) and other governments are having pervasive effects in markets worldwide. The Company is unable to determine at this time the future impacts of this conflict either directly or indirectly on the Company’s business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although COVID-19-related disruptions had some negative effects on sales for the first quarter of 2022, Merck continues to believe that global health systems and patients have largely adapted to the impacts of the COVID-19 pandemic. Merck’s sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir), an investigational oral antiviral COVID-19 medicine, were $3.2 billion in the first quarter of 2022. In the first quarter of 2021, COVID-19-related disruptions resulted in an estimated negative impact to Pharmaceutical segment sales of approximately $500 million because a substantial portion of Merck’s Pharmaceutical segment revenue is comprised of physician-administered products, which were unfavorably affected by social distancing measures and fewer well visits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, Merck announced it was discontinuing the development of MK-7110 for the treatment of hospitalized patients with COVID-19, which was obtained as part of Merck’s acquisition of OncoImmune (see Note 3 to the condensed consolidated financial statements). This decision resulted in charges of $170&nbsp;million to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the first quarter of 2021. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has caused some disruption and volatility in the Company’s global supply chain network, and the Company may in the future experience disruptions in availability and delays in shipments of raw materials and packaging, as well as related cost inflation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, Merck announced it had entered into multiple agreements to support efforts to expand manufacturing capacity and supply of SARS-CoV-2/COVID-19 medicines and vaccines. The Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, provided Merck with $102&nbsp;million of funding in the first quarter of 2022 to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2/COVID-19 vaccines and medicines. The funding will be recognized as a reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> over the production period, offsetting the depreciation expense related to the amounts that were capitalized in connection with the modification of the manufacturing facilities. Merck has also entered into agreements to support the manufacturing and supply of Johnson &amp; Johnson’s SARS-</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 30 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CoV-2/COVID-19 vaccine. Merck is using certain of its facilities in the U.S. to produce drug substance, formulate and fill vials of Johnson &amp; Johnson’s vaccine. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. Changes to the U.S. health care system enacted in prior years as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s sales performance in the first quarter of 2022 was negatively affected by other cost-reduction measures taken by governments and other third parties to lower health care costs. In the U.S., the Biden Administration and Congress continue to discuss legislation designed to control health care costs, including the cost of drugs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect sales performance.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Results</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,339&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,790&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,837&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,901&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,627&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales grew 50% to $15.9 billion in the first quarter of 2022. Revenue performance primarily reflects higher sales in the virology franchise attributable to $3.2 billion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (molnupiravir) sales, higher sales in the oncology franchise largely driven by strong growth of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) and increased alliance revenue from Lenvima (lenvatinib) and Lynparza (olaparib), as well as higher sales in the vaccines franchise, primarily attributable to growth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Human Papillomavirus Quadrivalent [Types 6, 11, 16 and 18] Vaccine, Recombinant)/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9 (Human Papillomavirus 9-valent Vaccine, Recombinant) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Rotavirus Vaccine, Live Oral, Pentavalent). Higher sales of hospital acute care products, including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection, higher third-party manufacturing sales and higher sales of Animal Health products also drove revenue growth in the first quarter of 2022. As discussed above, COVID-19-related disruptions had some negative effects on sales in the first quarter of 2022, but to a lesser extent than in the first quarter of 2021 which benefited year-over-year sales growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue growth in the first quarter of 2022 was partially offset by lower combined sales of diabetes products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sitagliptin and metformin HCl) and lower sales of virology products </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(raltegravir).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 15 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_94"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oncology</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,809&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,899&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">  Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 4 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma, cutaneous squamous cell carcinoma, endometrial carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancer (solid tumors) including MSI-H/dMMR colorectal cancer, primary mediastinal large B-cell lymphoma, tumor mutational burden-high (TMB-H) cancer (solid tumors), </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 31 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and urothelial carcinoma including non-muscle invasive bladder cancer. Additionally, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved as monotherapy for the adjuvant treatment of certain patients with renal cell carcinoma (RCC). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also approved for certain patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy, with or without bevacizumab for cervical cancer, in combination with chemotherapy for esophageal cancer, in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for human epidermal growth factor 2 (HER-2)-positive gastric or GEJ adenocarcinoma, in combination with chemotherapy for HNSCC, in combination with chemotherapy for TNBC, in combination with axitinib for advanced RCC, and in combination with Lenvima for both endometrial carcinoma and RCC. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical development program includes studies across a broad range of cancer types. See “Research and Development Update” below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> grew 23% in the first quarter of 2022. Sales growth was primarily driven by higher demand as the Company continues to launch </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with multiple new indications globally. Sales in the U.S. continue to build across the multiple approved indications, in particular for the treatment of advanced NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC, along with continued uptake in the TNBC, RCC, HNSCC, and MSI-H cancer indications. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales growth in international markets reflects continued uptake predominately for the NSCLC, HNSCC and RCC indications, particularly in Europe. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> received the following regulatory approvals thus far in 2022.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:6.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">European Commission (EC) approval as monotherapy for the adjuvant treatment of adults with RCC at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions based on the KEYNOTE-564 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan Ministry of Health, Labour and Welfare approval of the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> plus Lenvima for radically unresectable or metastatic RCC based on the CLEAR (Study 307)/KEYNOTE-581 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Japan Pharmaceuticals and Medical Devices Agency approval for the treatment of adult patients with advanced or recurrent TMB-H solid tumors that have progressed after chemotherapy (limited to use when difficult to treat with standard of care) based on the KEYNOTE-158 trial.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. Food and Drug Administration (FDA) approval as a single agent for the treatment of patients with advanced endometrial carcinoma that is MSI-H or dMMR who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation based on the KEYNOTE-158 trial (Cohorts D &amp; K). </span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approval in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in certain adults whose tumors express PD-L1 based on the KEYNOTE-826 trial.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EC approval as monotherapy for the treatment of certain patients with unresectable or metastatic MSI-H/dMMR colorectal, gastric, small intestine or biliary cancer, as well as advanced or recurrent MSI-H/dMMR endometrial cancer based on data from KEYNOTE-164 and KEYNOTE-158.</span></div></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 4 to the condensed consolidated financial statements). Lynparza is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza increased 17% in the first quarter of 2022 largely driven by continued uptake across the multiple approved indications globally, particularly in the U.S. In March 2022, Lynparza was approved by the FDA for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated, HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy based on the OlympiA trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lenvima is an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 4 to the condensed consolidated financial statements). Lenvima is approved for the treatment of certain types of thyroid cancer, RCC, HCC, in combination with everolimus for certain patients with RCC, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for both endometrial carcinoma and RCC. Alliance revenue related to Lenvima grew 75% in the first quarter of 2022 primarily reflecting higher demand in the U.S. and China. The growth in alliance revenue in the first quarter of 2022 also benefited from lower shared expenses.</span></div><div style="margin-top:12pt;text-align:justify"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 32 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaccines</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,460&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">ProQuad</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">II</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Varivax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax 23</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Combined worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gardasil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 9, vaccines to help prevent certain cancers and other diseases caused by certain types of human papillomavirus (HPV), grew 59% in the first quarter of 2022 driven primarily by strong demand outside of the U.S., particularly in China, which also benefited from increased supply. Additionally, sales increased in the U.S. due to public sector buying patterns. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">M‑M‑R&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">II (Measles, Mumps and Rubella Virus Vaccine Live), a vaccine to help protect against measles, mumps and rubella, grew 29% in the first quarter of 2022 primarily due to public sector buying patterns in the U.S. and higher demand in Latin America.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Varivax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Varicella Virus Vaccine Live), a vaccine to help prevent chickenpox (varicella), were flat in the first quarter of 2022 as higher demand and pricing in the U.S. were offset by lower government tenders in Brazil. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RotaTeq</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a vaccine to help protect against rotavirus gastroenteritis in infants and children, grew 36% in the first quarter of 2022 due to public sector buying patterns in the U.S.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pneumovax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 23 (pneumococcal vaccine polyvalent), a vaccine to help prevent pneumococcal disease, grew 1% in the first quarter of 2022 primarily reflecting higher demand in the U.S. that was largely offset by lower demand in Europe and Japan attributable in part to the COVID-19 pandemic. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hospital Acute Care</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*Calculation not meaningful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 16% in the first quarter of 2022 due to higher demand globally, particularly in the U.S. and Europe, largely attributable to an increase in surgical procedures resulting from the ongoing COVID-19 pandemic recovery. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company temporarily suspended sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ceftolozane and tazobactam), a combination antibacterial and beta-lactamase inhibitor for the treatment of certain bacterial infections, and subsequently issued a product recall, following the identification of product sterility issues. A phased resupply for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zerbaxa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was initiated in the fourth quarter of 2021 and was expanded to additional markets in the first quarter of 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cardiovascular</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance Revenue - Adempas/Verquvo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 4 to the condensed consolidated financial statements).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adempas (riociguat) and Verquvo (vericiguat) are part of a worldwide collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators (see Note 4 to the condensed consolidated financial statements). Adempas is approved for the treatment of certain types of pulmonary arterial hypertension. Verquvo was </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 33 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approved in the U.S. in January 2021 to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous diuretics in adults with symptomatic chronic heart failure and reduced ejection fraction. Verquvo was also approved in Japan in June 2021 and in the EU in July 2021. Alliance revenue from the collaboration was nearly flat in the first quarter of 2022. Revenue also includes sales of Adempas and Verquvo in Merck’s marketing territories. Sales of Adempas in Merck’s marketing territories grew 11% in the first quarter of 2022 primarily reflecting higher demand. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Virology</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Lagevrio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,247&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress HD</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is an investigational oral antiviral COVID-19 medicine being developed in a collaboration with Ridgeback (see Note 4 to the condensed consolidated financial statements). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has received multiple authorizations or approvals worldwide, including in the United Kingdom (UK) (under Conditional Marketing Authorization), the U.S. (under Emergency Use Authorization), and Japan (under Special Approval for Emergency). Sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were $3.2 billion in the first quarter of 2022 primarily consisting of sales in the U.S., the UK, Japan and Australia. Merck has entered into advance purchase and supply agreements for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in more than 30 markets. The Company expects that sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in each of the remaining quarters of 2022 will be lower than sales in the first quarter of 2022, with full-year 2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales anticipated to be between $5.0 billion to $5.5 billion.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 24% in the first quarter of 2022 due to lower global demand, reflecting competitive pressure particularly in Europe and the U.S., as well as the timing of a government tender. The Company expects competitive pressure for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Isentress/Isentress HD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to continue.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diabetes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Januvia/Janumet</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,233&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,295&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Worldwide combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, medicines that help lower blood sugar levels in adults with type 2 diabetes, declined 5% in the first quarter of 2022 primarily due to lower demand in the U.S., partially offset by higher demand in China, as well as Latin America reflecting in part the timing of government tenders. The Company anticipates U.S. pricing pressure will unfavorably affect sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in future periods. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will lose market exclusivity in China in July 2022, in the EU in September 2022, and in the U.S. in January 2023. The Company anticipates sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in these markets will decline substantially after the loss of exclusivity. Combined sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China, Europe and the U.S. represented 11%, 23% and 31%, respectively, of total combined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales in the first quarter of 2022.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Animal Health Segment</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:64.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change <br>Excluding <br>Foreign<br>Exchange</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Livestock</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Companion Animal</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">650&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">599&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of livestock products grew 2% in the first quarter of 2022 primarily due to higher demand globally for ruminant and poultry products. Sales of companion animal products grew 9% in the first quarter of 2022 primarily due to higher demand for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (fluralaner) line of products, as well as higher demand for vaccines. Sales of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bravecto</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line of products represented approximately 20% of animal health sales in the first quarter of 2022.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_100"></div><div style="margin-top:12pt"><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 34 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Costs, Expenses and Other</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:73.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.014%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">% Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,380&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,199&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,323&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,187&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,576&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,412&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">708&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,040&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,640&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*Calculation not meaningful.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased 68% in the first quarter of 2022. Cost of sales includes the amortization of intangible assets recorded in connection with acquisitions, collaborations and licensing arrangements, which totaled $683 million and $495 million in the first quarter of 2022 and 2021, respectively. Amortization expense in the first quarter of 2022 and 2021 includes $250&nbsp;million and $153&nbsp;million, respectively, of cumulative catch-up amortization related to Merck’s collaborations with AstraZeneca and Bayer, respectively, (see Note 4 to the condensed consolidated financial statements). Additionally, costs in the first quarter of 2021 include a charge of $188 million related to the discontinuation of COVID-19 development programs. Also included in cost of sales are expenses associated with restructuring activities which amounted to $46 million and $27 million in the first quarter of 2022 and 2021, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin was 66.2% in the first quarter of 2022 compared with 69.9% in the first quarter of 2021. The gross margin decline reflects the impact of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (which has a lower gross margin due to profit sharing with Ridgeback as discussed in Note 4 to the condensed consolidation financial statements), as well as higher manufacturing costs and higher amortization of intangible assets (noted above). The gross margin decline in 2022 was partially offset by the favorable effects of product mix and a charge in 2021 related to the discontinuation of COVID-19 development programs. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative (SG&amp;A) expenses increased 6% in the first quarter of 2022 primarily due to higher acquisition-related costs and higher administrative costs, including compensation and benefits, partially offset by the favorable effect of foreign exchange. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development (R&amp;D) expenses increased 7% in the first quarter of 2022 primarily due to higher clinical development spending, including compensation and benefit costs, as well as increased investments in technology in support of the digital enablement of Merck’s research operations, partially offset by the favorable effect of foreign exchange. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are comprised of the costs directly incurred by Merck Research Laboratories (MRL), the Company’s research and development division that focuses on human health-related activities, which were $1.8 billion and $1.7 billion in the first quarter of 2022 and 2021, respectively. Also included in R&amp;D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&amp;D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $750 million and $665 million for the first quarter of 2022 and 2021, respectively. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Merck&nbsp;approved a global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint.&nbsp;This program is a continuation of the Company’s plant rationalization and builds on prior restructuring programs. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $3.5 billion. Merck expects to record charges of approximately $400 million for the full year of 2022 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program will result in annual net cost savings of approximately $900 million by the end of 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $53 million and $297 million for the first quarter of 2022 and 2021, respectively. Separation costs incurred </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 35 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional costs associated with the Company’s restructuring activities are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs. The Company recorded aggregate pretax costs of $127 million and $334 million in the first quarter of 2022 and 2021, respectively, related to restructuring program activities (see Note 5 to the condensed consolidated financial statements). </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, was $708 million of expense in the first quarter of 2022 compared with $455 million of income in the first quarter of 2021 primarily due to net losses from investments in equity securities recorded in the first quarter of 2022, related to net unrealized losses, compared with net income from investments in equity securities recorded in the first quarter of 2021, related both to higher net realized and unrealized gains. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For details on the components of Other (income) expense, net, see Note 11 to the condensed consolidated financial statements. </span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:78.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.783%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment Profits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment profits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,501&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,589&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment profits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">585&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">572&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from Continuing Operations Before Taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,861&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&amp;A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&amp;A and R&amp;D expenses directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, R&amp;D expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of intangible assets and amortization of purchase accounting adjustments, intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits increased 44% in the first quarter of 2022 reflecting higher sales, partially offset by higher administrative costs and the unfavorable effect of foreign exchange. Animal Health segment profits grew 2% in the first quarter of 2022 reflecting higher sales, partially offset by higher selling and administrative costs, higher R&amp;D costs and the unfavorable effect of foreign exchange. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxes on Income</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates from continuing operations were 11.4% and 8.0% for the first quarter of 2022 and 2021, respectively, which reflect the beneficial impact of foreign earnings. The effective income tax rate from continuing operations in the first quarter of 2022 also includes the impact of lower U.S. income reflecting net unrealized losses from investments in equity securities. The effective income tax rate from continuing operations for the first quarter of 2021 also reflects a net tax benefit of $208&nbsp;million related to the settlement of certain federal income tax matters as discussed below. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2021, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company was required to make a payment of $190&nbsp;million (of which $172&nbsp;million related to continuing operations and $18&nbsp;million related to discontinued operations). The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 36 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore the Company recorded a $237&nbsp;million net tax benefit in the first quarter of 2021 (of which $208&nbsp;million related to continuing operations and $29 million related to discontinued operations). This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Income and Non-GAAP EPS from Continuing Operations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results since management uses non-GAAP measures to assess performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs, income and losses from investments in equity securities, and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-GAAP&nbsp;EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes a non-GAAP&nbsp;EPS metric. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using a non-GAAP pretax income metric. Since non-GAAP income and non-GAAP&nbsp;EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP&nbsp;EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the U.S. (GAAP). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company changed the treatment of certain items for purposes of its non-GAAP reporting. Historically, Merck’s non-GAAP results excluded expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions accounted for as asset acquisitions, to the extent the charges were considered by the Company to be significant to the results of a particular period (as well as any related adjustments recorded in a subsequent period). Beginning in 2022, Merck’s non-GAAP results will no longer exclude charges related to these items. This change did not affect non-GAAP results reported in the first quarter of 2022, nor did it affect previously reported first quarter 2021 non-GAAP results because the Company had no significant charges related to those items during these periods.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between GAAP financial measures and non-GAAP financial measures (from continuing operations) is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:83.708%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.276%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">($ in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before taxes as reported under GAAP</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,861&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase (decrease) for excluded items:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition and divestiture-related costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss (income) from investments in equity securities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(561)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other items:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charge for the discontinuation of COVID-19 development programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP income from continuing operations before taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,309&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,445&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes on income from continuing operations as reported under GAAP</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated tax benefit on excluded items</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net tax benefit from the settlement of certain federal income tax matters</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP taxes on income from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">883&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494&nbsp;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,426&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,951&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net (loss) income attributable to noncontrolling interests as reported under GAAP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP net income from continuing operations attributable to Merck&nbsp;&amp; Co., Inc.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,429&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,947&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS assuming dilution from continuing operations as reported under GAAP</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.70&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.08&nbsp;</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EPS difference</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.44&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.08&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-GAAP EPS assuming dilution from continuing operations</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></tbody></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.</span></div><div style="margin-top:6pt"><span><br></span></div><div><span><br></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 37 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition and Divestiture-Related Costs</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS exclude the impact of certain amounts recorded in connection with acquisitions and divestitures of businesses. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with acquisitions and divestitures of businesses. Non-GAAP income and non-GAAP EPS also exclude amortization of intangible assets related to collaborations and licensing arrangements.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring Costs</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS exclude costs related to restructuring actions (see Note&nbsp;5 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income and Losses from Investments in Equity Securities</span></div><div style="margin-top:4pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP&nbsp;EPS exclude realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds.</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain Other Items</span></div><div style="margin-top:3pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2021 is a charge related to the discontinuation of COVID-19 development programs (see Note 3 to the condensed consolidated financial statements) and a net tax benefit related to the settlement of certain federal income tax matters (see Note 12 to the condensed consolidated financial statements). </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Update</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company currently has several candidates under regulatory review in the U.S. and internationally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-4482, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is an investigational oral antiviral medicine for the treatment of mild to moderate COVID-19 in adults who are at risk for progressing to severe disease. Merck is developing </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in collaboration with Ridgeback. The FDA granted Emergency Use Authorization for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in December 2021; as updated in February 2022, to authorize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate. The authorization is based on the Phase 3 MOVe-OUT trial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is not approved for any use in the U.S. and is authorized only for the duration of the declaration that circumstances exist justifying the authorization of its emergency use under the Food, Drug and Cosmetic Act, unless the authorization is terminated or revoked sooner. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has also received Conditional Marketing Authorization in the UK and Special Approval for Emergency in Japan. In November 2021, the European Medicines Agency (EMA) issued a positive scientific opinion for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is intended to support national decision-making on the possible use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> prior to marketing authorization. In October 2021, the EMA initiated a rolling review for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of COVID-19 in adults. Merck plans to work with the Committee for Medicinal Products for Human Use (CHMP) of the EMA to complete the rolling review process to facilitate initiating the formal review of the Marketing Authorization Application. Applications to other regulatory bodies are underway. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also being evaluated for post-exposure prophylaxis in the Phase 3 MOVe-AHEAD trial, which is evaluating the efficacy and safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the prevention of COVID-19 in adults who reside with a person with COVID-19. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7264, gefapixant, is an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory chronic cough or unexplained chronic cough in adults under review by the FDA. The New Drug Application (NDA) for gefapixant is based on results from the COUGH-1 and COUGH-2 clinical trials. In January 2022, the FDA issued a Complete Response Letter (CRL) regarding Merck’s NDA for gefapixant. In the CRL, the FDA requested additional information related to measurement of efficacy. The CRL was not related to the safety of gefapixant. Merck is reviewing the letter and considering next steps. Gefapixant is also under review in the EU, although the review period has been extended pending the receipt of additional information from the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 38 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">V114, (Pneumococcal 15-valent Conjugate Vaccine), is an investigational 15-valent pneumococcal conjugate vaccine under review in Japan for use in adults. V114 was approved in the U.S. in 2021 for use in adults where it is marketed as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under priority review by the FDA for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age. The FDA grants priority review to medicines and vaccines that, if approved, would provide a significant improvement in the safety or effectiveness of the treatment or prevention of a serious condition. The supplemental biologics license application (BLA) is supported by results from Phase 2 and Phase 3 clinical studies in pediatric populations including infants, children, and adolescents. In April 2022, Merck announced that the FDA extended the Prescription Drug User Fee Act (PDUFA) date of the supplemental BLA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vaxneuvance</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in infants and children to July 1, 2022. The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA. No new studies have been requested by the FDA. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-3475, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,750 clinical trials, including more than 1,300 trials that combine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with other cancer treatments. These studies encompass more than 30 cancer types including: biliary, estrogen receptor positive breast cancer, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, non-small-cell lung, small-cell lung, melanoma, mesothelioma, ovarian, prostate, renal, triple-negative breast, and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the CHMP adopted a positive opinion recommending approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for adults with locally advanced, or early-stage TNBC at high risk of recurrence. The CHMP’s recommendation was based on results from the Phase 3 KEYNOTE-522 trial. The CHMP’s recommendation will now be reviewed by the EC for marketing authorization in the EU, and a final decision is expected in the second quarter of 2022. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review for this indication in Japan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review in the EU for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection based on data from the Phase 3 KEYNOTE-716 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review in Japan in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1 based on results from the Phase 3 KEYNOTE-826 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is also under review in Japan for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney) based on data from the Phase 3 KEYNOTE-564 trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is under review by the FDA for the treatment of patients with previously treated advanced HCC. This submission is based on data from the Phase 3 KEYNOTE-394 trial along with supportive data from KEYNOTE-240 and KEYNOTE-224. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MK-7339, Lynparza, is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca. Lynparza is under review in the EU and Japan for the adjuvant treatment of patients with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-mutated, HER2-negative high-risk, early-stage breast cancer who have already been treated with chemotherapy either before or after surgery based on the results from the Phase 3 OlympiA trial. Lynparza is also under review in the EU for the treatment of certain patients with metastatic castration-resistant prostate cancer based on the PROpel clinical trial. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, Merck announced that it will stop the Phase 3 KEYLYNK-010 trial investigating </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza for the treatment of patients with metastatic castration-resistant prostate cancer who progressed after treatment with chemotherapy and either abiraterone acetate or enzalutamide. Merck is discontinuing the study following the recommendation of an independent Data Monitoring Committee (DMC) after the DMC reviewed data from a planned interim analysis. At the interim analysis, the combination of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Lynparza did not demonstrate a benefit in overall survival, one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide. The trial’s other dual primary endpoint, radiographic progression free survival, was evaluated at an earlier interim analysis and did not demonstrate improvement compared to the control arm. Data from this study will be presented at an upcoming scientific congress.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, Merck announced that V116, the Company’s investigational 21-valent pneumococcal conjugate vaccine, has received Breakthrough Therapy Designation from the FDA for the prevention of invasive pneumococcal disease and pneumococcal pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A/C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B/C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B in adults 18 years of age and older. Phase 3 clinical trials for V116 are expected to be initiated later this year. The Breakthrough Therapy Designation is an FDA program designed to expedite the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 39 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and review of products intended for serious or life-threatening conditions. To qualify for this designation, preliminary clinical evidence must indicate that the product may demonstrate substantial improvement over currently available options on at least one clinically significant endpoint. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The charts below reflect the Company’s research pipeline as of May 3, 2022. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:32.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.658%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-0482</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1026 (nemtabrutinib)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hematological Malignancies</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308 (quavonlimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:13.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="padding-left:18pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-2140 (zilovertamab vedotin)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280 (favezelimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hematological Malignancies</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Renal Cell</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4830</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="padding-left:9pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell</span></div><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5890</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Small-Cell Lung</span></div><div style="text-indent:9pt"><span><br></span></div><div style="text-indent:9pt"><span><br></span></div><div style="text-indent:9pt"><span><br></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">MK-6440 (ladiratuzumab vedotin)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:115%">MK-6482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:115%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Rare cancers</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Von Hippel-Lindau Disease-Associated Tumors (EU)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Bladder</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cervical</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Advanced Solid Tumors</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684 (vibostolimab)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cervical</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Endometrial</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hematological Malignancies</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="text-indent:9pt"><span><br></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Glioblastoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Pancreatic</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V937</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Solid Tumors</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cardiovascular</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-2060</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Chikungunya Virus Vaccine</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V184</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591B (islatravir+MK-8507)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591D (islatravir+lenacapavir)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Hypercholesterolemia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-0616</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Nonalcoholic Steatohepatitis (NASH)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3655</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-6024</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Overgrowth Syndrome</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7075 (miransertib)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V116</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-5475</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Schizophrenia</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8189</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Treatment Resistant Depression</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1942</span></div><div style="text-indent:9pt"><span><br></span></div></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 40 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:35.625%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Phase 3 (Phase 3 entry date)</span></td><td colspan="6" style="border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Under Review</span></td></tr><tr style="height:251pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (U.S.) (May 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1308A (quavonlimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell (April 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Biliary (September 2019)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cutaneous Squamous Cell (August 2019) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (May 2015) (EU)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Hepatocellular (May 2016) (EU)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Mesothelioma (May 2018)</span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Ovarian (December 2018)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Prostate (May 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (May 2017)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 (pembrolizumab subcutaneous) </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (August 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4280A (favezelimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (November 2021)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-6482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Welireg</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Renal Cell (February 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7119 Tukysa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Breast (October 2019)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(3)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (August 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (June 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (December 2020)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7684A (vibostolimab+pembrolizumab)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Small-Cell Lung (March 2022)</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Colorectal (April 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Esophageal (July 2021)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Gastric (December 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Head and Neck (February 2020)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Melanoma (March 2019)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Non-Small-Cell Lung (March 2019)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Infection</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591A (doravirine+islatravir) (February 2020)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">HIV-1 Prevention</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-8591 (islatravir) (February 2021)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pulmonary Arterial Hypertension</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7962 (sotatercept) (January 2021)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Respiratory Syncytial Virus</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-1654 (clesrovimab) (November 2021)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">New Molecular Entities/Vaccines</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Antiviral COVID-19</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-4482 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Lagevrio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cough</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7264 (gefapixant) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%"> (EU)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Pneumococcal Vaccine Adult</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">V114 (JPN)</span></div><div><span><br></span></div><div><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Certain Supplemental Filings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:110%">Cancer</span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-3475 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">Keytruda</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    High-Risk Early-Stage Triple-Negative Breast Cancer </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-522) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    Adjuvent Treatment of Stage IIB and IIC Melanoma</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-716) (EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    Cervical Cancer (KEYNOTE-826) (JPN)</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    Adjuvent Renal Cell Cancer </span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-564) (JPN)</span></div><div style="padding-left:31.5pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    Second-Line Hepatocellular Cancer</span></div><div style="padding-left:31.5pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">(KEYNOTE-394) (U.S.) </span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7339 Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:110%">BRCA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">-Mutated HER2-Negative Adjuvant Breast</span></div><div style="padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">Cancer (OlympiA) (EU) (JPN)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    First-Line Metastatic Prostate Cancer (PROpel) EU)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span><br></span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">MK-7902 Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(1)(2)</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">•    First-Line Metastatic Hepatocellular Carcinoma</span></div><div style="padding-left:27pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:110%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(KEYNOTE-524) (U.S.)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:110%;position:relative;top:-2.62pt;vertical-align:baseline">(7)</span></div></td></tr><tr style="height:116pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Footnotes:</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Being developed in a collaboration.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Being developed in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Being developed as monotherapy and/or in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">Keytruda.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  On FDA clinical hold.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  Available in the U.S. under Emergency Use Authorization.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">In January 2022, the FDA issued a CRL for this application. Merck is reviewing the CRL and considering next steps.</span></div><div style="margin-bottom:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">  In July 2020, the FDA issued a CRL for Merck’s and Eisai’s applications. Merck and Eisai intend to submit additional data when available to the FDA. </span></div></td></tr></tbody></table></div><div id="ia10991337ee64bfe975ff621c73a0ff6_106"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,244&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,466&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,868&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,394&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt to total liabilities and equity</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.8&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.3&nbsp;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></tbody></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities of continuing operations was $4.8 billion in the first three months of 2022 compared with $1.2 billion in the first three months of 2021 reflecting stronger operating performance, including sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lagevrio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for which the related profit sharing payment to Ridgeback will be made in the second quarter of 2022 (see Note 4 to the condensed consolidated financial statements). Cash provided by operating activities from continuing operations in the first three months of 2022 was reduced by $1.2 billion of milestone payments related to collaborations compared with $325 million of milestone and option payments related to collaborations in the first three months of 2021. Cash provided by operating activities from continuing operations continues to be the Company’s primary source of funds to finance operating needs, with excess cash serving as the primary source of funds to finance capital expenditures, treasury stock purchases and dividends paid to shareholders. As a result of the mandatory change in R&amp;D capitalization rules that are effective for tax years beginning after December 31, 2021 (related to the Tax Cuts and Jobs Act of 2017), the Company expects taxes paid in the U.S. to increase significantly for the full year of 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities of continuing operations was $1.2 billion in the first three months of 2022 compared with $686 million in the first three months of 2021. The higher use of cash in investing activities was primarily due to lower proceeds from sales of securities and other investments coupled with higher purchases of securities and other investments, partially offset by lower capital expenditures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities of continuing operations was $3.1 billion in the first three months of 2022 compared with $2.1 billion in the first three months of 2021. The higher use of cash in financing activities was primarily due </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 41 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to a net increase in short-term borrowings in the prior period compared with no increase in short-term borrowings in the current period, higher dividends paid to stockholders and higher payments on debt (see below). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capital expenditures totaled $1.0 billion and $1.1 billion for the first three months of 2022 and 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.2 billion and $2.8 billion of accounts receivable at March&nbsp;31, 2022 and December&nbsp;31, 2021, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid to stockholders were $1.7 billion and $1.6 billion for the first three months of 2022 and 2021, respectively.&nbsp;In January 2022, the Board of Directors declared a quarterly dividend of $0.69 per share on the Company’s stock for the second quarter that was paid in April 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company’s $1.25 billion, 2.35% notes matured in accordance with their terms and were repaid. In January 2021, the Company’s $1.15 billion, 3.875% notes matured in accordance with their terms and were repaid. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. The Company did not purchase any shares of its common stock during the first three months of 2022. As of March&nbsp;31, 2022, the Company’s remaining share repurchase authorization was $5.0&nbsp;billion. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a $6.0 billion credit facility that matures in June 2026. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December&nbsp;31, 2021 included in Merck’s Form 10‑K filed on February&nbsp;25, 2022. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2022. A discussion of accounting estimates considered critical because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates are disclosed in the Critical Accounting Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K. There have been no significant changes in the Company’s critical accounting estimates since December&nbsp;31, 2021. </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_115"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in market risk exposures that affect the disclosures presented in “Item 7A. Quantitative and Qualitative Disclosures about Market Risk” in the Company’s 2021 Form 10-K filed on February 25, 2022. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The economy of Turkey was recently determined to be hyperinflationary. Consequently, in accordance with U.S. GAAP, the Company’s monetary assets and liabilities that are subject to remeasurement as a result of the changes in the Turkish lira will change beginning in the second quarter of 2022. This change will have an immaterial impact to Merck’s condensed consolidated financial statements. </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_118"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;4. Controls and Procedures</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of March&nbsp;31, 2022, the Company’s disclosure controls and procedures are effective. For the first quarter of 2022, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 42 -</span></div></div></div><div id="ia10991337ee64bfe975ff621c73a0ff6_121"></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can&nbsp;also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product approvals, product potential, development programs, environmental or other sustainability initiatives, and include statements related to the expected impact of the COVID-19 pandemic. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item&nbsp;1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December&nbsp;31, 2021, filed on February&nbsp;25, 2022, and in this Form 10-Q, the Company discusses in&nbsp;more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list&nbsp;to be a&nbsp;complete statement of all potential risks or uncertainties.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_124"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">PART II - Other Information</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;1. Legal Proceedings</span></div><div style="margin-top:8pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item is incorporated herein by reference to Note 8 included in Part I, Item&nbsp;1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;1A. Risk Factors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.&nbsp;There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on Form 10-K, except as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The ongoing war between Russia and Ukraine and related global disruptions could adversely affect the Company’s business, results of operations and financial condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing war between Russia and Ukraine, and the financial and economic sanctions imposed by the U.S., the European Union and other countries in response, are having pervasive direct and indirect effects on the global economy, and may adversely affect the Company’s business, results of operations and financial condition. The Company is working cross-functionally across the globe to monitor and mitigate interruptions to business continuity resulting from the war, including its impact on Merck’s supply chain, operations and clinical trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For humanitarian reasons, the Company is continuing to supply essential medicines and vaccines in Russia while working to maintain compliance with evolving international sanctions. Merck plans to donate profits resulting from its operations in Russia to humanitarian causes. The Company does not have research or manufacturing facilities in Russia, currently does not plan to make further investments in Russia, and has suspended screening and enrollment in ongoing clinical trials as well as planning for new studies in Russia, although the Company continues to treat patients already enrolled in existing clinical trials and collect data from these studies. The Company is also using its resources to help alleviate the humanitarian crisis in Ukraine, including through donations of funds and products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial impacts of the war between Russia and Ukraine were immaterial to the Company’s consolidated financial statements for the first quarter of 2022. However, the degree to which the war and related disruptions will impact the Company’s results for the remainder of 2022 or beyond is difficult to predict and will depend on developments outside of the Company’s control, including, but not limited to, the duration and severity of the conflict, ongoing and additional financial and economic sanctions imposed by governments in response, restrictions on travel, regional instability, geopolitical shifts, and adverse effects on fuel and energy costs, supply chains, macroeconomic conditions, currency exchange rates and financial markets. Such developments may negatively impact the Company directly or indirectly as well as the parties with which the Company conducts business. In addition, the effects of the war between Russia and Ukraine could heighten other risks </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 43 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, which could materially adversely affect the Company’s business, results of operations and financial condition. </span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuer purchases of equity securities for the three months ended March&nbsp;31, 2022 were as follows:</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:27.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.551%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.926%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.092%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($&nbsp;in&nbsp;millions)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Period</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total&nbsp;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Average&nbsp;Price<br>Paid Per<br>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Approximate&nbsp;Dollar&nbsp;Value&nbsp;of&nbsp;Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">That May Yet Be Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1 - January 31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1 - February 28</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 1 - March 31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.00</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">—&nbsp;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td></tr></tbody></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> The Company did not purchase any shares during the three months ended March 31, 2022 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.</span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_136"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Item&nbsp;6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000119312509223917/dex31.htm">Restated Certificate of Incorporation of Merck &amp; Co., Inc. (November 3, 2009) – Incorporated by reference to Current Report on Form 8-K filed on November&nbsp;4, 2009 (No. 1-6571)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/310158/000031015822000006/exhibit31-byxlawsasamended.htm">By-Laws of Merck &amp; Co., Inc. (effective March 22, 2022) – Incorporated by reference to Current Report on Form 8-K filed on March 25, 2022 (No. 1-6571)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-rule13ax14a15dx.htm">Rule 13a – 14(a)/15d – 14(a) Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-rule13ax14a15dx.htm">Rule 13a – 14(a)/15d – 14(a) Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-section1350cert.htm">Section 1350 Certification of Chief Executive Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit322-section1350cert.htm">Section 1350 Certification of Chief Financial Officer</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&nbsp;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 44 -</span></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><span><br></span></div></div><div><span><br></span></div><div id="ia10991337ee64bfe975ff621c73a0ff6_139"></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span><br></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Signatures</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&nbsp;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tbody><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MERCK &amp; CO., INC.</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jennifer Zachary</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JENNIFER ZACHARY</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and General Counsel</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rita A. Karachun</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RITA A. KARACHUN</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&nbsp;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President Finance - Global Controller</span></td></tr></tbody></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">- 45 -</span></div></div></div>
</div>


	</div>

	<div id="form-information-modal" data-test="form-information-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="form-information-modal-title" data-test="form-information-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">
				<i id="form-information-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="14"></i>

				<i id="dialog-box-copy-content" title="Click to Copy all Dialog Box Content." class="reboot fas fa-copy m-1 click" tabindex="14"></i>

				<i id="dialog-box-close" data-name="Form Information Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="14"></i>

			</div>
		</div>
		<div class="reboot dialog-content">
			<div id="form-information-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="dialog-content-copy-content" class="reboot float-right click color-inherit" tabindex="14">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="14"></textarea>
			</div>
			<div id="form-information-modal-carousel" class="reboot carousel pointer-event" data-interval="false" data-ride="carousel">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-1" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-2" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-3" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="form-information-modal-carousel-page-4" tabindex="14">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button id="form-information-prev" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="prev" tabindex="14">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="form-information-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button id="form-information-next" data-test="form-information-next" class="reboot btn btn-link text-dark" href="#form-information-modal-carousel" role="button" data-slide="next" tabindex="14">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="settings-modal" data-test="settings-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="settings-modal-title" data-test="settings-modal-title" class="reboot lead mb-0">Settings</p>
			<div class="reboot dialog-header-actions">
				<i id="settings-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="15"></i>

				<i id="settings-modal-close" data-name="Settings Modal" title="Click to Close this Dialog Box." class="reboot fas fa-times m-1 click" tabindex="15"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<form class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Hover
						over Fact for quick information.</label>
					<select id="hover-option-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="true">On</option>
						<option class="reboot" value="false">Off</option>
					</select>
				</div>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">Auto
						Scrolling Position</label>
					<select id="scroll-position-select" class="reboot col-sm-8 form-control" tabindex="15">
						<option class="reboot" value="start">Top</option>
						<option class="reboot" value="center">Center</option>
					</select>
					<small class="reboot form-text text-muted col-sm-12" tabindex="15">Selecting
						a fact from the Sections Menu or the Fact Menu will automatically
						scroll that element to the (Top, or Middle) of the viewer window.
						This setting will have no use on IE 10, or Safari.</small>
				</div>
				<hr class="reboot">
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tagged-data-example-1">Tagged Data</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tagged-data-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 6.66667%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 102, 0); color: rgb(255, 102, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 102, 0), rgba(255, 102, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 102, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot search-results-example-1">Search
							Results</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="search-results-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 14.0523%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 215, 0); color: rgb(255, 215, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 215, 0), rgba(255, 215, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(255, 215, 0);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot selected-fact-example-1">Selected Fact</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="selected-fact-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot tag-shading-exmple-1">Tag Shading
							(hover)</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="tag-shading-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 0%;"></div></div><div class="picker_sl" style="background-color: rgb(255, 0, 0); color: rgb(255, 0, 0);"><div class="picker_selector" style="left: 100%; top: 50%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(255, 0, 0), rgba(255, 0, 0, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 70%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgba(255, 0, 0, 0.3);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
				<hr>
				<div class="reboot form-group row">
					<label class="reboot col-sm-4 col-form-label" tabindex="15">
						<span class="reboot text-block-exmple-1">Text Block Indicators</span>
					</label>
					<div class="reboot col-sm-4">
						<div class="reboot" id="text-block-color-picker" tabindex="15"><div class="picker_wrapper layout_default no_alpha no_editor" tabindex="-1"><div class="picker_arrow"></div><div class="picker_hue picker_slider" style="color: rgb(0, 135, 255);"><div class="picker_selector" style="left: 57.8526%;"></div></div><div class="picker_sl" style="background-color: rgb(0, 135, 255); color: rgb(0, 55, 104);"><div class="picker_selector" style="left: 100%; top: 79.6078%;"></div></div><div class="picker_alpha picker_slider" style="background-image: linear-gradient(rgb(0, 55, 104), rgba(0, 55, 104, 0)), url(&quot;data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E&quot;);"><div class="picker_selector" style="top: 0%;"></div></div><div class="picker_editor"><input aria-label="Type a color name or hex value"></div><div class="picker_sample" style="color: rgb(0, 55, 104);"></div><div class="picker_done"><button>Save</button></div><div class="picker_cancel"><button>Reset</button></div></div></div>
					</div>
				</div>
			</form>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around"></div>
	</div>

	<div id="taxonomy-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p id="taxonomy-modal-title" class="reboot lead mb-0"></p>
			<div class="reboot dialog-header-actions">

				<i id="taxonomy-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="16"></i>

				<i id="taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="16"></i>
				<i id="taxonomy-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="16"></i>

				<i id="taxonomy-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="16"></i>

				<i id="taxonomy-modal-close" class="reboot fas fa-times m-1 click" tabindex="16"></i>
			</div>
		</div>
		<div class="reboot dialog-content">
			<p id="taxonomy-modal-subtitle" class="reboot text-center font-weight-bold"></p>
			<div id="taxonomy-copy-paste" class="reboot form-group d-none">
				<label>Copy and Paste Below Content.</label>
				<a id="taxonomy-copy-content" class="reboot float-right click color-inherit" tabindex="16">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="16"></textarea>
			</div>
			<div id="taxonomy-modal-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-1" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-2" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-3" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm" id="taxonomy-modal-carousel-page-4" tabindex="16">
							<!-- Below is populated dynamically VIA JS -->
							<tbody class="reboot">
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="prev" tabindex="16">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#taxonomy-modal-carousel" role="button" data-slide="next" tabindex="16">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>

	<div id="taxonomy-nested-modal" class="reboot dialog-box fixed-dialog-box d-none bg-white">
		<div class="reboot dialog-header bg-sec text-white px-1 d-flex justify-content-between">
			<p class="reboot lead mb-0">
				Nested Facts
				<span class="reboot" id="nested-page"></span>
				<span class="reboot">/</span>
				<span class="reboot" id="nested-count"></span>
			</p>
			<div class="reboot dialog-header-actions">
				<i id="taxonomy-nested-modal-drag" title="Click and drag to move this Dialog Box." class="reboot fas fa-arrows-alt m-1 drag-icon d-none d-sm-inline-block" tabindex="17"></i>

				<i id="nested-taxonomy-modal-jump" title="Click to see this in the Facts sidebar." class="reboot fas fa-directions m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-copy-content" class="reboot fas fa-copy m-1 click" tabindex="17"></i>

				<i id="taxonomy-nested-modal-compress" class="reboot fas fa-compress m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-expand" class="reboot fas fa-expand m-1 click d-none" tabindex="17"></i>

				<i id="taxonomy-nested-modal-close" class="reboot fas fa-times m-1 click" tabindex="17"></i>
			</div>
		</div>
		<div class="reboot dialog-content pt-0">
			<div id="modal-nested-fact-labels" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot d-flex">
					<button data-test="modal-taxonomy-nested-prev" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="prev" tabindex="17">
						<i class="reboot fas fa-chevron-left" title="Previous"></i>
						<span class="reboot sr-only">Previous</span>
					</button>
					<div id="modal-taxonomy-nested-label-carousel" class="reboot carousel-inner">
						<!-- Below is populated dynamically VIA JS -->
					</div>
					<button data-test="modal-taxonomy-nested-next" class="reboot btn btn-link text-dark" href="#modal-nested-fact-labels" role="button" data-slide="next" tabindex="17">
						<i class="reboot fas fa-chevron-right" title="Next"></i>
						<span class="reboot sr-only">Next</span>
					</button>
				</div>
			</div>
			<div id="taxonomy-nested-copy-paste" class="reboot form-group d-none">
				<label class="reboot">Copy and Paste Below Content.</label>
				<a id="taxonomy-nested-copy-content" class="reboot float-right click color-inherit" tabindex="17">
					<i class="reboot fas fa-times-circle mt-2"></i>
				</a>
				<textarea class="reboot form-control" rows="5" tabindex="17"></textarea>
			</div>
			<div id="modal-taxonomy-nested-content-carousel" class="reboot carousel" data-interval="false" data-keyboard="false">
				<div class="reboot carousel-inner">
					<div class="reboot carousel-item table-responsive active">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-1" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-bordered table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-2" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-3" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
					<div class="reboot carousel-item table-responsive">
						<table class="reboot table table-striped table-sm">
							<tbody class="reboot" id="modal-taxonomy-nested-content-carousel-page-4" tabindex="17">
								<!-- Below is populated dynamically VIA JS -->
								<tr class="reboot">
									<td class="reboot text-center">
										<i class="reboot fas fa-spinner fa-spin"></i>
									</td>
								</tr>
							</tbody>
						</table>
					</div>
				</div>
			</div>
		</div>
		<div id="taxonomy-nested-nav-controls" class="reboot dialog-footer d-flex justify-content-around">
			<button data-test="modal-taxonomy-prev" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="prev" tabindex="17">
				<i class="reboot fas fa-chevron-left" title="Previous"></i>
				<span class="reboot sr-only">Previous</span>
			</button>
			<ol id="taxonomy-nested-modal-carousel-indicators" class="reboot carousel-indicators mx-0 my-3 p-initial">
				<!-- Below is populated dynamically VIA JS -->
			</ol>
			<button data-test="modal-taxonomy-next" class="reboot btn btn-link text-dark" href="#modal-taxonomy-nested-content-carousel" role="button" data-slide="next" tabindex="17">
				<i class="reboot fas fa-chevron-right" title="Next"></i>
				<span class="reboot sr-only">Next</span>
			</button>
		</div>
	</div>



</body></html>